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I. Summary 
 
The evolutionarily conserved protein ubiquitin serves as a posttranslational 
modification in eukaryotic cells. Ubiquitylation links specific proteins with different 
effector reactions and pathways, including proteasomal degradation. The canonical 
ubiquitylation machinery transfers ubiquitin to substrate proteins in a cascade 
reaction comprising three different enzymes (E1, E2, E3). In human cells, there exist 
more than 600 E3s, denoted ubiquitin ligases. Ubiquitin ligases provide the ubiquitin 
system with substrate specificity as they directly interact with the target proteins and 
mediate the final step of the ubiquitylation reaction.  
Cullin-RING ubiquitin ligases are the largest subfamily of ubiquitin ligases. The SCF 
complex is a Cullin-RING ubiquitin ligase that contains a central CUL1 subunit, the 
RING domain containing protein RBX1, the adaptor protein SKP1 and an F-box 
protein. The F-box protein is the SCF subunit that recruits the substrate. In humans, 
there are about 70 F-box proteins. They are interchangeable within the SCF complex 
and have different substrate specificities.  
One of the best-characterized F-box proteins is FBXW7. FBXW7 promotes the 
proteasomal degradation of important oncoproteins, including Cyclin E, MYC, JUN 
and NOTCH. Accordingly, FBXW7 functions as a tumor suppressor protein. Indeed, 
FBXW7 is frequently mutated in human cancers. While the downstream effects of 
FBXW7 are already well-characterized, the upstream regulation of FBXW7 is only 
poorly understood so far. In order to unravel novel regulation mechanisms for 
FBXW7, a biochemical screen for FBXW7 interaction partners was performed in the 
presented study. 
Immunoprecipitation combined with mass spectrometry identified FBXO45, MYCBP2, 
XIAP and RAE1 as putative interaction partners of FBXW7. In vivo verification of the 
putative interactions revealed that FBXO45, MYCBP2, XIAP and RAE1 specifically 
interact with a negatively charged motif within the N-terminal domain of the FBXW7 
α-isoform. Additional interaction studies indicated that FBXW7α, FBXO45, MYCBP2, 
XIAP and RAE1 are found in a complex. In vitro, only FBXO45 interacted with the N-
terminus of FBXW7α, suggesting that FBXO45 is the direct interaction partner of 
FBXW7α within the complex. 
FBXO45 and MYCBP2 have been described to form a ubiquitin ligase complex. 
siRNA-mediated downregulation of FBXO45 and MYCBP2 caused an increase in 
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FBXW7α protein levels, which was specifically observed during mitotic arrest. 
Furthermore, FBXO45 and MYCBP2 promoted ubiquitylation of FBXW7α. FBXO45 
depletion led to a stabilization of FBXW7α in a cycloheximide chase experiment. 
These findings suggest that FBXO45 and MYCBP2 promote the proteasomal 
degradation of FBXW7α upon mitotic arrest. 
FBXW7 is a known regulator of mitotic cell fate. Upon mitotic arrest, FBXW7 
promotes mitotic cell death and prevents mitotic slippage. In contrast to FBXW7, this 
thesis identified FBXO45 and MYCBP2 to promote mitotic slippage and to prevent 
mitotic cell death. Hence, FBXW7 and FBXO45/MYCBP2 have opposing effects on 
mitotic cell fate. 
In conclusion, this thesis describes FBXO45 and MYCBP2 as novel regulators of 
FBXW7α protein levels during mitotic arrest. Thus, the presented thesis contributes 
to a better understanding of the regulatory mechanisms underlying the function of the 
important tumor suppressor protein FBXW7. As FBXW7 contributes to mitotic cell 
death, the FBXO45/MYCBP2-FBXW7α axis could be a novel target for the 
improvement of chemotherapy approaches. 
	 	 Zusammenfassung 
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II. Zusammenfassung 
 
Das evolutionär konservierte Protein Ubiquitin dient in eukaryontischen Zellen als 
posttranslationale Proteinmodifikation. Die Ubiquitylierung verknüpft spezifische 
Proteine mit unterschiedlichen Effektor-Reaktionen und -Signalwegen, wie z. B. der 
proteasomalen Degradation. In einer kaskadenartigen Reaktion, die drei 
unterschiedliche Enzyme (E1, E2, E3) benötigt, wird Ubiquitin auf Substrat-Proteine 
übertragen. In menschlichen Zellen existieren mehr als 600 E3-Enzyme, die auch als 
Ubiquitin-Ligasen bezeichnet werden. Ubiquitin-Ligasen verleihen dem Ubiquitin-
System die Substrat-Spezifität, da sie direkt mit den Ziel-Proteinen interagieren und 
den finalen Schritt der Ubiquitylierungsreaktion vermitteln. 
Cullin-RING Ubiquitin-Ligasen bilden die größte Unterfamilie der Ubiquitin-Ligasen. 
Als SCF-Komplex wird eine Cullin-RING Ubiquitin-Ligase bezeichnet, die die zentrale 
Untereinheit CUL1, das RING-Domäne enthaltende Protein RBX1, das Adapter-
Protein SKP1 sowie ein F-Box-Protein enthält. Die Bindung des Substrats an den 
SCF-Komplex erfolgt über das F-Box-Protein. Humane Zellen verfügen über 
ungefähr 70 F-Box-Proteine. Diese sind innerhalb des SCF-Komplexes austauschbar 
und besitzen unterschiedliche Substrat-Spezifitäten. 
Eines der am besten charakterisierten F-Box-Proteine ist FBXW7. FBXW7 vermittelt 
die proteasomale Degradation von wichtigen Onkoproteinen, wie z.B. Cyclin E, MYC, 
JUN und NOTCH. Dementsprechend wirkt FBXW7 als Tumorsuppressor-Protein und 
liegt bei verschiedenen Krebsarten häufig mutiert vor. Während bereits eine Reihe 
von Substraten des FBXW7-Proteins beschrieben wurden, sind die 
Regulationsmechanismen von FBXW7 selbst bisher nur in Ansätzen verstanden. Um 
neue Regulationsmechanismen von FBXW7 zu finden, wurde in der vorliegenden 
Arbeit ein biochemischer Screen für FBXW7-Interaktionspartner durchgeführt. 
Immunpräzipitation kombiniert mit Massenspektrometrie identifizierten FBXO45, 
MYCBP2, XIAP und RAE1 als mögliche Interaktionspartner von FBXW7. Die in vivo 
Verifikation dieser Interaktionen zeigte, dass FBXO45, MYCBP2, XIAP und RAE1 
spezifisch mit einem negativ geladenen Motiv in der N-terminalen Domäne der α-
Isoform von FBXW7 interagierten. Weitere Interaktionsstudien deuteten darauf hin, 
dass FBXW7α, FBXO45, MYCBP2, XIAP und RAE1 einen Komplex bilden. In vitro 
interagierte nur FBXO45 mit dem N-Terminus von FBXW7α. Dieses Ergebnis deutet 
Zusammenfassung 
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darauf hin, dass FBXO45 in dem Komplex der direkte Interaktionspartner von 
FBXW7α ist. 
Es wurde bereits in der Literatur beschrieben, dass FBXO45 und MYCBP2 einen 
Ubiquitin-Ligase-Komplex bilden. Eine durch siRNA vermittelte Runterregulation von 
FBXO45 und MYCBP2 verursachte einen Anstieg der FBXW7α-Proteinmengen. 
Dieser Anstieg wurde spezifisch während eines mitotischen Arrests beobachtet. 
Außerdem bewirkten FBXO45 und MYCBP2 die Ubiquitylierung von FBXW7α. Eine 
Verringerung von FBXO45 führte in einem Cycloheximid-Experiment zu einer 
erhöhten Stabilität von FBXW7α. Diese Erkenntnisse lassen darauf schließen, dass 
FBXO45 und MYCBP2 während eines mitotischen Arrests den proteasomalen Abbau 
von FBXW7α stimulieren. 
Es ist bekannt, dass FBXW7 den mitotischen Zelltod reguliert. Während eines 
mitotischen Arrests fördert FBXW7 den Zelltod und verhindert so das Entkommen 
von Zellen aus dem mitotischen Arrest. In dieser Arbeit wurde gezeigt, dass FBXO45 
und MYCBP2 – im Gegensatz zu FBXW7 – den mitotischen Arrest auflösen und auf 
diese Weise den mitotischen Zelltod verhindern. 
Zusammenfassend kann gesagt werden, dass in der vorliegenden Arbeit ein 
Komplex aus FBXO45 und MYCBP2 als neuer Regulator von FBXW7α während 
eines mitotischen Arrests gefunden wurde. Daher tragen die vorliegenden 
Ergebnisse zu einem besseren Verständnis der Regulationsmechanismen des 
Tumorsuppressor-Proteins FBXW7 bei. Da FBXW7 den mitotischen Zelltod reguliert, 
könnte die Regulation von FBXW7α durch FBXO45/MYCBP2 neue Ansätze für eine 
effizientere Chemotherapie liefern. 
  Introduction	 	  
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1. Introduction 
 
Specific and efficient degradation of target proteins is required for many important 
cellular processes. For example, cell-cycle progression could not be maintained in an 
ordered and unidirectional manner without the highly regulated and fast degradation 
of cell-cycle key players, such as cyclins (Evans et al., 1983; Glotzer et al., 1991).  
The ubiquitin-proteasome system, which mediates the specific degradation of target 
proteins, uses a small, ~9 kDa protein called ubiquitin as a posttranslational 
modification to induce the recognition and degradation of the target protein by the 
proteasome. In addition to protein degradation, the ubiquitin system has been found 
to cause other effects, depending on the type of ubiquitin modification. The ubiquitin 
system and the types of ubiquitylation turned out to be highly complex and they are 
now thought to be involved in most, if not all, processes within the cell. Accordingly, 
misfunction of ubiquitin system components can cause a plethora of diseases, 
including cancer (reviewed by Hoeller et al., 2006). Because of the immense 
importance of the ubiquitin system for the cell, Aaron Ciechanover, Avram Hershko 
and Irwin Rose were awarded the Nobel Prize in Chemistry 2004 for the original 
discovery of ubiquitin-mediated protein degradation (Ciechanover et al., 1978, 1980, 
1981, Hershko et al., 1979, 1980, 1983). 
 
1.1. The ubiquitin system 
 
1.1.1. The ubiquitylation reaction 
For the modification of a substrate protein with ubiquitin (Fig. 1), a three-step 
cascade reaction is performed by three sequentially acting enzymes (E1, E2, E3). In 
a first, ATP-dependent reaction, the C-terminal carboxyl group of ubiquitin gets 
covalently bound to a cysteine residue of the E1 enzyme (ubiquitin activating 
enzyme), forming a thioester bond. The ubiquitin molecule is then transferred from 
the E1 enzyme to a cysteine residue of the E2 enzyme (ubiquitin conjugating 
enzyme). Finally, the E3 enzyme (ubiquitin ligase) mediates the direct or indirect 
transfer of ubiquitin from the E2 to the substrate protein. In most cases, the C-
terminal carboxyl group of ubiquitin gets covalently bound to the ε-amino group of a 
lysine residue in the substrate protein, forming an isopeptide bond (reviewed by 
Buetow and Huang, 2016). 
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In an antagonizing reaction, the ubiquitin modification can specifically be cleaved 
from the substrate protein by members of the de-ubiquitylating enzyme (DUB) family. 
In human cells, there are about 100 different DUBs (reviewed by Komander et al., 
2009). 
 
Fig. 1: The ubiquitin-proteasome pathway. 
Ubiquitin is attached to a substrate in a three-step cascade reaction mediated by E1, E2 and E3 
enzymes. First, ubiquitin is activated in an ATP-dependent reaction and covalently attached to a 
catalytic cysteine of the ubiquitin activating enzyme (E1). The activated ubiquitin is then transferred 
from the E1 to a catalytic cysteine of the ubiquitin conjugating enzyme (E2). Finally, the ubiquitin 
ligase (E3) catalyzes the transfer of the activated ubiquitin to the substrate. While ubiquitin forms 
thioester bonds with the enzymes of the ubiquitylation pathway, it is bound to the substrate via an 
isopeptide bond. Depending on the type of ubiquitin ligase, ubiquitin is either directly transferred from 
the E2 to the substrate (RING E3s) or ubiquitin is first attached to a catalytic cysteine of the E3 and 
then transferred to the substrate (HECT and RBR E3s). Ubiquitylation can have different 
consequences depending on the type of modification. For example, K48-linked polyubiquitylation is 
one of the most important modifications that targets the substrate protein for proteasomal degradation 
(modified from Nakayama and Nakayama, 2006).  
 
E1, E2 and E3 enzymes are hierarchically organized, with only two E1 enzymes, 
about 40 E2 enzymes and more than 600 E3 enzymes encoded by the human 
genome. As implicated by this organization, E3 enzymes are the components of the 
system that provide substrate specificity, whereas they share a limited number of E1 
and E2 enzymes with less specificity (Buetow and Huang, 2016). 
The above described ubiquitylation reaction represents the canonical and major 
pathway for labeling of substrate proteins with ubiquitin molecules. However, it has 
recently been discovered that this is not the only type of ubiquitylation reaction. 
  Introduction	 	  
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SdeA, a Legionella effector protein secreted into the host cytosol, is able to catalyze 
substrate ubiquitylation without the need for host E1, E2, E3 or ATP. Instead, it 
mediates the ADP-ribosylation of an arginine residue (R42) of ubiquitin in an NAD+-
dependent reaction. The ADP-ribosylated ubiquitin is then transferred to a serine 
residue of the substrate, releasing AMP and thereby forming a phospho-diester bond 
between the substrate and the phospho-ribosylated ubiquitin (Bhogaraju et al., 2016; 
Kotewicz et al., 2017; Qiu et al., 2016). In the future, it will be interesting to see 
whether this type of ubiquitylation reaction is also used by other pathogenic enzymes 
or even mammalian enzymatic systems and whether there are additional, yet 
undiscovered pathways that differ from the canonical ubiquitylation machinery. 
 
1.1.2. Types of ubiquitin ligases 
As already mentioned above, the family of E3 ubiquitin ligases represents the most 
diverse part of the ubiquitylation machinery. Based on their functional domains, 
ubiquitin ligases can be subdivided into three families, RING (Really Interesting New 
Gene), HECT (Homologous to E6-AP carboxyl terminus) and RBR (RING-
betweenRING-RING) ubiquitin ligases. 
There are about 600 RING ubiquitin ligases in humans. They either contain a RING 
domain, which binds zinc, or a U-box domain, which has a similar structure as the 
RING domain but lacks zinc. The RING or U-box domain is responsible for the 
recruitment of the E2, whereas other domains bind to the substrates. With respect to 
the ubiquitylation reaction, RING ubiquitin ligases serve as adaptors for the direct 
transfer of ubiquitin from the E2 to the substrate without covalently binding the 
transferred ubiquitin themselves (reviewed by Lipkowitz and Weissman, 2011). 
In contrast to RING E3s, the subfamily of HECT ubiquitin ligases is much smaller, 
comprising about 30 enzymes in humans. The HECT domain recruits the E2 enzyme. 
From the E2, the activated ubiquitin is first transferred to a catalytic cysteine in the 
HECT domain and is then transferred to the substrate. Therefore, in contrast to RING 
E3s, HECT ubiquitin ligases do not catalyze the direct transfer of ubiquitin to the 
substrate, but they form a ubiquitin-bound intermediate (reviewed by Rotin and 
Kumar, 2009). 
Finally, there are about 10 RBR ubiquitin ligases in humans. RBR E3s contain two 
predicted RING domains (RING1 and RING2), which are separated by an in-
between-RING (IBR) domain. RING1 recruits the E2, whereas RING2 contains a 
Introduction 
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catalytic cysteine. Similar to HECT E3s, the catalytic cysteine of RING2 covalently 
binds the activated ubiquitin before it is transferred to the substrate protein (reviewed 
by Smit and Sixma, 2014).  
 
1.1.3. The ubiquitin code 
The modification of a substrate protein with a single ubiquitin (monoubiquitylation) is 
only one possible outcome of the ubiquitylation reaction. Several additional types of 
ubiquitylation are possible, thus adding complexity to the ubiquitin code (reviewed by 
Komander and Rape, 2012; Yau and Rape, 2016). Instead of a single substrate 
lysine being modified by a single ubiquitin, multiple lysines can be modified by single 
ubiquitin molecules (multi-monoubiquitylation). In addition, ubiquitin chains can be 
formed on a substrate by adding further ubiquitin molecules to an already existing 
ubiquitin modification (polyubiquitylation). For this polyubiquitylation, the C-terminal 
carboxyl group of the newly attached ubiquitin gets covalently attached to the already 
existing ubiquitin modification via one of its lysine residues (K6, K11, K27, K29, K33, 
K48, K63) or via its N-terminal amino group (M1). The resulting polyubiquitin chain is 
either homotypic, with only one linkage type occurring in the whole chain, or 
heterotypic, with different ubiquitin linkage types within the chain. Heterotypic chains 
can be mixed chains, where every ubiquitin is linked to only one additional ubiquitin 
via one of its lysines or its N-terminus, or branched chains, where at least one 
ubiquitin in the chain is linked to more than one ubiquitin via its lysines or its N-
terminus. Moreover, the ubiquitin molecules can be modified themselves, for 
example by acetylation or by phosphorylation. In summary, these complexities 
enable the ubiquitin system to encode highly diverse information by modifying a 
specific substrate protein. 
 
1.1.4. Effects of substrate ubiquitylation 
The diverse topologies of different ubiquitin modifications are specifically recognized 
by ubiquitin receptors that use ubiquitin-binding domains (UBDs) to interact with 
ubiquitylated proteins. By specifically binding to ubiquitylated proteins, ubiquitin 
receptors are able to interprete the ubiquitin code and to link ubiquitylated proteins to 
corresponding effector pathways. For example, K48-linked polyubiquitin chains are 
recognized by the proteasome, which then degrades the ubiquitylated substrate 
protein and releases free ubiquitin monomers (Fig. 1). But also other effects apart 
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from degradation can be caused by ubiquitylation. Ubiquitylation plays a central role 
for important cellular processes such as NF-κB signaling, DNA repair, as well as 
xenophagy and mitophagy (reviewed by Dikic et al., 2009). 
 
1.1.5. Ubiquitin-like modifiers 
Similar to ubiquitin, ubiquitin-like modifiers have been discovered to become 
covalently attached to substrate proteins by a comparable machinery of E1s, E2s 
and E3s. Examples for ubiquitin-like modifiers are SUMO, NEDD8, ATG8, ATG15, 
ISG15 and FAT10. SUMO modifications have various effects, for example on the 
regulation of protein localization, signaling, DNA replication, transcription as well as 
DNA repair (reviewed by Flotho and Melchior, 2013). NEDD8 has mainly been 
characterized as an activator of Cullin-RING ubiquitin ligases, but also has other 
functions (reviewed by Enchev et al., 2015). ATG8 and ATG15 are regulators of 
autophagy (reviewed by Ohsumi, 2001). ISG15 and FAT10 are involved in the 
regulation of the immune system (reviewed by Liu et al., 2005). 
 
1.2. The SCF complex is a Cullin-RING ubiquitin ligase 
 
1.2.1. Cullin-RING ubiquitin ligases (CRLs) 
Among the large subfamily of RING E3s, there is a group of multi-subunit ubiquitin 
ligase complexes called Cullin-RING ubiquitin ligases (CRLs). CRLs have a modular 
organization (Fig. 2) and dramatically increase their potential of substrate binding by 
incorporating numerous interchangeable substrate recognition subunits (reviewed by 
Petroski and Deshaies, 2005; Skaar et al., 2013). 
CRLs all contain a central Cullin subunit. In humans, there are 6 closely related Cullin 
family members (CUL1, CUL2, CUL3, CUL4A, CUL4B and CUL5). In addition, there 
are two more distantly related Cullin proteins (CUL7 and CUL9), which form atypical 
Cullin-based ligase complexes. Also APC2, a central subunit of the APC/C, is related 
to the Cullin protein family. 
Within CRL complexes, the Cullin subunit serves as a central scaffold. On the one 
hand, it interacts with a RING domain containing protein (either RBX1 or RBX2), 
which is responsible for the recruitment of the E2 enzyme to the complex. On the 
other hand, the Cullin protein interacts with a substrate recognition module that 
recruits the substrate to the complex. In most cases, the substrate recognition 
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module consists of several subunits, a substrate binding subunit and one or two 
adaptor proteins that link the substrate binding subunit to the Cullin scaffold.  
 
Fig. 2: Overview of Cullin-RING ubiquitin ligases (CRLs). 
Six Cullin proteins (CUL1, CUL2, CUL3, CUL4A, CUL4B and CUL5) form canonical CRL complexes in 
humans. The Cullin protein serves as the central scaffold and recruits other subunits that mediate 
interactions with E2s and substrates. The RING domain containing proteins RBX1 and RBX2 recruit 
E2 enzymes to CRLs, whereas different substrate recognition modules have evolved for the different 
CRL complexes. SKP1 and F-box proteins form the substrate recognition module in CRL1 (SCF 
complex). SKP1 acts as an adaptor protein that interacts with the F-box domain of the F-box protein 
and thereby links the F-box protein to the rest of the complex. The F-box protein directly interacts with 
the substrate. Adaptor and substrate binding proteins are also found in CRL2/CRL5 (Elongin B and 
Elongin C as well as SOCS box proteins) and CRL4A/B (DDB1 and DCAF proteins). In CRL3, a BTB 
protein unites the functions of adaptor and substrate binding proteins. Atypical CRL complexes are 
formed by CUL7 and CUL9. Also the APC2 subunit of the APC/C is related to the Cullin protein family 
(adopted from Skaar et al., 2013). 
 
CUL1 binds to the adaptor protein SKP1 (S phase kinase-associated protein 1), 
which interacts with a substrate binding F-box protein. CUL2 as well as CUL5 use the 
two adaptor proteins Elongin B and Elongin C to recruit a SOCS (suppressor of 
cytokine signaling) box protein for substrate binding. CUL4A and CUL4B bind to the 
adaptor protein DDB1 (DNA damage-binding protein 1), whereas a DCAF (DDB1- 
and CUL4-associated factor) protein serves as the substrate binding subunit. CUL3, 
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however, interacts with a single BTB (bric-a-brac-tramtrack-broad complex) protein, 
which unites the functions of the adaptor and substrate binding proteins (reviewed by 
Petroski and Deshaies, 2005; Skaar et al., 2013). 
 
1.2.2. Regulation of CRL activity 
There are several mechanisms for the fine-tuning of CRL activity. Whereas many of 
them target specific CRL subunits and thereby have a limited effect on CRL 
complexes, other regulators have a more general effect on CRL activity. NEDD8 is a 
ubiquitin-like modifier that can be attached to a Cullin protein in a cascade reaction 
requiring E1, E2 and E3 enzymes. Modification of the Cullin subunit by neddylation 
causes a conformational change that increases the efficiency of ubiquitin transfer 
from the E2 to the substrate, thus enhancing CRL activity (Osaka et al., 1998; Read 
et al., 2000). On the other hand, the NEDD8 modification can be removed from the 
Cullin by the COP9 signalosome (Cope et al., 2002; Lyapina et al., 2001; Yang et al., 
2002). Furthermore, CAND1 (Cullin-associated and neddylation-dissociated 1) is a 
protein that binds to Cullins in their deneddylated state and promotes the interchange 
of substrate recognition modules within CRLs (Goldenberg et al., 2004; Liu et al., 
2002; Pierce et al., 2013; Zheng et al., 2002a). 
 
1.2.3. The SCF complex uses F-box proteins to target its substrates 
As described above, CRL1 complexes consist of a central CUL1 subunit, the RING 
domain containing protein RBX1, the adaptor protein SKP1 and an F-box protein. 
According to this composition, a CRL1 complex is also referred to as the SCF (SKP1-
CUL1-F-box protein) complex (Feldman et al., 1997). The SCF complex is the best-
characterized complex among the CRLs as many important substrates of the SCF 
have been identified and characterized. 
In humans, there are about 70 F-box proteins. They all share a conserved F-box 
domain, which was originally identified in Cyclin F (FBXO1) and which mediates the 
interaction with SKP1 (Bai et al., 1996; Skowyra et al., 1997). The F-box domain is 
necessary but not sufficient for the incorporation of an F-box protein into the SCF 
complex. In addition to the SKP1-F-box protein interaction, there is a direct 
interaction between the F-box protein and CUL1 (Zheng et al., 2002b). Therefore, F-
box proteins that interact with SKP1 are not necessarily incorporated into the SCF 
complex (Galan et al., 2001; Kaplan et al., 1997; Seol et al., 2001). 
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In addition to the F-box domain, there are further domains in F-box proteins that 
mediate interactions with substrates. According to these substrate binding domains, 
F-box proteins can be classified into three major subfamilies, FBXW proteins (with a 
WD40 domain), FBXL proteins (with a leucine-rich domain) and FBXO proteins (with 
other domains). 12 FBXW, 21 FBXL and 36 FBXO proteins are encoded by the 
human genome. As they are interchangeable within the SCF complex and many F-
box proteins have been shown to target numerous substrates for ubiquitylation, the 
SCF complex regulates a broad range of substrates and processes in the cell 
(reviewed by Skaar et al., 2013). 
Several F-box proteins recognize their substrate proteins upon posttranslational 
modification of degron motifs within the substrates. In many cases, F-box proteins 
bind to their substrates in a phospho-dependent manner, but also other 
modifications, such as glycosylation, induce substrate binding by F-box proteins 
(reviewed by Skaar et al., 2013). 
The SCF complex has a predominant role in the regulation of the cell cycle. 
Numerous F-box proteins were identified as regulators of important cell-cycle 
processes. For example, β-TRCP (FBXW1/FBXW11) regulates EMI1, an inhibitor of 
the APC/C, and PLK4, the master regulator of the centrosome-cycle (Cunha-Ferreira 
et al., 2009; Margottin-Goguet et al., 2003). FBXW5 mediates the degradation of 
SAS6 and EPS8, thus regulating centrosome duplication and mitotic progression 
(Puklowski et al., 2011; Werner et al., 2013). FBXW7 regulates Cyclin E (Koepp et 
al., 2001; Moberg et al., 2001; Strohmaier et al., 2001) and SKP2 (FBXL1) promotes 
the degradation of CDK inhibitors (Carrano et al., 1999; Tsvetkov et al., 1999; Yu et 
al., 1998), whereas FBXO28 promotes mitotic progression (Kratz et al., 2016). There 
are further examples of cell-cycle regulation by F-box proteins. But F-box proteins 
also control other essential cellular processes, such as NF-κB signaling, DNA 
damage repair and apoptosis. 
There are some well-characterized F-box proteins with pronounced roles in cancer. 
On the one hand, F-box proteins can have oncogenic functions by inducing the 
degradation of proteins with tumor suppressor functions. An example for such an 
oncogenic F-box protein is SKP2, which promotes the degradation of the CDK 
inhibitors p21 and p27. A well-characterized F-box protein with a tumor suppressor 
function is FBXW7 (reviewed by Wang et al., 2014). 
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1.3. FBXW7 is a tumor suppressor protein 
 
1.3.1. FBXW7 is conserved from yeast to human 
The F-box protein FBXW7 (also called FBW7, Fig. 3) was originally identified in 
Saccharomyces cerevisiae as CDC4 in a genetic screen for cell division cycle 
mutants (Hartwell et al., 1973). Additional orthologues were identified in 
Caenorhabditis elegans (SEL-10), Drosophila melanogaster (Archipelago, AGO) and 
mouse (Fbxw7). Identification of substrates in Caenorhabditis elegans and 
Drosophila melanogaster led to the characterization of the first FBXW7 substrates in 
humans, NOTCH1 and Cyclin E (Hubbard et al., 1997; Koepp et al., 2001; Moberg et 
al., 2001; Strohmaier et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: FBXW7 mediates the SCF-dependent ubiquitylation of important oncoproteins. 
FBXW7 (or FBW7) is an F-box protein that serves as the substrate binding subunit of the SCF 
complex. In addition to the F-box protein, the SCF complex contains the subunits CUL1, SKP1 and 
RBX1. The E2 binds to RBX1 and transfers an activated ubiquitin to the substrate. FBXW7 is able to 
dimerize, which is thought to increase substrate ubiquitylation efficiency. FBXW7 interacts with its 
substrates in a phospho-dependent manner. The CDC4 phosphodegron (CPD) is the motif that is 
recognized by FBXW7. CPDs usually contain two conserved phosphorylation sites, but one of the 
phosphorylation sites is also replaced by a negatively charged amino acid residue in some CPDs. 
Among the substrates of FBXW7 are important oncoproteins, like Cyclin E, NOTCH, MYC and JUN 
(shown in green). Also other cancer-related substrates are targeted by FBXW7, such as KLF5, TGIF1, 
MCL1, C/EBPδ, PGC-1α and MED13/MED13L (shown in blue). By promoting the proteasomal 
degradation of these substrates, FBXW7 has a pronounced tumor suppressor function (adopted from 
Davis et al., 2014). 
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1.3.2. Domain organization of human FBXW7 
FBXW7 contains several conserved domains with important functions. Like all F-box 
proteins, FBXW7 contains an F-box domain that mediates the interaction with SKP1 
and thereby enables the incorporation of FBXW7 into the SCF complex (Fig. 4). 
Moreover, FBXW7 contains a WD40 domain for substrate binding and a dimerization 
domain (reviewed by Davis et al., 2014; Welcker and Clurman, 2008). FBXW7 
dimerization has been shown to improve the efficiency of substrate ubiquitylation as 
the number of lysines within the substrate that can be attacked by E2s from two 
different positions is increased (Hao et al., 2007; Kominami et al., 1998; Tang et al., 
2007; Welcker and Clurman, 2007; Welcker et al., 2013; Zhang and Koepp, 2006). 
 
Fig. 4: FBXW7 domain organization. 
In humans, there are three FBXW7 isoforms, called FBXW7α, FBXW7β and FBXW7γ. The isoforms 
only differ in their N-terminal domains, whereas the rest of the protein is conserved among the 
isoforms. Due to an NLS in its N-terminal domain, FBXW7α is localized in the nucleoplasm. FBXW7β 
contains a transmembrane domain (TMD) in its N-terminal domain, which targets it to cytoplasmic 
membranes of the ER. FBXW7γ is localized in nucleoli. The conserved part of FBXW7 contains the F-
box domain, which interacts with SKP1, a WD40 domain, which binds FBXW7 substrates, and a 
dimerization (DD) domain (modified from Welcker and Clurman, 2008). 
 
1.3.3. Human FBXW7 isoforms 
In humans, there are three FBXW7 isoforms, FBXW7α, FBXW7β and FBXW7γ. The 
different isoforms are produced by alternative splicing and the isoform transcripts 
only differ in their first exon (Fig. 4). Consistently, the protein isoforms contain 
different N-terminal domains, whereas the rest of the protein, including the 
dimerization, F-box and WD40 domains, is shared by all FBXW7 isoforms (Spruck et 
al., 2002). 
The differences in the N-terminal FBXW7 domains lead to different FBXW7 isoform 
localizations. FBXW7α localizes to the nucleoplasm, whereas FBXW7β resides in the 
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cytoplasm and FBXW7γ is found in nucleoli (Kimura et al., 2003; Welcker et al., 
2004).  
FBXW7 isoforms also show tissue-specific expression. While FBXW7α is 
ubiquitously expressed, FBXW7β is mainly found in the brain and FBXW7γ is highly 
expressed in muscles. In general, FBXW7α shows higher expression levels than 
FBXW7β and FBXW7γ in many cell lines (Matsumoto et al., 2006; Spruck et al., 
2002). 
 
1.3.4. The CDC4 phosphodegron 
FBXW7 recognizes its substrates via a short, phosphorylated degron motif that was 
first identified in yeast and is therefore called CDC4 phosphodegron or CPD (Nash et 
al., 2001). The CPD usually contains two conserved phosphorylation sites, which are 
embedded in a proline-rich environment (Table 1). Instead of the phosphorylation 
sites, some CPDs contain negatively charged amino acid residues (glutamate or 
aspartate). CPDs with negatively charged residues instead of one or both 
phosphorylation sites are considered as weak degrons. Substrates with weak CPDs 
usually require the dimerization of FBXW7 for their efficient ubiquitylation, whereas 
dimerization-deficient mutants of FBXW7 are not able to mediate the ubiquitylation of 
these substrates (Welcker et al., 2013). 
 
Table 1: Overview of representative CDC4 phosphodegron (CPD) motifs in Cyclin E, NOTCH1, 
MYC and JUN.  
For each protein, the known degron sequences are specified. A CPD usually contains a central 
phosphorylation site (marked in red), which is embedded in a proline-rich environment. Counting from 
the central phosphorylation site, there is an additional phosphorylation site or a negatively charged 
amino acid residue in the +4 position (marked in bold). The position of the central phosphorylation site 
in the protein sequence is indicated. The conserved CPD motif has also been discovered in other 
FBXW7 substrates. 
protein name degron sequence position reference 
Cyclin E 
 
NOTCH1 
MYC 
JUN 
LIPTPDKEDDD 
GLLTPPQSGKK 
PFLTPSPESPD 
LLPTPPLSPSR 
PGETPPLSPID 
T62 
T380 
T2512 
T58 
T239 
(Strohmaier et al., 2001) 
 
(Thompson et al., 2007) 
(Yada et al., 2004) 
(Wei et al., 2005) 
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The phospho-dependent recognition of substrates by FBXW7 enables different 
kinases to mediate the regulation of substrates by FBXW7. FBXW7 thereby 
integrates signals from different pathways in order to ensure ubiquitylation of its 
substrates in the correct context and under the right conditions. A kinase that is 
involved in the phosphorylation of many FBXW7 substrates is GSK3 (reviewed by 
Davis et al., 2014; Welcker and Clurman, 2008). 
 
1.3.5. FBXW7 substrates 
 
1.3.5.1. FBXW7 mediates the degradation of important oncoproteins 
One of the first identified FBXW7 substrates was Cyclin E (Koepp et al., 2001; 
Moberg et al., 2001; Strohmaier et al., 2001). Cyclin E is an important oncoprotein 
that regulates cell-cycle entry and proliferation in cooperation with CDK2 (Dulić et al., 
1992; Koff et al., 1992). Cyclin E contains two CPDs (Table 1), a strong degron 
around threonine 380 (T380) and a weak degron around threonine 62 (T62). 
Interestingly, Cyclin E is involved in its own degradation because CDK2 
phosphorylates T380 together with GSK3 and a second phosphorylation site in the 
strong degron motif, S384. By this feedback mechanism, Cyclin E degradation is 
coupled to CDK2 activity (Clurman et al., 1996; Welcker et al., 2003; Won and Reed, 
1996; Ye et al., 2004). A mechanism that opposes the autocatalytically induced 
degradation of Cyclin E is the dephosphorylation of S384 by the PP2A-B56 
phosphatase (Davis et al., 2017). 
NOTCH is an additional important oncoprotein that is regulated by FBXW7 (Hubbard 
et al., 1997). NOTCH is a transmembrane protein, whose intracellular domain gets 
cleaved by the γ-secretase proteolytic complex and translocates to the nucleus. In 
the nucleus, the NOTCH intracellular domain acts as a transcription factor that 
regulates differentiation (reviewed by Artavanis-Tsakonas et al., 1999; Radtke et al., 
2005). Interestingly, the NOTCH pathway is not only regulated by FBXW7 via the 
degradation of its key player NOTCH. In addition, FBXW7 mediates the degradation 
of Presenilin, which has a NOTCH-activating function because it is part of the γ-
secretase proteolytic complex (Li et al., 2002; Wu et al., 1998). 
MYC and JUN are transcription factors that are frequently found overexpressed in 
cancer. By regulating the expression levels of their downstream target genes, MYC 
and JUN positively regulate cell growth and proliferation (reviewed by Grandori et al., 
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2000; Shaulian and Karin, 2002). FBXW7 has a negative effect on this regulation by 
mediating the degradation of MYC and JUN (Nateri et al., 2004; Yada et al., 2004). 
Because of the immense importance of the oncoproteins Cyclin E, NOTCH, MYC and 
JUN for the cell, their protein levels are tightly regulated. Therefore, not all of these 
proteins are solely regulated by the SCF-FBXW7 complex. For example, Cyclin E is 
additionally regulated by SCF-SKP2 and a CRL3 complex (Nakayama et al., 2000; 
Singer et al., 1999). However, as FBXW7 is involved in the regulation of these 
important oncoproteins, FBXW7 has a prominent tumor suppressor function within 
the cell. 
 
1.3.5.2. Regulation of transcription by FBXW7 
As already described above, FBXW7 regulates the protein levels of transcription 
factors with important oncogenic functions. In addition, FBXW7 mediates the 
degradation of further proteins involved in the regulation of transcription, whose roles 
in FBXW7-linked cancers are not well-characterized so far. However, it is interesting 
that FBXW7 is able to indirectly regulate the levels of a plethora of proteins involved 
in many different processes by mediating the degradation of their upstream 
transcription factors.  
For example, FBXW7 has been shown to regulate the lipid and energy metabolism 
via SREBP and PGC-1α (Olson et al., 2008; Sundqvist et al., 2005), angiogenesis via 
HIF-1α (Cassavaugh et al., 2011; Flügel et al., 2012), pancreatic cell differentiation 
via NGN3 (Sancho et al., 2014), heat-shock response via HSF1 (Kourtis et al., 2015) 
and the amplitude of the circadian clock via REV-ERBα (Zhao et al., 2016). 
Moreover, the cancer-related transcription factors SRC3, KLF5 and MYB were 
identified as FBXW7 substrates (Kanei-Ishii et al., 2008; Liu et al., 2010; Wu et al., 
2007b; Zhao et al., 2010). FBXW7 indirectly regulates TGFβ signaling by mediating 
the degradation of TGIF1, a negative regulator of TGFβ-dependent transcription 
(Bengoechea-Alonso and Ericsson, 2010). 
In addition to transcription factors, FBXW7 has also been identified as a regulator of 
the Mediator complex. The Mediator subunits MED13 and MED13L serve as the 
direct substrates of FBXW7 within the Mediator complex (Davis et al., 2013). The 
Mediator complex is involved in a broad range of transcriptional processes, thus 
highlighting the pronounced role of FBXW7 in the regulation of transcription. 
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1.3.5.3. FBXW7 is a regulator of cell survival 
FBXW7 regulates apoptosis by mediating the degradation of MCL1. MCL1 is an 
oncogenic protein with an anti-apoptotic function. In the absence of FBXW7, cell 
survival is increased, thus promoting chemoresistance (Inuzuka et al., 2011; Wertz et 
al., 2011). 
FBXW7 additionally regulates cell survival by targeting the NF-κB pathway. The NF-
κB pathway component p100 is a substrate of FBXW7. Depending on the tissue 
context, the regulation of p100 by FBXW7 has different effects on cell survival. 
Whereas some publications have shown a negative regulation of cell survival by 
FBXW7-mediated p100 degradation, FBXW7 was shown to act as a pro-survival 
factor in multiple myeloma (Arabi et al., 2012; Busino et al., 2012; Fukushima et al., 
2012). 
 
1.3.5.4. Other substrates of FBXW7 
There are additional FBXW7 substrates in the literature that cannot be classified 
according to the above categories. The Aurora kinases Aurora-A and Aurora-B are 
important cell-cycle regulators. They have both been suggested as substrates of 
FBXW7 (Mao et al., 2004; Teng et al., 2012). Also the mTOR kinase, which regulates 
cell growth and proliferation, is regulated by FBXW7 (Mao et al., 2008). Finally, 
FBXW7 supports antiviral responses by mediating the degradation of SHP2, which 
leads to the stabilization of RIG-I, a receptor that recognizes RNA viruses (Song et 
al., 2017). 
 
1.3.6. FBXW7 is frequently mutated in human cancers 
Consistent with its role as a tumor suppressor protein, FBXW7 is frequently found 
mutated in cancer. While FBXW7 is mutated in about 10% of all human tumors, there 
are clear differences in FBXW7 mutation rates depending on the cancer type. While 
FBXW7 is often found mutated in T-ALL, cholangiocarcinoma, colorectal cancer and 
endometrial cancer, it hardly shows mutations in breast cancer or leukemia apart 
from T-ALL (reviewed by Davis et al., 2014; Welcker and Clurman, 2008). 
Interestingly, there is a strong selection for certain heterozygous FBXW7 hot-spot 
mutations in cancer. Most mutations are found in the WD40 domain of FBXW7, and 
especially three arginine residues (R465, R479, R505) that mediate interactions with 
substrate CPDs are frequently mutated. These point mutations occur much more 
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often than truncations or heterozygous deletions of FBXW7. This surprising finding is 
explained by the fact that arginine point mutants of FBXW7 are still able to form 
dimers with wild-type FBXW7 via their dimerization domain. It is thought that this 
dimerization of wild-type and mutated versions of FBXW7 could have dominant-
negative effects (reviewed by Davis et al., 2014; Welcker and Clurman, 2008). 
 
1.3.7. Regulation of FBXW7 
As described above, the downstream effects of FBXW7 are already well-
characterized. On the other hand, the upstream regulation mechanisms of FBXW7 
are still being identified and are only poorly understood so far. In the following, known 
mechanisms for the regulation of FBXW7 expression, protein stability, localization 
and activity will be described. 
 
1.3.7.1. Regulation of FBXW7 expression by transcription factors 
p53 has been described to positively regulate FBXW7 transcription. However, p53 
does not have a general effect on overall FBXW7 transcript levels, but specifically 
induces the expression of FBXW7β (Kimura et al., 2003; Mao et al., 2004). On the 
other hand, C/EBP-δ and HES5 were shown to repress FBXW7 expression. HES5 
was described to specifically target FBXW7β expression (Balamurugan et al., 2010; 
Sancho et al., 2013). 
 
1.3.7.2. Regulation of FBXW7 expression by microRNAs 
Protein expression is negatively regulated by microRNAs as they cause degradation 
of the corresponding mRNA or inhibition of translation (reviewed by Jonas and 
Izaurralde, 2015). FBXW7 expression is targeted by several microRNAs, including 
miR-25, miR-27a, miR-92a and miR-223 (Lerner et al., 2011; Lu et al., 2012; Xu et 
al., 2010; Zhou et al., 2015). 
 
1.3.7.3. Regulation of FBXW7 protein stability 
Like many other ubiquitin ligases, FBXW7 performs auto-ubiquitylation within the 
SCF complex (Galan and Peter, 1999). The level of FBXW7 auto-ubiquitylation is 
regulated by other proteins. For example, GLMN binds to the RBX1 subunit of the 
SCF complex and inhibits its activity. The inhibition of SCF-FBXW7 activity caused by 
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GLMN binding causes an increased FBXW7 auto-ubiquitylation, thus leading to 
decreased FBXW7 protein levels (Tron et al., 2012).  
Another regulator of FBXW7 auto-ubiquitylation is PIN1. PIN1 was suggested to 
directly bind FBXW7 and inhibit its dimerization. The resulting FBXW7 monomers 
showed an increase in auto-ubiquitylation (Min et al., 2012). However, these findings 
are still under debate because another study showed that only ectopic FBXW7 
monomers are unstable, whereas there is no difference between endogenous 
FBXW7 monomer and dimer stabilities. Moreover, the inhibitory effect of PIN1 on 
FBXW7 dimerization could not be confirmed (Welcker et al., 2013). 
PLK2 was shown to phosphorylate FBXW7, thereby promoting its destabilization 
(Cizmecioglu et al., 2012). An additional study showed that FBXW7 is stabilized upon 
phosphorylation by PI3K (Schülein et al., 2011). 
The only ubiquitin ligase that has been identified as a regulator of FBXW7 protein 
levels so far is Parkin. However, Parkin is not a general regulator of all human 
FBXW7 isoforms. Instead, it specifically regulates the protein levels of FBXW7β 
(Ekholm-Reed et al., 2013). 
It was suggested that FAM83D regulates the protein levels of FBXW7 (Wang et al., 
2013). However, the mechanism of this putative regulation is only poorly 
characterized so far and further investigation is required to confirm this observation. 
As observed for many other proteins that are degraded after ubiquitylation, FBXW7 is 
stabilized by the de-ubiquitylating activity of DUBs. USP28 is involved in the 
regulation of FBXW7 protein levels (Schülein-Völk et al., 2014). 
 
1.3.7.4. Regulation of FBXW7 protein localization 
As the three human FBXW7 isoforms reside in different compartments of the cell, a 
change in FBXW7 isoform localization affects FBXW7 function. In the literature, there 
are examples for factors that are able to regulate FBXW7 localization. The FBXW7 
pseudosubstrate EBP2 was shown to mediate the nucleolar localization of FBXW7γ 
(Welcker et al., 2011). Moreover, protein kinase C (PKC) phosphorylates FBXW7α in 
close proximity of one of its NLS motifs and thereby modulates the nuclear 
localization of FBXW7α (Durgan and Parker, 2010). 
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1.3.7.5. Regulation of SCF-FBXW7 ubiquitin ligase activity 
The ubiquitin ligase activity of the SCF-FBXW7 complex can be regulated without 
affecting the protein levels of FBXW7 or other SCF subunits. As described above, 
there are general mechanisms for the regulation of overall SCF activity, including 
neddylation or CAND1 activity. However, there are proteins that have been described 
as specific regulators of SCF-FBXW7 activity. 
The pseudophosphatase STYX has been suggested to inhibit SCF-FBXW7 activity 
by the direct interaction with the F-box domain of FBXW7, thereby preventing the 
incorporation into the SCF complex. As the F-box domain is conserved among F-box 
proteins, further analysis of the specificity of this mechanism is required (Reiterer et 
al., 2017). On the other hand, NUMB4 has been suggested to promote the formation 
of the SCF-FBXW7 complex (Jiang et al., 2012). 
 
1.4. MYCBP2 and FBXO45 form a ubiquitin ligase complex 
MYCBP2 (MYC binding protein 2) or PAM (protein associated with MYC) is a large, 
~500 kDa protein that was originally identified as a MYC interaction partner in human 
cells (Guo et al., 1998). MYCBP2 is a member of the conserved PHR protein family. 
Its orthologues are called RPM-1 in Caenorhabditis elegans, Highwire in Drosophila 
melanogaster and Phr1 in mouse. Apart from an RCC1-like domain and two PHR 
domains, whose functions are only poorly characterized so far, MYCBP2 contains a 
RING domain, providing MYCBP2 with ubiquitin ligase activity (reviewed by Grill et 
al., 2016; Po et al., 2010).  
FBXO45 is an F-box protein that has been shown to interact with MYCBP2. The 
interaction between FBXO45 and MYCBP2 is conserved, as the FBXO45 
orthologues (FSN-1 in Caenorhabditis elegans and DFsn in Drosophila 
melanogaster) interact with the corresponding orthologues of MYCBP2 (Liao et al., 
2004; Saiga et al., 2009; Wu et al., 2007a). Together with MYCBP2, FBXO45 forms a 
RING ubiquitin ligase complex, where the RING domain is provided by MYCBP2. 
This complex also contains SKP1, whereas it is not clear whether CUL1 is involved in 
the complex formation. FBXO45 contains a conserved F-box domain and a SPRY 
domain, which recruits substrates to the ubiquitin ligase complex (Chen et al., 2014; 
Kugler et al., 2010). 
MYCBP2 and FBXO45 show high expression levels in the nervous system. In 
invertebrates, they are specifically expressed in the nervous system, while they are 
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also found in other tissues in vertebrates. They have conserved functions in the 
nervous system, including the regulation of synapse and axon formation (reviewed by 
Grill et al., 2016; Po et al., 2010). MYCBP2 and FBXO45 orthologues partly fulfill their 
functions in the nervous system by mediating the ubiquitin-dependent degradation of 
the MAP kinase pathway regulator DLK-1/Wallenda in C. elegans and Drosophila 
(Nakata et al., 2005; Wu et al., 2007a). 
In human cells, MYCBP2 was described as a negative regulator of adenylyl cyclase 
activity (Pierre et al., 2004). In addition, it was shown to promote the degradation of 
Tuberin and the GDP/GTP exchange of Rheb, leading to a positive regulation of 
mTOR signaling (Han et al., 2008; Maeurer et al., 2009; Murthy et al., 2004). 
Furthermore, a guanosine exchange factor function of MYCBP2 with respect to Ran 
was proposed in the nervous system (Dörr et al., 2015). 
Human FBXO45 inhibits apoptosis by promoting the degradation of p73 and PAR4 
(Chen et al., 2014; Peschiaroli et al., 2009). The degradation of p73 has been 
suggested to depend on the canonical SCF complex. Therefore, the question 
remains whether FBXO45 can act as an E3 ligase only in complex with MYCBP2 or 
also in complex with the canonical SCF. 
 
1.5. RAE1 is a mitotic regulator that interacts with MYCBP2 
RAE1 is a WD40 domain containing protein that was originally identified as an mRNA 
export factor in yeast (Brown et al., 1995). In vertebrates, RAE1 has been described 
to regulate the mitotic checkpoint as loss of RAE1 leads to mitotic checkpoint defects 
and chromosome missegregation (Babu et al., 2003). Furthermore, RAE1 mediates 
mitotic spindle assembly in a ribonucleoprotein complex as well as in cooperation 
with NUMA (Blower et al., 2005; Wong et al., 2006). In addition, RAE1 inhibits 
APC/C-CDH1 during mitosis (Jeganathan et al., 2005).These findings indicate that 
RAE1 has important functions with respect to mitotic progression. 
Two studies in Drosophila melanogaster and Caenorhabditis elegans have identified 
RAE1 as an interaction partner of the corresponding MYCBP2 orthologues (Grill et 
al., 2012; Tian et al., 2011). The interaction between RAE1 and MYCBP2 is 
conserved. However, the functional mechanism of this interaction remains elusive. 
While Drosophila RAE1 stabilizes Highwire by preventing its autophagy-dependent 
degradation, C. elegans RAE1 is proposed to act downstream of RPM-1. 
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1.6. XIAP is an anti-apoptotic ubiquitin ligase 
XIAP (X chromosome-linked IAP, also called BIRC4) is a RING ubiquitin ligase that 
belongs to the IAP (inhibitor of apoptosis protein) family. Additional IAP family 
members that are encoded by the human genome are cellular IAPs (cIAP1 and 
cIAP2) as well as neuronal IAP (NIAP), melanoma IAP (MLIAP), IAP-like protein 2 
(ILP2), Survivin and Apollon (reviewed by Fulda and Vucic, 2012). 
Similar to other IAP family members, XIAP has an anti-apoptotic function. On the one 
hand, XIAP prevents apoptosis by inhibiting caspases. XIAP is both able to promote 
the ubiquitin-dependent degradation of caspases and to inhibit caspases in a 
ubiquitin-independent manner (Deveraux et al., 1997; Eckelman et al., 2006; Suzuki 
et al., 2001a). Moreover, XIAP negatively regulates apoptosis by stimulating the NF-
κB pathway (Hofer-Warbinek et al., 2000). 
XIAP binds to its substrates via BIR (baculoviral IAP repeat) domains, which are 
conserved among the IAP family (reviewed by Fulda and Vucic, 2012). Interestingly, 
XIAP inhibitors have evolved which act as pseudosubstrates and bind to the BIR 
domains of XIAP and other IAP family members, thereby preventing the interaction of 
IAPs with their substrates. Two proteins that have been identified as IAP inhibitors 
are SMAC and HTRA2/OMI (Du et al., 2000; Suzuki et al., 2001b). 
XIAP and other IAPs are frequently found overexpressed in human cancers and are 
thought to promote cancer by inhibiting cancer cell apoptosis. Therapeutic 
approaches aim at mimicking the SMAC motif that is responsible for the interactions 
with IAPs. The corresponding drugs are called SMAC mimetics. They are tested in 
clinical trials as they have the potential to sensitize cancer cells to apoptotic stimuli 
(reviewed by Fulda and Vucic, 2012). 
 
1.7. Objectives 
FBXW7 is an important tumor suppressor protein that is frequently found mutated in 
human cancers (reviewed by Davis et al., 2014; Welcker and Clurman, 2008). The 
downstream network of FBXW7 substrates is already well-characterized. As 
described above, FBXW7 promotes the degradation of proteins that are involved in 
the regulation of processes like transcription, cell-cycle progression and cell survival. 
However, the regulation of FBXW7 itself by upstream effectors is only poorly 
understood so far. Apart from factors that influence FBXW7 expression, there are 
only few known regulators of FBXW7 protein stability. It has been described that 
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FBXW7 protein levels are regulated by auto-ubiquitylation (Galan and Peter, 1999). 
In addition, auto-ubiquitylation can be modulated by additional factors, such as PIN1 
and GLMN (Min et al., 2012; Tron et al., 2012). Moreover, kinases like PLK2 and 
PI3K were shown to phosphorylate FBXW7 and thereby regulate FBXW7 protein 
stability (Cizmecioglu et al., 2012; Schülein et al., 2011). However, it is not clear 
whether phospho-dependent changes in FBXW7 stability are solely mediated by its 
auto-ubiquitylation or whether there are additional E3 ligase(s) regulating FBXW7 
degradation. The only E3 ligase that has been shown to regulate FBXW7 protein 
levels so far is Parkin (Ekholm-Reed et al., 2013). But this regulation has only been 
observed for the FBXW7β isoform, whereas E3 ligases regulating the other FBXW7 
isoforms remain to be identified. In the literature, there are several well-studied 
examples of key ubiquitin ligases, which are regulated by other E3s. For example, 
the degradation of the oncogenic F-box protein SKP2 is promoted by APC/C-CDH1 
(Bashir et al., 2004; Wei et al., 2004). It is conceivable that ubiquitin ligases with 
pronounced tumor suppressor or oncogenic functions need to be tightly controlled by 
several upstream pathways in order to prevent cancer formation. The identification of 
novel FBXW7 regulators has the potential to link an important tumor suppressor with 
novel upstream oncogenic pathways. 
This study therefore aims to identify and characterize novel regulators of FBXW7. In 
order to identify such regulators, I will perform a screen for FBXW7 interaction 
partners. The screen will be based on an immunoprecipitation and mass 
spectrometry approach. FBXW7 interaction partners with E3 ubiquitin ligase activity 
are regarded as putative FBXW7 regulators. In order to confirm the regulation of 
FBXW7 by the identified proteins, the interactions between FBXW7 and its regulators 
will be verified. Moreover, I will analyze the effects of the putative regulators on 
FBXW7 protein levels. Finally, the functional mechanism underlying FBXW7 
regulation needs to be identified and characterized. 
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2. Materials and methods 
 
2.1. Materials 
 
2.1.1. Chemicals and reagents 
Acetic acid Sigma-Aldrich 
Agar Sigma-Aldrich 
Agarose Sigma-Aldrich 
Ammonium peroxodisulfate (APS) Roth 
Ampicillin AppliChem 
Amylose resin New England Biolabs 
Aprotinin Roche 
Bio-Rad Protein Assay Bio-Rad 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
CL4B sepharose Pharmacia 
Coomassie Brilliant Blue G250 Roth 
CnBr-activated sepharose 4B GE Healthcare 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dithiothreitol (DTT) Roth 
1 kb DNA ladder Invitrogen 
100 bp DNA ladder Invitrogen 
DNA polymerase (DeepVent) New England Biolabs 
dNTPs  GE Healthcare 
ECL Western blotting substrate Millipore 
Ethanol Sigma-Aldrich 
Ethanolamine Sigma-Aldrich 
Ethidiumbromide AppliChem 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Fetal bovine serum (FBS) Sigma-Aldrich, 
 Thermo Scientific 
Flag M2 affinity gel, 3xFlag peptide Sigma-Aldrich 
Glucose Merck 
Glycerol VWR 
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Glycine AppliChem 
α-HA agarose Sigma-Aldrich 
Hydrochloric acid VWR 
Kanamycin AppliChem 
IPTG Biomol 
Isopropanol Sigma-Aldrich 
Leupeptin Roche 
Lipofectamine 2000 Invitrogen 
Maltose Sigma-Aldrich 
β-mercaptoethanol Sigma-Aldrich 
Methanol Sigma-Aldrich 
Milk powder Roth 
MG132 (Z-Leu-Leu-Leu-al) Sigma-Aldrich 
N-ethylmaleimide (NEM) Sigma-Aldrich 
Nocodazole Applichem 
Nonidet NP40 (Igepal) MP Biochemicals 
Oligonucleotides/primers Sigma-Aldrich 
PBS Thermo Scientific 
Ortho-Phosphoric acid 85% Roth 
PIN Roche 
Ponceau S solution Serva 
Polyethylenimine linear MW ~25000 Polysciences 
Prolong Gold Molecular Probes 
Protein A Sepharose GE Healthcare 
Protein marker PageRuler Thermo Scientific 
Protogel (acrylamide/bisacrylamide) National Diagnostic 
Restriction enzymes New England Biolabs 
RiboLock RNase inhibitor Thermo Scientific 
[35S]-methionine Perkin Elmer 
Sodium azide Merck 
Sodium chloride Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Gerbu 
Sodium fluoride Merck 
Sodium hydroxide J.T. Baker 
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Sodium vanadate Sigma-Aldrich 
T4 DNA ligase Thermo Scientific 
N,N,N‘,N‘-Tetramethylethylenediamine (TEMED) Roth 
Thymidine Sigma-Aldrich 
TLCK (1-Chloro-3-tosylamido-7-amino-2-butanon) Roche 
TPCK (1-Chloro-3-tosylamido-7-amino-2-heptanon) Roche 
Triton X-100 Sigma-Aldrich 
Trizma base Sigma-Aldrich 
0.05% Trypsin-EDTA Thermo Scientific 
Trypton Roth 
Tween 20 Sigma-Aldrich 
Yeast extract Gerbu 
 
2.1.2. Laboratory equipment 
Autoradiography cassettes Dr. Goos Suprema Neolab 
Autoradiography films Fuji X-Ray Film RX1824 Fuji 
Cell counting chamber Neubauer Improved Brand 
Cell culture dishes Cellstar Greiner Bio-One 
Centrifuges 5415 R Eppendorf 
 5810 R Eppendorf 
 Fresco 17 Thermo Scientific 
 Megafuge 1.0R Heraeus 
 RC5C Sorvall 
 Varifuge RF Heraeus 
 WX Ultra 80 Thermo Scientific 
Developing machine CURIX 60 AGFA 
DNA gel electrophoresis Wide Mini-Sub Cell Bio-Rad 
Electrotransfer unit Transblot SD Bio-Rad 
Filter paper  Whatman 
Fluorescence microscope Cell Observer Z1 Zeiss 
Fridge (4°C) ProfiLine Liebherr 
Freezer (-20°C) Premium Liebherr 
Freezer (-80°C) -80°C/HeraFreeze Heraeus/Sanyo 
Gel documentation Gelstick Intas 
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Glassware Glass pipettes, measuring Brand, Schott 
 cylinders, flasks, bottles 
Heat block Thermomixer Compact Eppendorf 
Incubation shaker Minitron Infors HT 
Laboratory balance Extend Sartorius 
Light microscope Axio Vert. A1 Zeiss 
Live-cell imaging dish µ-Slide 8 Well Ibidi 
Luminescent image analyzer ImageQuant LAS 4000 GE Healthcare 
Magnetic stirrers Ikamag RTC IKA Labortechnik 
Microplate absorbance reader SPECTROstar Nano BMG Labtech 
Microwave  Sharp 
Nitrocellulose membrane Amersham Protran 0.45 µm GE Healthcare 
PAGE system Mini Protean III Bio-Rad 
Parafilm Parafilm M New England Biolabs 
PCR thermocycler Mastercycler epgradient S Eppendorf 
pH-meter Seven Easy Mettler Toledo 
Photometer BioPhotometer Eppendorf 
Pipettes Pipetman Gilson 
Pipettor Pipetboy Integra 
Plasticware Reaction tubes, falcons, Eppendorf, Nerbe 
 pipette tips, PCR tubes, Plus, Falcon, Biozym, 
 petri dishes Greiner Bio-One 
Power supply PowerPac Basic/HC Bio-Rad 
Rocking platform shaker Duomax 2030 Heidolph 
Rotating wheel Test tube rotator Snijders 
Sonifier Sonifier 250 Branson 
Sterile workbench Sterile GARD Hood A/B3 Baker Company 
(Ultra)centrifuge tubes  Beckmann 
Vacuum dryer Geldryer 583 Bio-Rad 
Vortex shaker VF2 IKA Labortechnik 
Water bath 12B Julabo EM 
 WNB7 Memmert 
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2.1.3. Buffers and media 
Column buffer: 20 mM Tris-HCl pH 7.4 
 200 mM NaCl 
 1 mM EDTA 
 10 mM β-mercaptoethanol 
 
6x DNA sample buffer: 0.25% bromophenol blue 
 50 mM Tris-HCl pH 7.6 
 60% glycerol in ddH2O 
 
4x Laemmli buffer: 0.1 M Tris-HCl pH 6.8 
 4% SDS 
 20% glycerol 
 0.1 M DTT 
 0.02% bromophenol blue 
 
LB agar plates: 3% agar in LB medium 
 
LB medium: 10 g/l Trypton 
 5 g/l yeast extract 
 10 g/l NaCl 
 pH 7.0 
 
NP40 lysis buffer: 40 mM Tris-HCl pH 7.5 
 150 mM NaCl 
 5 mM EDTA 
 10 mM β-glycerophosphate 
 5 mM NaF 
 0.5% NP40 
 freshly added before use: 
 1 mM DTT 
 10 µg/ml TPCK 
 5 µg/ml TLCK     
 0.1 mM Na3VO4 
Materials and methods 
30 
 1 µg/ml Aprotinin 
 1 µg/ml Leupeptin 
 10 µg/ml Trypsin inhibitor from soybean 
 
PBS: 140 mM NaCl 
 2.7 mM KCl 
 1.5 mM KH2PO4 
 8.1 mM Na2HPO4 
 pH 7.4 
 
PBST: 0.05% Tween-20 in PBS 
 
RIPA lysis buffer: 50 mM Tris-HCl pH 7.4 
 1% NP40 
 0.5% Na-deoxycholate 
 0.1% SDS 
 150 mM NaCl 
 2 mM EDTA 
 50 mM NaF 
 freshly added before use: 
 1 mM DTT 
 10 µg/ml TPCK 
 5 µg/ml TLCK     
 0.1 mM Na3VO4 
 1 µg/ml Aprotinin 
 1 µg/ml Leupeptin 
 10 µg/ml Trypsin inhibitor from soybean 
 
SDS running buffer: 190 mM glycine 
 25 mM Tris-HCl, pH 8.3 
 0.1% SDS 
 
Semi-dry transfer buffer: 39 mM glycine 
 48 mM Tris 
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 3.7% SDS 
 20% methanol 
 
TAE buffer: 40 mM Tris-HCl pH 7.6 
 20 mM acetic acid 
 1 mM EDTA 
 
TBS: 50 mM Tris-HCl pH 7.4 
 150 mM NaCl 
 
Western blot blocking buffer: 5% milk powder in PBST 
 
Wet transfer buffer: 25 mM Tris 
 192 mM glycin 
 20% methanol 
 
2.1.4. Antibodies 
 
2.1.4.1. Primary antibodies 
Primary antibodies that were used in the presented thesis are summarized in 
Table 2. 
 
Table 2: List of primary antibodies. 
antibody origin WB 
dilution 
clone source 
Caspase-3 
Cyclin B1 
Cyclin E 
FBXO45 
FBXW7α 
Flag (tag) 
HA (tag) 
MCL1 
rabbit 
rabbit 
mouse 
rabbit 
rabbit 
mouse 
mouse 
rabbit 
1:500 
1:1000 
1:1000 
1:500 
1:1000 
1:5000 
1:1000 
1:1000 
H-277 
--- 
HE12 
NBP1-91891 
A301-720A 
M2 (F3165) 
16B12 
4572 
Santa Cruz 
I.Hoffmann, DKFZ 
Santa Cruz 
Novus 
Bethyl 
Sigma-Aldrich 
Babco 
Cell Signaling 
MYC rabbit 1:1000 9402 Cell Signaling 
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Myc (tag) 
MYCBP2 
RAE1 
SKP1 
α-Tubulin 
Ubiquitin 
Vinculin 
mouse 
rabbit 
rabbit 
rabbit 
mouse 
mouse 
mouse 
1:500 
1:750 
1:1000 
1:1000 
1:10000 
1:1000 
1:5000 
9E10 
--- 
--- 
H-163 
B-5-1-2 
P4D1 (sc-8017) 
hVIN-1 
Santa Cruz 
(Dörr et al., 2015) 
(Blower et al., 2005) 
Santa Cruz 
Sigma-Aldrich 
Santa Cruz 
Sigma-Aldrich 
WDR5 
XIAP 
rabbit 
mouse 
1:1000 
1:5000 
--- 
610763 
(Wysocka et al., 2003) 
BD Biosciences 
 
 
2.1.4.2. Secondary antibodies 
Secondary antibodies that were used in the presented thesis are summarized in 
Table 3. 
 
Table 3: List of secondary antibodies. 
antibody origin WB dilution source 
α-mouse IgG HRP 
α-rabbit IgG HRP 
goat 
donkey 
1:5000 
1:5000 
Novus 
Jackson Laboratories 
 
 
2.1.5. Small interfering RNAs (siRNAs) 
Small interfering RNAs (siRNAs) that were used in the presented thesis are 
summarized in Table 4. 
 
Table 3: List of siRNAs. 
siRNA name siRNA sequence (5‘-3‘) target gene source 
cIAP1 
CUL4A 
DCAF7 
DDB1 
FBXO45 #1 
FBXO45 #2 
FBXO45 #3 
 
GGCUUGAGGUGUUGGGAAUtt 
GACAAUCCGAAUCAGUACCtt 
GCUGAUCGCCCAUGACAAAtt 
ACACUUUGGUGCUCUCUUUtt 
GGAGAAAGAAUUCGAGUCAtt 
ACACAUGGUUAUUGCGUAUtt 
GGAGAAAGAAUUCGAGUCA 
ACACAUGGUUAUUGCGUAU 
cIAP1 
CUL4A 
DCAF7 
DDB1 
FBXO45 
FBXO45 
FBXO45 
 
Ambion 
Ambion 
Ambion 
Ambion 
Eurofins 
Eurofins 
Dharmacon 
(SMARTpool) 
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FBXW2 #1 
FBXW2 #2 
FBXW7 
GL2 
MYCBP2 #1 
MYCBP2 #2 
 
 
 
SHPRH #1 
SHPRH #2 
TRAF2 #1 
TRAF2 #2 
UBR5 
VPRBP 
XIAP 
AAACACAUGAAGUCGUAAA 
GUAUGAAACUGGUUGGGUU 
CGGUGAAGUUUGAUGAACAtt 
CAUGCUGCCUCGUCUCUAAtt 
ACAGGACAGUGUUUACAAAtt 
CGUACGCGGAAUACUUCGAtt 
CCCGAGAUCUUGGGAAUAAtt 
GGAAGUAGUUCUGUUAUUU 
GCAGAAAUGCCCACACUUU 
GAAUAGUUGUGGUUGGUUU 
GCAAGGAUUUGGUGUGUGU 
GAUACGAUGUUCAACGGAAtt 
GGUCUGAAACUCUACUAUAtt 
CGAGGGCAUAUAUGAAGAAtt 
GGACCACGUCAAGACUUGUtt 
AGACAAAUCUCGGACUUGAtt 
GAUGGCGGAUGCUUUGAUAtt 
AAGTGCTTTCACTGTGGAGGA 
 
 
FBXW2 
FBXW2 
FBXW7 
firefly luciferase 
MYCBP2 
MYCBP2 
 
 
 
SHPRH 
SHPRH 
TRAF2 
TRAF2 
UBR5 
VPRBP 
XIAP 
 
 
Ambion 
Ambion 
Ambion 
Ambion/Eurofins 
Eurofins 
Dharmacon 
(SMARTpool) 
 
 
Ambion 
Ambion 
Ambion 
Ambion 
Ambion 
Ambion 
Eurofins 
 
 
2.1.6. Primers 
Primers that were used in the presented thesis for the generation of plasmids are 
summarized in Table 4. 
 
Table 4: List of primers for the generation of plasmids. 
primer name primer sequence (5’-3’) no. 
Flag_Fbxo45_1-110_BamHI_Fw 
 
Flag_Fbxo45_1-110_XhoI_Rv 
 
Flag_Fbxo45_111-287_BamHI_Fw 
 
Flag_Fbxo45_111-287_XhoI_Rv 
 
Flag_MycBP2_1-1500_XhoI_Fw 
GCATGGATCCATGGCGGCGC
CG 
GCATCTCGAGTCAAGCACGTA
TCTTGGCCTTG 
GCATGGATCCTTTCAACATGC
CTTCAGC 
GCATCTCGAGCGGCCGCTCAT
C 
GCATCTCGAGATGCCGGTTCC
1 
 
2 
 
3 
 
4 
 
5 
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Flag_MycBP2_1-1050_XhoI_Rv 
 
Flag_MycBP2_1051-1950_XhoI_Fw 
 
Flag_MycBP2_1051-1950_XhoI_Rv 
 
Flag_MycBP2_1951-2950_XhoI_Fw 
 
Flag_MycBP2_1951-2950_XhoI_Rv 
 
Flag_MycBP2_2951-3600_XhoI_Fw 
 
Flag_MycBP2_2951-3600_XhoI_Rv 
 
Flag_MycBP2_3601-4640_XhoI_Fw 
 
Flag_MycBP2_2951-4640_XhoI_Rv 
 
Myc-Flag-Rae1_EcoRI_Fw 
 
Myc-Flag-Rae1_HindIII_Rv 
 
Flag-Fbxw7_C322_deltaF4_HindIII_Rv 
 
Flag_Fbxw7_C9_EcoRI_Fw 
 
Flag_Fbxw7_C19_EcoRI_Fw 
 
Flag_Fbxw7_C40_EcoRI_Fw 
 
Flag_Fbxw7_C85_EcoRI_Fw 
 
Flag_Fbxw7_C127_EcoRI_Fw 
CGACGGC 
GCATCTCGAGCTAGCCTATTA
TGTGTTTACTGGC 
GCATCTCGAGTTGGTACCTGC
TTCTATATCAGAACC 
GCATCTCGAGCTAATACTTCT
GATTCAAAATGGCAACTG 
GCATCTCGAGGCACCGCCTGC
CTTCAACC 
GCATCTCGAGCTATATTTTGG
GAGATGCTCTCATTTCC 
GCATCTCGAGAGTCGAAAATG
TGCTAATAGACAC 
GCATCTCGAGCTAGTCTGAGA
GTGGATGTTCAC 
GCATCTCGAGATAGTGATTGC
CGGGGAAGC 
GCATCTCGAGCTAAAAAGTGT
GGGCATTTCTGC 
GCATGAATTCATGAGTCTGTTT
GGATCAACC 
GCATAAGCTTCTATTTCTTATT
CCTTGGCTTTAGC 
GCATAAGCTTTCACTTCATGTC
CACATC 
GCATGAATTCGGGCAGCAAAA
GACGACGAACTGG 
GCATGAATTCGCTGAGAGGTA
ACCCTTCCTCAAGCC 
GCATGAATTCGGAACAGCAAC
AGCAACTCAG 
GCATGAATTCGATTTCGGTAG
ATGAGGACTCC 
GCATGAATTCGCAGTCTGATG
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
 
15 
 
16 
 
17 
 
18 
 
19 
 
20 
 
21 
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Flag_Fbxw7_C148_EcoRI_Fw 
 
Flag_Fbxw7_C168_EcoRI_Fw 
 
Flag_Fbxw7_C322_EcoRI_Fw 
 
Flag_Fbxw7_N283_N515_deltaF1_ 
EcoRI_Fw 
Flag_Fbxw7_delta40-167_Fw 
 
Flag_Fbxw7_delta40-167_Rv 
 
Flag_Fbxw7_delta40-84_Fw 
 
Flag_Fbxw7_delta40-84_Rv 
 
Flag_Fbxw7_delta85-167_Fw 
 
Flag_Fbxw7_delta85-167_Rv 
 
Flag_Fbxw7_delta106-126_Fw 
 
Flag_Fbxw7_delta106-126_Rv 
 
Flag_Fbxw7_deltaF2_Rv 
 
Flag_Fbxw7_deltaF3_Fw 
 
Flag_Fbxw7_N105_HindIII_Rv 
 
Flag_Fbxw7_N117_HindIII_Rv 
 
Flag_Fbxw7_N126_HindIII_Rv 
ATAGTAGCAGAG 
GCATGAATTCGAGTATTGTGG
ACCTGCCCGTTC 
GCATGAATTCGATGAAAAGAA
AGTTGGACCATG 
GCATGAATTCGAGAGAGAAAT
GCAAAGAAGAGG 
GCATGAATTCGATGAATCAGG
AACTGCTC 
CGTGTGGTAGAGGAGATGAAA
AGAAAGTTGG 
CCAACTTTCTTTTCATCTCCTC
TACCACACG 
CGTGTGGTAGAGGAGATTTCG
GTAGATGAG 
CTCATCTACCGAAATCTCCTCT
ACCACACG 
GAAAACAATAATAGATTTATGA
AAAGAAAGTTGG 
CCAACTTTCTTTTCATAAATCT
ATTATTGTTTTC 
GATGAAGAACATGCTCAGTCT
GATGATAGTAG 
CTACTATCATCAGACTGAGCAT
GTTCTTCATC 
TTTGCATTTCTCTCTCAATGAA
ATGAAGTC 
GACTTCATTTCATTGAGAGAGA
AATGCAAA 
GCATAAGCTTTCAAGCATGTTC
TTCATCTTCCTC 
GCATAAGCTTTCACTCCTCCTC
CTCCTCATCC 
GCATAAGCTTTCAATCAAAATC
 
23 
 
24 
 
25 
 
26 
 
27 
 
28 
 
29 
 
30 
 
31 
 
32 
 
33 
 
34 
 
35 
 
36 
 
37 
 
38 
 
39 
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Flag_Fbxw7_N137_HindIII_Rv 
 
Flag_Fbxw7_N147_HindIII_Rv 
 
Flag_Fbxw7_N157_HindIII_Rv 
 
Flag_Fbxw7_N167_new_HindIII_Rv 
 
Flag_Fbxw7_N283_HindIII_Rv 
 
Flag_Fbxw7_N515_HindIII_Rv 
 
His_XIAP_NdeI_Fw 
 
His_XIAP_SalI_Rv 
 
MBP_Fbxw7_FL_N167_EcoRI_Fw 
 
MBP_Fbxw7_N283_HindIII_Rv 
GTCACTCTCC 
GCATAAGCTTTCAATGTTCATC
TTCTCTGCTAC 
GCATAAGCTTTCAACTGGAGT
TCGTGACACTG 
GCATAAGCTTTCAGAGTTGGT
GAACGGGCAGG 
GCATAAGCTTTCATTTTGTTGT
TTTTGTATAGAATGG 
GCATAAGCTTTCACAATGAAAT
GAAGTCTCGTTG 
GCATAAGCTTTCAAACAACCCT
CCTGCCATCATATTG 
GATCCATATGACTTTTAACAGT
TTTG 
GATCGTCGACCGTAATACGAC
TCACTATAG 
GATCGAATTCATGAATCAGGA
ACTGCTCTCTG 
GATCAAGCTTTCACAATGAAAT
GAAGTCTCGTTG 
 
40 
 
41 
 
42 
 
43 
 
44 
 
45 
 
46 
 
47 
 
48 
 
49 
 
 
2.1.7. Plasmids 
Provided and generated plasmids that were used in the presented thesis are 
summarized in Table 5 and in Table 6. 
 
Table 5: List of provided plasmids. 
plasmid (antibiotic resistance, used as  
DNA template no.) 
source 
HA-mRAE1 (ampicillin, 1) 
HA-Ubiquitin (ampicillin) 
pCDNA3-Flag-FBXW7αΔWD40 (ampicillin) 
pCDNA3.1-Flag-FBXO45 (ampicillin, 2) 
D. Lyles, Wake Forest Bapt. Health 
T. Hofmann, DKFZ 
M. Pagano, New York, USA 
A. Peschiaroli, Rome 
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pCDNA3.1-Flag-FBXW5 (ampicillin) 
pCDNA-Flag-SKP2 (ampicillin) 
pCMV-3Tag1A/C, pCMV-3Tag2A (kanamycin) 
pCMV-3Tag1A-Flag-DCAF5 (kanamycin) 
pCMV-3Tag1A-Flag-FBXO28 (kanamycin) 
pCMV-3Tag1A-Flag-PLK4 (kanamycin) 
pCMV-3Tag1C-Flag-FBXW7α (kanamycin, 3) 
pCMV-Flag-FBXW7β (ampicillin) 
pCMV-Flag-FBXW7γ (ampicillin) 
pCMV-Flag-MISP (kanamycin) 
pCMV-Myc-CUL4A (kanamycin) 
pCMV-Myc-DDB1 (kanamycin) 
pCMV-Myc-MYCBP2 (kanamycin, 4) 
pCS2-HA-XIAP (ampicillin, 5) 
pCS2-Myc-XIAP (ampicillin) 
pMAL-C2 (ampicillin) 
F. Melchior, ZMBH Heidelberg 
I. Hoffmann, DKFZ 
Agilent 
A.-S. Kratz, DKFZ 
M. Schmitt, DKFZ 
M. Arnold, DKFZ 
O. Cizmecioglu, DKFZ 
B. Clurman, Seattle, USA 
B. Clurman, Seattle, USA 
F. Settele, DKFZ 
Y. Xiong, Chapel Hill, USA 
M. Arnold, DKFZ 
Addgene #42570 
E. Lee, Vanderbilt university 
E. Lee, Vanderbilt university 
NEB 
 
 
Table 6: List of plasmids generated by PCR or by PCR-free subcloning. 
plasmid DNA 
template 
no. 
primer no. enzymes 
pCDNA3.1-HA-FBXO45 
pCMV-3Tag1A-Flag-FBXO45 
pCMV-3Tag1A-Flag-FBXO45-N110 
pCMV-3Tag1A-Flag-FBXO45-C111 
pCMV-3Tag2A-Myc-FBXO45 
pCMV-3Tag1A-Flag-MYCBP2(1-1050) 
pCMV-3Tag1A-Flag-MYCBP2(1051-1950) 
pCMV-3Tag1A-Flag-MYCBP2(1951-2950) 
pCMV-3Tag1A-Flag-MYCBP2(2951-3600) 
pCMV-3Tag1A-Flag-MYCBP2(3601-4640) 
pCMV-3Tag1A-Flag-RAE1 
pCMV-3Tag1A-Flag-XIAP 
2 
2 
2 
2 
2 
4 
4 
4 
4 
4 
1 
5 
--- 
--- 
1,2 
3,4 
--- 
5,6 
7,8 
9,10 
11,12 
13,14 
15,16 
--- 
BamHI/XhoI 
BamHI/XhoI 
BamHI/XhoI 
BamHI/XhoI 
BamHI/XhoI 
XhoI 
XhoI 
XhoI 
XhoI 
XhoI 
EcoRI/HindIII 
EcoRI/SalI 
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pCMV-3Tag1C-Flag-FBXW7α-C9 
pCMV-3Tag1C-Flag-FBXW7α-C19 
pCMV-3Tag1C-Flag-FBXW7α-C40 
pCMV-3Tag1C-Flag-FBXW7α-C85 
pCMV-3Tag1C-Flag-FBXW7α-C127 
pCMV-3Tag1C-Flag-FBXW7α-C148 
pCMV-3Tag1C-Flag-FBXW7α-C168 
pCMV-3Tag1C-Flag-FBXW7α-C322 
pCMV-3Tag1C-Flag-FBXW7αΔ40-167 
pCMV-3Tag1C-Flag-FBXW7αΔ40-84 
pCMV-3Tag1C-Flag-FBXW7αΔ85-167 
pCMV-3Tag1C-Flag-FBXW7αΔ106-126 
pCMV-3Tag1C-Flag-FBXW7αΔF-box 
pCMV-3Tag1C-Flag-FBXW7α-N105 
pCMV-3Tag1C-Flag-FBXW7α-N117 
pCMV-3Tag1C-Flag-FBXW7α-N126 
pCMV-3Tag1C-Flag-FBXW7α-N137 
pCMV-3Tag1C-Flag-FBXW7α-N147 
pCMV-3Tag1C-Flag-FBXW7α-N157 
pCMV-3Tag1C-Flag-FBXW7α-N167 
pCMV-3Tag1C-Flag-FBXW7α-N283 
pCMV-3Tag1C-Flag-FBXW7α-N515 
pET22b-His-XIAP 
pMAL-MBP-FBXW7α-N167 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
5 
3 
17,18 
17,19 
17,20 
17,21 
17,22 
17,23 
17,24 
17,25 
17,26,27,28 
17,26,29,30 
17,26,31,32 
17,26,33,34 
17,26,35,36 
26,37 
26,38 
26,39 
26,40 
26,41 
26,42 
26,43 
26,44 
26,45 
46,47 
48,49 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
EcoRI/HindIII 
NdeI/SalI 
EcoRI/HindIII 
 
 
2.1.8. Bacterial strains 
The following bacterial strains were used in the presented thesis: 
E. coli XL1-Blue: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
 [F‘ proAB lacIqZΔM15 Tn10 (Tetr)]; Agilent Technologies 
E. coli Rosetta (DE3): F-ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR); 
 Merck 
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2.1.9. Cell lines 
Cell lines that were used in the presented thesis are summarized in Table 7. 
 
Table 7: List of cell lines. 
cell line cell type source 
HCT116 FBXW7 +/+, 
HCT116 FBXW7-/- 
 
 
HEK-293T 
 
 
HeLa 
 
U2OS 
Human colorectal carcinoma cells; the 
FBXW7 alleles are either wild-type (+/+) or 
have been inactivated by homologous 
recombination (-/-) 
Human embryonic kidney cells; the cells 
constitutively express the SV40 large T 
antigen 
Human epithelial cervix adenocarcinoma 
cells; the cells contain HPV-18 sequences 
Human osteosarcoma cells 
(Rajagopalan et 
al., 2004) 
 
 
ATCC 
 
 
ATCC 
 
ATCC 
 
 
2.1.10. Kits 
The following kits were used in the presented thesis: 
PureLink Quick Gel Extraction Kit Invitrogen 
QIAGEN Plasmid Maxi Kit QIAGEN 
QIAGEN Plasmid Midi Kit QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
TNT Coupled Reticulocyte Lysate System Promega 
 
2.1.11. Antibiotics 
Antibiotics that were used in the presented thesis are summarized in Table 8. 
 
Table 8: List of antibiotics. 
antibiotic stock concentration working concentration 
ampicillin 
kanamycin 
100 mg/ml in ddH2O 
50 mg/ml in ddH2O 
100 µg/ml 
50 µg/ml 
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2.2. Methods 
 
2.2.1. Methods in molecular biology 
 
2.2.1.1. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was performed in order to amplify DNA fragments 
for molecular cloning. Forward and reverse primers were designed so that they 
contained restriction sites. By using these primers for the PCR, the amplified DNA 
fragments contained the corresponding restriction sites at their 5’ and 3’ ends. Thus, 
the DNA fragments could be inserted into DNA vectors with the same restriction 
sites. 
 
PCR reactions were composed as follows: 
ThermoPol Reaction Buffer (NEB): 1x 
DNA template: 50 ng 
Forward primer: 1 µM 
Reverse primer: 1 µM 
dNTP mix: 0.5 mM 
Deep Vent DNA polymerase (NEB): 1 U 
ddH2O: add to 50 µl 
 
The PCR was performed in a PCR thermocycler with the following settings: 
Initial denaturation: 95°C, 2 min 
Denaturation:  95°C, 30 s 
Annealing: 50-60°C, 30s 30 cycles 
Elongation: 72°C, 1 min/kb 
Final elongation:  72°C, 5 min 
Cooling: 4°C 
 
The annealing temperature was chosen depending on the melting temperatures (Tm) 
of the primers. The time for the elongation step depended on the length of the 
amplified DNA fragment. After the PCR, the amplified DNA fragment was analyzed 
by agarose gel electrophoresis or purified using the PureLink Quick or the QIAquick 
gel extraction kits. 
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2.2.1.2. Agarose gel electrophoresis 
Agarose gel electrophoresis was performed in order to separate DNA fragments 
according to their size. Agarose gels were prepared by boiling 1% agarose in TAE 
buffer. After the agarose was completely dissolved, the solution was poured into a 
gel chamber. A comb was inserted into the solution in order to allow well formation. 
Ethidium bromide was added to a final concentration of 0.5 µg/ml to the solution. 
After the gel had solidified, it was placed into an electrophoresis chamber. The 
electrophoresis chamber was filled with TAE buffer until the gel was covered. The 
DNA samples were mixed with 6x DNA sample buffer and loaded into the wells of the 
gel. A molecular weight DNA ladder (100 bp or 1 kb) was loaded into an additional 
well of the gel in order to allow estimation of DNA fragment sizes. The gel was run at 
100 V until the dye line was approximately 50% of the way down the gel. DNA 
fragments in the gel were visualized by UV light. UV light at a wavelength of either 
312 nm (for analytical gels) or 366 nm (for preparative gels) was used. 
 
2.2.1.3. Restriction digest of DNA 
DNA fragments or DNA vectors were digested by different combinations of restriction 
enzymes (NEB). In the case of DNA fragments obtained after PCR, the entire PCR 
product was used for the restriction digest. In the case of DNA vectors, 1-5 µg of 
DNA were used for the restriction digest. Reactions were performed with 0.5-1 µl of 
each restriction enzyme and the corresponding NEB reaction buffer in a total volume 
of 50 µl. The restriction digest reaction was incubated at 37°C for 1-2 h or over night. 
Reaction buffers, enzyme combinations, and the length of incubation was chosen 
according to the manufacturer’s recommendations. Digested DNA was separated by 
analytical or preparative agarose gel electrophoresis. Digested DNA was extracted 
from preparative gels as described in 2.2.1.4. 
 
2.2.1.4. Extraction of DNA fragments from agarose gels 
In order to extract DNA fragments from preparative agarose gels, DNA fragments in 
the gel were visualized by UV light at a wavelength of 366 nm. The desired DNA 
band was cut out from the gel and transferred to a reaction tube. The DNA was 
extracted from the agarose gel using the PureLink Quick or the QIAquick gel 
extraction kit. The extraction was performed according to the manufacturer’s 
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instructions. The DNA was finally eluted with 30-50 µl ddH2O. DNA concentration 
was determined as described in 2.2.1.8. 
 
2.2.1.5. Ligation of DNA fragments 
After restriction digest, preparative agarose gel electrophoresis and gel extraction, 
purified PCR products and DNA vector backbones were ligated. 50 ng of linearized 
vector DNA was mixed with a fourfold molar concentration of the insert. The DNA 
mixture was incubated with 2 U of T4 DNA ligase and 1x T4 DNA ligase buffer 
(Thermo) in a total volume of 10 µl. The ligation reaction was carried out at RT for 
1 h. The whole ligation reaction was used for the transformation of chemically 
competent E. coli XL1-Blue as described in 2.2.1.6. 
 
2.2.1.6. Transformation of chemically competent E. coli 
Chemically competent E. coli XL1-Blue were transformed for plasmid amplification 
and cloning purposes, whereas chemically competent E. coli Rosetta (DE3) were 
transformed for protein expression. 1 µg of plasmid DNA or 10 µl of a ligation 
reaction were mixed with 100 µl of chemically competent E. coli and incubated on ice 
for 15 min. The bacteria were then heat-shocked at 42°C for 90 s. After the heat-
shock, the transformation reactions were incubated on ice for 2 min. 1 ml of LB 
medium was added to the bacteria and the cell suspension was incubated at 37°C for 
1 h with gentle shaking at 180 rpm. Finally, the bacteria were centrifuged at maximal 
speed in an Eppendorf 5415 R centrifuge for 1 min. The cell pellet was resuspended 
in 100 µl of LB medium and the cell suspension was evenly spread on an LB agar 
plate containing the appropriate antibiotic (for antibiotic concentrations, see 2.1.11.). 
The LB agar plate was incubated over night at 37°C. Single E. coli colonies were 
used for the inoculation of overnight cultures containing the appropriate antibiotic. 
 
2.2.1.7. Isolation of plasmid DNA from E. coli 
E. coli XL1-Blue cells transformed with plasmid DNA were incubated over night in 
5 ml (for Miniprep) or 200-250 ml (for Midi- and Maxiprep) LB medium containing the 
appropriate antibiotic at 37°C with constant shaking at 180 rpm. The plasmid DNA 
was isolated from the bacteria with the QIAprep Spin Miniprep Kit or the QIAGEN 
Plasmid Midi/Maxi Kits according to the manufacturer’s instructions. Finally, the DNA 
was dissolved in ddH2O. DNA concentration was measured as described in 2.2.1.8. 
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0.5-1 µg of isolated plasmid DNA was analyzed by restriction digest. Plasmid DNA 
was sequenced with the sequencing services of GATC Biotech or LGC Genomics. 
 
2.2.1.8. Determination of DNA concentration 
DNA concentration was determined with a microplate absorbance reader 
(SPECTROstar Nano, BMG Labtech). 2 µl of the DNA solution were applied onto an 
LVis plate (BMG Labtech). 2 µl of ddH2O were used as a blank. The optical density of 
the samples was measured at 260 nm and 280 nm. The DNA concentration was 
calculated based on the fact that for a pathlength of 1 cm, an OD260 of 1 corresponds 
to a concentration of double-stranded DNA of 50 µg/ml. The ratio of OD260 and OD280 
was calculated in order to evaluate the quality of the isolated DNA. An OD260/OD280 
ratio of about 1.8 indicates that the DNA solution is pure. 
 
2.2.2. Methods in cell biology 
 
2.2.2.1. Cell culture 
Human cell lines were grown in a humidified atmosphere with 5% CO2 at 37°C. HeLa 
and U2OS cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma-Aldrich) with 1 g/l glucose. HEK-293T cells were grown in DMEM with 4.5 g/l 
glucose. HCT116 cells were cultured in McCoy’s 5A Modified Medium. The media 
were supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich or Thermo 
Scientific).  
When the cells reached a confluency of 80-90%, they were subcultured. They were 
washed once with PBS (Thermo Scientific) and were then incubated for 3-5 min with 
0.05% Trypsin-EDTA (Thermo Scientific) at 37°C. After the cells had detached from 
the cell culture dish, they were resuspended in fresh growth medium. 10-40% of the 
cell suspension were transferred into a fresh cell culture dish for further culturing. 
Cell culture work was performed under sterile conditions. Cell line authentication was 
regularly performed by Multiplexion in Heidelberg. 
 
2.2.2.2. Harvesting and freezing of cells 
HeLa, U2OS and HCT116 cells were harvested by washing with PBS and incubation 
with 0.05% Trypsin-EDTA for 5 min at 37°C. After the cells had detached from the 
cell culture dish, they were resuspended in fresh growth medium. Alternatively, HEK-
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293T cells were detached from the cell culture dish by rinsing them with growth 
medium. Cell suspensions were transferred to centrifuge tubes and they were 
centrifuged at 1300 rpm for 3 min (Eppendorf 5810 R or Heraeus Megafuge 1.0R). 
Cell pellets were washed once with PBS. Finally, the cell pellets were directly used 
for the preparation of cell extracts or they were stored at -80°C. 
For cell freezing, the cells were washed with PBS and detached from the cell culture 
dish by incubation with 0.05% Trypsin-EDTA for 5 min at 37°C. The cells were 
resuspended in growth medium and centrifuged at 1300 rpm for 3 min. The cell pellet 
was washed with PBS once. Finally, the cell pellet was resuspended in 1 ml of 
freezing medium (growth medium supplemented with 10% DMSO and 20% FBS 
instead of 10% FBS) and the cell suspension was transferred to a 1.5 ml cryo vial 
(Thermo Scientific). The cell suspension was frozen using a freezing container 
(Nalgene, Thermo Scientific) with a rate of cooling of -1°C/min. When the cryo vial 
had reached a temperature of -80°C, it was transferred to liquid nitrogen for long-
term storage. 
 
2.2.2.3. Transient transfection of mammalian cells 
 
2.2.2.3.1. Transfection of cells with plasmid DNA using polyethylenimine (PEI) 
HEK-293T cells were transiently transfected with plasmid DNA using 
polyethylenimine (PEI, Polysciences). Cells were seeded into cell culture dishes so 
that they reached a confluency of 70-80% on the day of transfection. For 
transfections in 10 cm/15 cm dishes, 5-10 µg/10-15 µg of plasmid DNA were mixed 
with 1.7 ml/4.6 ml of DMEM (4.5 g/l glucose, without FBS) and 34.2 µl/92.5 µl PEI 
(1 mg/ml in ddH2O, pH 7.4, sterile filtered). The transfection mixture was vortexed 
and incubated at RT for 10 min. 5 ml/14 ml of DMEM (4.5 g/l glucose, 5% FBS) were 
added to the transfection mixture. The transfection mixture was vortexed and added 
to the cells. The cells were incubated at 37°C and harvested 24-48 h after 
transfection. If the cells were harvested 48 h after transfection, the transfection 
mixture was removed 24 h after transfection and replaced by fresh growth medium. 
 
2.2.2.3.2. Transfection of cells with siRNA using Lipofectamine 2000 
For the transfection of HeLa or U2OS cells with siRNA, the transfection reagent 
Lipofectamine 2000 was used according to the manufacturer’s instructions. Cells 
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were seeded into 6-well plates (1x105 cells/well) one day before transfection. For 
each well, 5 µl of Lipofectamine 2000 were diluted in 150 µl of DMEM (1 g/l glucose, 
without FBS). In addition, 30 pmol of siRNA (for a final concentration of 30 nM) were 
diluted in 150 µl of DMEM (1 g/l glucose, without FBS). After an incubation for 5 min 
at RT, both mixtures were combined and incubated for 15 min at RT. The transfection 
mixture was added to the cells in a dropwise manner in a final volume of 1 ml. The 
cells were harvested 72 h after transfection. 
 
2.2.2.4. Cell cycle synchronization 
In order to arrest HeLa cells in G1/S phase, a double-thymidine block was performed. 
The cells were treated with 2 mM thymidine for 16 h. After the first thymidine block, 
the cells were released into the cell cycle by washing three times with PBS and 
incubation in fresh growth medium for 8 h. The release was followed by a second 
thymidine block with 2 mM thymidine for 16 h. The cells were finally released from 
the double-thymidine block by washing three times with PBS and incubation in fresh 
growth medium. 10-12 h after the release, the cells were enriched in mitosis. 
In order to arrest HeLa cells in prometaphase, cells were first synchronized in G1/S 
phase by treatment with 2 mM thymidine for 17 h. The cells were released into the 
cell cycle by washing three times with PBS and incubation with fresh growth medium 
for 5 h. Finally, the cells were treated with 100-250 ng/ml nocodazole for 16-17 h. 
Mitotic cells were collected by a mitotic shake-off. 
 
2.2.2.5. MG132 and cycloheximide treatment 
In order to inhibit proteasomal degradation in HEK-293T cells, the cells were treated 
with 10 µM MG132 (Sigma-Aldrich) for 4-5 h before harvesting. In order to inhibit 
protein synthesis in HeLa cells, they were treated with 100 µg/ml cycloheximide 
(Sigma-Aldrich). For a cycloheximide chase assay, the cells were harvested at 
different time points after cycloheximide treatment. 
 
2.2.2.6. Live-cell imaging 
For the analysis of mitotic cell fate, live-cell imaging was performed. U2OS cells were 
transfected with 30 nM siRNA targeting GL2, FBXW7, FBXO45 or MYCBP2. 48 h 
after transfection, 2.5 x 104 cells were seeded into Ibidi dish chambers. 72 h after 
transfection, the cells were treated with 250 ng/ml nocodazole. 4 h after the 
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nocodazole treatment, the cells were monitored by a 10x/0.3 EC PlnN Ph1 DICI 
objective on a Zeiss Cell Observer Z1 inverted microscope (AxioCam MRm camera 
system) with incubation at 5% CO2 and 37°C. Multi-tile phase-contrast images were 
taken every 10 min for 48 h using the Zeiss ZEN blue software. Data analysis was 
performed with ImageJ Fiji software. Cell death was defined by cell morphology and 
cessation of movement. Mitotic slippage was defined by mitotic exit without cell 
division. 
 
2.2.3. Methods in protein biochemistry 
 
2.2.3.1. Preparation of protein extracts from mammalian cells 
For the preparation of HeLa, HEK-293T or HCT116 cell extracts, the cells were 
harvested as described in 2.2.2.2. Cell pellets were resuspended in 3-5 volumes of 
RIPA or NP40 lysis buffer. RIPA lysis buffer was used for the preparation of HCT116 
cell extracts. HEK-293T and HeLa cell extracts were either prepared with NP40 lysis 
buffer (for immunoprecipitations) or with RIPA lysis buffer (for the analysis of protein 
levels in whole cell extracts and for in vivo ubiquitylation assays). The cell lysates 
were incubated on ice for 30 min with short vortexing every 5-10 min. The lysates 
were cleared by centrifugation at maximal speed and 4°C in an Eppendorf 5415 R 
centrifuge for 15 min. The supernatants were transferred to fresh reaction tubes. The 
protein concentration of the extracts was determined as described in 2.2.3.2. For 
long-term storage, the cell extracts were frozen in liquid nitrogen and kept at -80°C. 
For SDS-PAGE, the cell extracts were mixed with equal volumes of 2x Laemmli 
buffer and incubated at 95°C for 5 min. 
 
2.2.3.2. Determination of protein concentration 
The protein concentration of a cell extract was determined according to the Bradford 
method in a Bio-Rad Protein assay. 1 µl of a cell extract was diluted in 800 µl of 
ddH2O. For the calibration curve, different amounts of BSA (0 µg, 3 µg, 5 µg, 7 µg, 
10 µg) were diluted in 800 µl of ddH2O. 200 µl of Bio-Rad Protein Assay solution 
were added to each reaction tube and the solutions were mixed by inverting the 
tubes three times. 200 µl of each mixture were transferred to a 96-well plate and the 
OD595 was measured with a microplate reader. Protein concentration of the cell 
extract was calculated by comparing the OD595 with the calibration curve. 
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2.2.3.3. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed in order to 
separate proteins according to their molecular weight. For the preparation and 
running of polyacrylamide gels, the Mini-Protean vertical electrophoresis system (Bio-
Rad) was used. Each polyacrylamide gel consisted of a stacking gel and a 
separating gel. The stacking gel contained 5% acrylamide (5% 
acrylamide/bisacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0.1% 
TEMED), whereas the separating gel contained 7-15% acrylamide depending of the 
size of the proteins to be resolved (7-15% acrylamide/bisacrylamide, 375 mM Tris-
HCl pH 8.8, 0.1% SDS, 0.1% APS, 0.1% TEMED). After the polyacrylamide gel had 
polymerized, 10-30 µg of protein of each sample were incubated in Laemmli buffer at 
95°C for 5 min and loaded onto the gel. 3 µl of a prestained protein marker 
(PageRuler) were also loaded onto the gel in order to allow estimation of protein size. 
The gel was run at 20 mA/gel in an electrophoresis chamber filled with SDS running 
buffer. 
 
2.2.3.4. Electrotransfer and Western blot 
After SDS-PAGE, the proteins were transferred from the polyacrylamide gel onto a 
nitrocellulose membrane. Electrotransfer of the proteins was performed using a semi-
dry blotting apparatus (Semi-dry blotter MAXI, Roth) or using a wet blotting chamber 
(Mini Trans-Blot Cell, Bio-Rad). Semi-dry electrotransfer was carried out with semi-
dry transfer buffer at 60 mA/gel for 70 min. Wet electrotransfer was performed with 
wet transfer buffer at 100 V for 60 min or at 30 V over night with constant cooling at 
4°C. 
In order to assess the quality of the electrotransfer, the nitrocellulose membrane was 
stained with Ponceau S solution. For the reduction of unspecific antibody binding, the 
membrane was then incubated with Western blot blocking buffer (5% milk powder, 
0.05% Tween-20 in PBS) for 30 min at RT with gentle shaking. In order to detect the 
protein of interest, the membrane was first incubated with the primary antibody 
diluted in Western blot blocking buffer for 2 h at RT or over night at 4°C (primary 
antibodies were diluted as indicated in 2.1.4.1.). After the incubation with the primary 
antibody, the membrane was washed three times for 10 min each with the washing 
buffer PBST (0.05% Tween-20 in PBS). The membrane was then incubated with the 
appropriate HRP-conjugated secondary antibody diluted in Western blot blocking 
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buffer for 1-2 h at RT (secondary antibodies were diluted as indicated in 2.1.4.2.). 
The membrane was washed with PBST three times for 10 min each. 
Chemiluminescence signals were detected using the luminescent image analyzer 
ImageQuant LAS4000 after incubation of the membrane with ECL Western blotting 
substrate (Millipore) according to the manufacturer’s instructions. Data were 
processed using the ImageJ Fiji software. 
 
2.2.3.5. Immunoprecipitation assays 
 
2.2.3.5.1. Immunoprecipitation of Flag-tagged proteins using Flag M2 affinity 
beads 
Immunoprecipitations of Flag-tagged proteins were performed using α-Flag M2 
affinity beads (Sigma-Aldrich). For each immunoprecipitation reaction, 10-40 µl of the 
α-Flag M2 affinity bead suspension were used. The beads were washed twice with 
TBS, once with glycine buffer (0.1 M glycine-HCl pH 3.5) and three times with TBS. 
Buffers and beads were kept on ice and centrifugations were performed at 5000 rpm 
and 4°C for 2 min in an Eppendorf 5415 R centrifuge. HEK-293T cell extracts were 
prepared with NP40 lysis buffer (as described in 2.2.3.1.) and 6-15 mg of each 
extract were transferred to the prepared beads. Each reaction was filled up to a final 
volume of 1 ml using NP40 lysis buffer. The reactions were incubated over night on a 
rotating wheel at 4°C. After the incubation, the beads were washed 3-5 times with 
NP40 lysis buffer. Immunoprecipitated proteins were eluted from the beads by 
competition with 100 µl of a 3x Flag peptide solution (100-500 ng/µl in NP40 lysis 
buffer). The elution was carried out on ice for 30 min with short vortexing every 5-
10 min. After the elution, the beads were centrifuged at 5000 rpm and 4°C for 2 min. 
90 µl of the supernatant were transferred to a fresh reaction tube and 30 µl of 4x 
Laemmli buffer were added. After incubation at 95°C for 2 min, 20-40% of the 
immunoprecipitation sample were analyzed by SDS-PAGE and Western blotting. 
 
2.2.3.5.2. Immunoprecipitation of endogenous proteins using NHS-activated 
sepharose 
Endogenous XIAP was immunoprecipitated using XIAP antibodies covalently bound 
to NHS sepharose beads (GE). For the coupling of the antibodies to the beads, 20 µl 
of the NHS sepharose bead suspension were activated with 1 mM HCl and washed 
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three times with PBS. 3 µg of the XIAP antibody were added to the beads with PBS 
in a total volume of 50 µl. For the control reaction, 3 µg of mouse IgG were added to 
the beads. The reaction was incubated on a rotating wheel at 4°C over night. The 
beads were centrifuged at 5000 rpm and 4°C for 2 min and the supernatant was 
removed. 1 ml of a glycine solution (200 mM glycine pH 8.0) was added to the beads 
and the suspension was incubated on a rotating wheel at RT for 2 h. The beads were 
washed with PBS twice. HeLa cell extract was prepared using NP40 lysis buffer (as 
described in 2.2.3.1.). 5-6 mg of the HeLa cell extract were added to the prepared 
beads in a final volume of 1 ml. The reactions were incubated on a rotating wheel at 
4°C over night. After the incubation, the beads were washed three times with NP40 
lysis buffer. Finally, the beads were incubated with 30 µl of 2x Laemmli buffer at 95°C 
for 5 min. After a final centrifugation at 5000 rpm for 5 min, the supernatant was 
transferred to a fresh tube. 20-25 µl of each sample were analyzed by SDS-PAGE 
and Western blotting. 
 
2.2.3.5.3. Sequential immunoprecipitation for the analysis of protein complexes 
In order to analyze whether proteins exist in ternary complexes, sequential 
immunoprecipitations were performed. In the first step of the experiment, 15-20 mg of 
HEK-293T cell extracts were used for an immunoprecipitation directed against a 
Flag-tagged protein (Flag-FBXW7α or Flag-MYCBP2). The immunoprecipitation was 
performed as described above (see 2.2.3.5.1.). Instead of mixing the eluate with 
Laemmli buffer, it was used for a second immunoprecipitation directed against 
endogenous XIAP or HA-FBXO45. For the XIAP immunoprecipitation, the procedure 
was as described above (see 2.2.3.5.2.). HA-FBXO45 was immunoprecipitated with 
20 µl of α-HA agarose beads (Sigma-Aldrich) according to the manufacturer’s 
instructions. Finally, the beads were incubated with 30 µl of 2x Laemmli buffer at 
95°C for 5 min. The supernatant was analyzed by SDS-PAGE and Western blotting. 
 
2.2.3.6. Colloidal Coomassie staining 
As an alternative to electrotransfer and Western blotting after SDS-PAGE, proteins in 
a polyacrylamide gel were visualized by Colloidal Coomassie staining. Gels were 
fixed and stained by an incubation with Colloidal Coomassie solution (2% ortho-
phosphoric acid, 10% ammonium sulfate, 0.1% Brilliant Blue G250, 20% methanol) 
with gentle shaking at RT over night. The gel was destained with ddH2O until the 
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desired staining intensity was achieved. Stained gels were either analyzed by mass 
spectrometry or dried on filter paper at 80°C for 1 h in a vacuum dryer. 
 
2.2.3.7. Mass spectrometry analysis 
In order to identify interaction partners of Flag-FBXW7α, Flag-XIAP, Flag-RAE1 or of 
the Flag-FBXW7α/XIAP complex, immunoprecipitation assays were performed (as 
described in 2.2.3.5.). Immunoprecipitation samples were analyzed by SDS-PAGE 
and stained by Colloidal Coomassie. Analysis was performed by M. Schnölzer (DKFZ 
Protein Analysis Facility, Heidelberg). Briefly, whole gel lanes were cut into slices. 
Proteins were reduced and alkylated by incubation with 10 mM DTT in 40 mM 
NH4HCO3 for 1 h at 56°C in the dark and incubation with 55 mM iodoacetamide in 
40 mM NH4HCO3 for 30 min at 25°C. After washing of the slices with H2O and 50% 
acetonitrile, they were dried with 100% acetonitrile. Proteins were digested in-gel with 
trypsin (0.17 µg in 10 µl 40 mM NH4HCO3, Promega) at 37°C over night. Tryptic 
peptides were extracted with 50% acetonitrile/0.1% TFA and 100% acetonitrile. 
Supernatants were lyophilized and redissolved in 0.1% TFA/5% 
hexafluoroisopropanol. Solutions were analyzed by nanoLC-ESI-MS/MS. Peptides 
were separated with a nanoAcquity UPLC system (Waters GmbH). Peptides were 
loaded on a C18 trap column with a particle size of 5 µm (Waters GmbH). Liquid 
chromatography was carried out on a BEH130 C18 column with a particle size of 
1.7 µm (Waters GmbH). A 1 h gradient was applied for protein identification. The 
nanoUPLC system was connected to an LTQ Orbitrap XL mass spectrometer 
(Thermo Scientific). Data were acquired with the Xcalibur software 2.1 (Thermo 
Scientific). The SwissProt database (taxonomy human) was used for database 
searches with the MASCOT search engine (Matrix Science). Data from individual gel 
slices were merged. Peptide mass tolerance was 5 ppm, fragment mass tolerance 
was 0.4 Da and significance threshold was p<0.01. 
 
2.2.3.8. In vivo ubiquitylation assays 
HEK-293T cells transiently transfected with the indicated plasmids were treated with 
10 µM MG132 4-5 h before harvesting. Cells were harvested (as described in 
2.2.2.2.) and cell extracts were prepared with RIPA lysis buffer containing 10 mM of 
the DUB inhibitor N-ethylmaleimide (NEM, cell extract preparation as described in 
2.2.3.1.). 2-3 mg of protein extract were used for each sample. Flag-FBXW7α was 
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immunoprecipitated with α-Flag affinity beads (as described in 2.2.3.5.1.). 
Immunoprecipitation and washing steps were performed with RIPA lysis buffer 
containing 10 mM NEM. Alternatively, endogenous FBXW7α was 
immunoprecipitated by incubation of each protein extract with 1 µg of FBXW7α 
antibody on a rotating wheel at 4°C over night. After the incubation with the antibody, 
the extracts were incubated with 15 µl of protein A sepharose beads (GE Healthcare) 
on a rotating wheel at 4°C for 1 h. The beads were washed four times with RIPA lysis 
buffer containing 10 mM NEM. Finally, the beads were incubated in 30 µl of 2x 
Laemmli buffer at 95°C for 5 min. 25 µl of the supernatant were analyzed by SDS-
PAGE and Western blotting. 
 
2.2.3.9. Expression and purification of recombinant proteins 
 
2.2.3.9.1. Expression and purification of MBP-tagged proteins 
Chemically competent E. coli Rosetta (DE3) were transformed with pMAL-MBP-
FBXW7α-N167 (as described in 2.2.1.6.). A single colony was used to inoculate 
10 ml of LB medium containing 100 µg/ml ampicillin and 0.2% glucose. The culture 
was incubated over night at 30°C with constant shaking at 180 rpm. The overnight 
culture was used to inoculate 1 l of LB medium containing 100 µg/ml ampicillin and 
0.2% glucose. The culture was incubated at 37°C with constant shaking at 180 rpm. 
When an OD600 of 0.5 was reached, the culture was cooled down on ice at 4°C and 
protein expression was induced by the addition of 0.4 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). The culture was further incubated over night at 18°C 
with constant shaking at 180 rpm. Bacteria were harvested by centrifugation at 
5000 rpm and 4°C for 15 min (F10-6x500Y rotor, Piramoon). The pellet was 
resuspended in 25 ml of cold column buffer. Cell lysis was performed with a high 
pressure homogenizer (15000-17000 psi/1030-1170 bar for one pass, EmulsiFlex 
C5, Avestin). The lysate was centrifuged at 20000 g and 4°C for 20 min (WX Ultra 
80, Thermo Scientific). The supernatant was applied onto a column with 1 ml of 
equilibrated amylose resin (NEB). The column with the beads and the extract was 
incubated on a rotating wheel at 4°C for 1 h. Afterwards, the beads were washed 
three times with 15 ml of column buffer. Finally, the proteins bound to the beads were 
eluted with 5 ml of column buffer containing 10 mM maltose. 10 fractions of 500 µl 
each were collected. Protein containing fractions were identified by spotting the 
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fractions on nitrocellulose and staining with Ponceau S solution. Protein containing 
fractions were pooled and MBP-FBXW7α-N167 was further purified with a 
preparative Superdex 200 column in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM β-
mercaptoethanol, 5% glycerol. Purified MBP-FBXW7α-N167 fractions were analyzed 
by SDS-PAGE and Colloidal Coomassie staining. Protein containing fractions were 
aliquoted, frozen in liquid nitrogen and stored at -80°C.  
 
2.2.3.9.2. Expression and purification of His-tagged proteins 
Chemically competent E. coli Rosetta (DE3) were transformed with pET22b-His-XIAP 
(as described in 2.2.1.6.). Protein expression and purification was performed as 
described in 2.2.3.9.1. with the following modifications: The LB medium was not 
supplemented with glucose. Instead of column buffer, an E. coli lysis buffer (50 mM 
Tris-HCl pH 8.0, 300 mM NaCl, 5 mM β-mercaptoethanol, 10 mM imidazole) was 
used. Moreover, 1 ml of Ni-NTA agarose (Qiagen) was used instead of amylose 
resin. Washing was performed with E. coli lysis buffer containing 20 mM imidazole. 
Proteins were eluted with 10 ml of elution buffer (50 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 250 mM imidazole, 1 mM β-mercaptoethanol). 
 
2.2.3.10. In vitro transcription and translation and in vitro binding assays 
For in vitro binding assays, XIAP, RAE1, FBXO45 and MYCBP2(1951-2950) cDNA 
sequences in pCMV-3Tag1A backbones were transcribed and translated in vitro 
using the TNT T3 coupled reticulocyte system (Promega) according to the 
manufacturer’s instructions. The proteins were synthesized in the presence of 20 µCi 
[35S]-methionine so that synthesized proteins were radioactively labelled. 20 µl of the 
in vitro translated proteins were incubated with 10 µg of MBP-FBXW7α-N167 or MBP 
alone coupled to 10 µl of amylose beads in a final volume of 500 µl NP40 lysis buffer 
on a rotating wheel at 4°C for 2 h. The beads were washed five times with 800 µl of 
NP40 lysis buffer. Finally, the beads were incubated with 30 µl of 2x Laemmli buffer 
at 95°C for 5 min. Input and pull-down samples were analyzed by SDS-PAGE and 
stained with Colloidal Coomassie. The gel was then incubated with Amersham 
Amplify Fluorographic reagent (GE Healthcare) for 30 min with gentle shaking. 
Afterwards, the gel was dried at 80°C for 1 h in a vacuum dryer and analyzed by 
autoradiography. 
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2.2.3.11. Pull-down assay with recombinant proteins 
In order to analyze the direct interaction between FBXW7α-N167 and XIAP, a pull-
down assay with recombinant MBP-FBXW7α-N167 and His-XIAP was performed. 
10 µg of either MBP alone or MBP-FBXW7α-N167 were incubated with 10 µg of His-
XIAP in a total volume of 500 µl NP40 lysis buffer on a rotating wheel at 4°C for 1 h. 
10 µl of amylose beads were added to each reaction and the reactions were 
incubated on a rotating wheel at 4°C for 2 h. The beads were washed five times with 
800 µl of NP40 lysis buffer. Finally, the beads were incubated with 30 µl of 2x 
Laemmli buffer at 95°C for 5 min and 25 µl of the supernatant were analyzed by 
SDS-PAGE and Western blotting. 
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3. Results 
 
3.1. Identification of novel FBXW7α interaction partners 
 
3.1.1. Identification of FBXW7α interaction partners by Flag-FBXW7α 
immunoprecipitation and mass spectrometry analysis 
In order to identify novel interaction partners of FBXW7, a screen based on  
immunoprecipitation and mass spectrometry analysis was performed. For this 
approach, HEK-293T cells were transfected with a plasmid encoding Flag-FBXW7α. 
The resulting cell extracts were then used for an immunoprecipitation directed 
against the Flag tag. The immunoprecipitated proteins were eluted by competition 
with Flag peptide. The eluates were finally analyzed by Western blotting in order to 
evaluate the quality of the immunoprecipitation experiment. As shown in Fig. 5A, 
Flag-FBXW7α was successfully immunoprecipitated. In addition, MYC was 
specifically found in co-immunoprecipitation with Flag-FBXW7α, whereas it was not 
detected in the control. This was expected since MYC is a known substrate of 
FBXW7 (Yada et al., 2004). Next, the samples were analyzed by SDS-PAGE and 
Coomassie staining for subsequent mass spectrometry analysis.  
Several protein bands were specifically stained in the Flag-FBXW7α 
immunoprecipitation sample, whereas they were not detectable in the control lane 
(Fig. 5B). Consistently, mass spectrometry analysis detected numerous proteins that 
specifically co-immunoprecipitated with Flag-FBXW7α. A selection of these proteins 
is shown in Fig. 5C. Among the identified proteins were several known interaction 
partners of FBXW7. Apart from FBXW7 itself, the whole SCF complex (CUL1, SKP1 
and RBX1) was identified. Also NEDD8, a small ubiquitin-like protein that serves as a 
CUL1 modification and stimulates SCF activity (Freed et al., 1999; Osaka et al., 
1998; Read et al., 2000), was found. Moreover, some well-characterized FBXW7 
substrates were detected, as for example MYC (Yada et al., 2004), NOTCH 
(Hubbard et al., 1997), MED13/MED13L (Davis et al., 2013), Aurora B (Teng et al., 
2012) and mTOR (Mao et al., 2008). Finally, ARIH1 was identified as an FBXW7 
interacting protein. ARIH1 is an E3 ligase that has been shown to cooperate with 
many Cullin-RING E3 ligases for the ubiquitylation of their substrates (Scott et al., 
2016). The identification of several known FBXW7 interaction partners suggests that 
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Fig. 5: Immunoprecipitation and mass spectrometry identify putative novel FBXW7α interaction 
partners. 
A: HEK-293T cells were transfected for 24 h with a construct encoding Flag-FBXW7α or with an empty 
vector (EV) as a control. 5 h before harvesting, the cells were treated with MG132 in order to inhibit 
proteasomal degradation. Flag-FBXW7α was immunoprecipitated from the cell extracts with α-Flag M2 
agarose beads. Immunoprecipitated proteins were eluted from the beads by competition with Flag 
peptide. Eluted proteins were analyzed by Western blotting using α-Flag, α-FBXW7α and α-MYC 
antibodies. WCE: Whole cell extract. B: Immunoprecipitated proteins from A were additionally 
analyzed by SDS-PAGE and stained by Colloidal Coomassie. The position of the Flag-FBXW7α 
protein band is marked by an arrow. Whole lanes were cut out from the gel and analyzed by mass 
spectrometry. C: Selection of proteins that were specifically identified in co-immunoprecipitation with 
Flag-FBXW7α. For each protein, the MASCOT score, the mass, the number of significant sequences 
and the coverage are specified.  
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3.1.2. WDR5 is a putative substrate of FBXW7 
Before the mass spectrometry results were analyzed for putative regulators of 
FBXW7, WDR5 was analyzed in more detail. WDR5 is part of a histone-lysine 
methyltransferase complex that is involved in the regulation of transcription (Rao and 
Dou, 2015). Interestingly, WDR5 has been described to cooperate with MYC in 
oncogenic pathways (Thomas et al., 2015). It is therefore interesting that WDR5 was 
also identified as a putative interaction partner by mass spectrometry (Fig. 5C).  
Because WDR5 cooperates with MYC, it was analyzed as a putative FBXW7 
substrate. In order to confirm the interaction between WDR5 and FBXW7α, cell 
extracts were prepared from HCT116 cells. As a control, HCT116 cells, where 
FBXW7 had been inactivated by homologous recombination (HCT116 FBXW7-/-), 
were used (Rajagopalan et al., 2004). The cell extracts were used for 
immunoprecipitations directed against endogenous FBXW7α. The 
immunoprecipitates were analyzed by Western blotting. As expected, FBXW7α could 
only be detected in the immunoprecipitate from HCT116 FBXW7+/+ cells, but not from 
HCT116 FBXW7-/- cells (Fig. 6A). The known FBXW7α substrates MYC and Cyclin E 
were specifically identified in co-immunoprecipitation with FBXW7α. Interestingly, 
WDR5 was also found to co-immunoprecipitate with FBXW7α (Fig. 6A), hence 
confirming the interaction between FBXW7α and WDR5. 
In order to analyze putative effects of FBXW7α on WDR5 protein levels, whole cell 
extracts of HCT116 FBXW7+/+ and HCT116 FBXW7-/- were subjected to Western blot 
analysis. Interestingly, WDR5 protein levels were increased in the absence of 
FBXW7 (Fig. 6B).  
In order to confirm this result, an siRNA-mediated downregulation of FBXW7 was 
performed in HeLa cells. As shown in Fig. 6C, WDR5 protein levels were increased 
upon downregulation of FBXW7.  
In summary, FBXW7α interacts with WDR5 in vivo and negatively regulates WDR5 
protein levels. Therefore, WDR5 is a promising candidate to be a novel FBXW7 
substrate, but further validation will be required. As the main focus of this study is the 
characterization of FBXW7 regulation, only putative regulators of FBXW7 will be 
analyzed from here on. 
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Fig. 6: WDR5 is a putative novel substrate of FBXW7. 
A: FBXW7α and WDR5 interact in vivo. Endogenous FBXW7α was immunoprecipitated from HCT116 
cells. HCT116 FBXW7-/- cells were used as a control. Immunoprecipitates were analyzed by Western 
blotting with α-FBXW7α, α-WDR5, α-MYC and α-Cyclin E antibodies. FBXW7α signals were obtained 
after short and long exposure times. B-C: WDR5 protein levels increase upon depletion of FBXW7. 
WDR5 protein levels were analyzed by Western blotting in HCT116 FBXW7-/- cells (B) and after 
siRNA-mediated downregulation (30 nM siRNA for 72 h) of FBXW7 in HeLa cells (C). In B, HCT116 
FBXW7+/+ cells were used as a control, whereas firefly luciferase (GL2) siRNA was used as a control 
in C. For each blot, quantifications of relative WDR5 signal intensities are shown. Relative WDR5 
signals in the HCT116 FBXW7+/+ or GL2 controls were set to 1. Average signal intensities and 
standard deviations from n=3 experiments were calculated. Statistical significance was analyzed by a 
two-tailed, unpaired t-test with unequal variance. * p<0.05. 
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3.1.3. Analysis of putative FBXW7 regulators 
Among the proteins that were identified as putative interaction partners of FBXW7α 
by mass spectrometry (Fig. 5C), there were several proteins with known E3 ligase 
activity. These E3 ligases were considered as putative regulators of FBXW7 protein 
levels.  
 
 
Fig. 7: Analysis of CUL4A, DCAF7, DDB1, UBR5 and VPRBP as putative FBXW7α regulators. 
A: Myc-DDB1 interacts with Flag-FBXW7α. Flag-FBXW7α was co-expressed with Myc-DDB1 or Myc-
CUL4A in HEK-293T cells for 24 h. The resulting cell extracts were used for immunoprecipitations with 
α-Myc antibodies. Immunoprecipitates were analyzed by Western blotting with α-Myc, α-Flag and α-
Tubulin antibodies. Tubulin was used as a loading control. B: FBXW7α protein levels do not increase 
upon siRNA-mediated downregulation of putative regulators. HeLa cells were transfected with 30 nM 
of the indicated siRNAs for 72 h. Cell extracts were analyzed by Western blotting with α-FBXW7α and 
α-Vinculin antibodies. Vinculin was used as a loading control. Quantifications of relative FBXW7α 
protein levels are shown. Relative FBXW7α signal intensity in the GL2 control was set to 1. Average 
signal intensities and standard deviations from n=3 experiments were calculated. Statistical 
significance was analyzed by a two-tailed, unpaired t-test with unequal variance. ** p<0.01, n.s.: not 
significant. 
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DDB1 is a component of Cullin4-RING E3 ligases (CRL4s). It serves as an adaptor 
protein between the central CUL4A/B subunit and the substrate recognition subunit, 
the DCAF protein (Lee and Zhou, 2007). DDB1 was identified as a putative FBXW7α 
interaction partner (Fig. 5C). In order to confirm the interaction between FBXW7α and 
DDB1, an immunoprecipitation experiment was performed. Hence, Flag-FBXW7α 
and Myc-DDB1 were overexpressed in HEK-293T cells. The cell extracts were used 
for an immunoprecipitation directed against the Myc tag. The immunoprecipitates 
were analyzed by Western blotting. Fig. 7A shows that the interaction between DDB1 
and FBXW7α could be confirmed. CUL4A, another subunit of the CRL4 complex, did 
not interact with FBXW7α. 
Next, FBXW7α protein levels were analyzed upon siRNA-mediated downregulation of 
DDB1. Depletion of an FBXW7α regulator is expected to cause an increase in 
FBXW7α protein levels. However, there was no change in FBXW7α protein levels 
upon downregulation of DDB1 (Fig. 7B). CUL4A depletion did not cause any increase 
in FBXW7α protein levels either. Instead, it led to a decrease in FBXW7α protein 
levels. DCAF7 is a DCAF protein that was also identified in the screen as a putative 
interaction partner of FBXW7α (Fig. 5C). Thus, its effects on FBXW7α protein levels 
were tested in the same experiment, but no increase in FBXW7α protein levels was 
observed (Fig. 7B). DDB1 is not only found as a subunit of CRL4s, but it can also 
form complexes with other proteins. It was shown to form an alternative E3 ligase 
complex with VPRBP and UBR5 (Maddika and Chen, 2009), which was also found 
as a putative FBXW7α interaction partner in the screen (Fig. 5C). However, similar to 
DDB1 depletion, siRNA-mediated downregulation of UBR5 or VPRBP did not cause 
any increase in FBXW7α protein levels (Fig. 7B). Together, these results suggest 
that CRL4 and DDB1-UBR5-VPRBP E3 ligase complexes do not regulate FBXW7α 
protein levels. 
In additional experiments, further putative FBXW7α regulators from the screen were 
analyzed in respect to their effects on FBXW7α protein levels. However, siRNA-
mediated downregulation of FBXW2, TRAF2, SHPRH, XIAP or cIAP1 did not cause 
any increase in FBXW7α protein levels (Fig. 8A-B). 
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Fig. 8: Analysis of FBXW2, TRAF2, SHPRH, XIAP and cIAP1 as putative FBXW7α regulators. 
A-B: FBXW7α protein levels do not increase upon siRNA-mediated downregulation of putative 
regulators. HeLa cells were transfected with 30 nM of the indicated siRNAs for 72 h. Cell extracts were 
analyzed by Western blotting with α-FBXW7α, α-XIAP and α-Tubulin antibodies. Tubulin was used as 
a loading control. Quantifications of relative FBXW7α protein levels are shown. Relative FBXW7α 
signal intensity in the GL2 control was set to 1. Average signal intensities and standard deviations 
from n=3 experiments were calculated. Statistical significance was analyzed by a two-tailed, unpaired 
t-test with unequal variance. n.s.: not significant. 
 
3.2. Characterization of XIAP as a novel interaction partner of FBXW7α 
 
3.2.1. XIAP interacts with FBXW7α in vivo 
Depletion of XIAP did not cause an increase in FBXW7α protein levels (Fig. 8B). 
However, XIAP has been described as an inhibitor of apoptosis protein that is 
frequently found overexpressed in human cancers (reviewed by Gyrd-Hansen and 
Meier, 2010). Since an interaction between an oncoprotein and a tumor suppressor 
protein seems likely, it could be meaningful to study the interaction between XIAP 
and FBXW7α in more detail. 
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Fig. 9: In vivo interaction between FBXW7α and XIAP. 
A: Flag-FBXW7α interacts with endogenous XIAP in HEK-293T cells. Flag-FBXW7α was 
overexpressed in HEK-293T cells for 24 h. An empty vector (EV) was used as a control. The 
corresponding cell extracts were used for an immunoprecipitation directed against the Flag tag. 
Immunoprecipitates were analyzed by Western blotting with α-Flag and α-XIAP antibodies. B: 
Endogenous FBXW7α interacts with endogenous XIAP in HeLa cells. Endogenous XIAP was 
immunoprecipitated from HeLa cell extracts. Mouse IgG was used for a control immunoprecipitation 
(ctrl). Immunoprecipitates were analyzed by Western blotting with FBXW7α and XIAP antibodies. 
 
In order to confirm the interaction between XIAP and FBXW7α, Flag-FBXW7α was 
overexpressed in HEK-293T cells. An immunoprecipitation directed against the Flag 
tag was performed. Endogenous XIAP was found in co-immunoprecipitation with 
Flag-FBXW7α (Fig. 9A). It was also tested whether an interaction between the 
endogenous proteins exists. HeLa cell extracts were used for an immunoprecipitation 
directed against endogenous XIAP. Endogenous FBXW7α co-immunoprecipitated 
with endogenous XIAP (Fig. 9B). These results show that XIAP and FBXW7α interact 
in vivo, thus confirming the results from the screen (Fig. 5C). 
 
3.2.2. XIAP specifically interacts with FBXW7α 
In order to test the specificity of the interaction between XIAP and FBXW7α, it was 
compared with the interaction between XIAP and other F-box proteins (FBXW5, 
SKP2 and FBXO28), a substrate recognition subunit of the CRL4 complex (DCAF5) 
and two other proteins that have no E3 ligase activity (PLK4 and MISP). Flag-tagged 
versions of these proteins were overexpressed in HEK-293T cells and 
immunoprecipitated from the corresponding cell extracts via their Flag tags. The 
immunoprecipitates were analyzed for the presence of endogenous XIAP by Western 
blotting (Fig. 10). XIAP could only clearly be detected in co-immunoprecipitation with 
Flag-FBXW7α, suggesting that the interaction between these two proteins is specific. 
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Fig. 10: Specific interaction of XIAP with FBXW7α. 
Flag-tagged FBXW7α, FBXW5, SKP2, FBXO28, DCAF5, PLK4 and MISP proteins were 
overexpressed in HEK-293T cells for 24 h. An empty vector (EV) was used as a control. Cell extracts 
were used for immunoprecipitations with α-Flag agarose beads. Immunoprecipitates were analyzed by 
Western blotting with α-XIAP and α-Flag antibodies. 
 
3.2.3. The interaction between FBXW7α and XIAP does not require the F-box or 
WD40 domains of FBXW7α 
FBXW7α interacts with SKP1 via its F-box domain, thereby enabling the 
incorporation of FBXW7α into the SCF complex (reviewed by Davis et al., 2014; 
Welcker and Clurman, 2008). In order to exclude that the observed interaction 
between FBXW7α and XIAP is indirectly mediated by other SCF subunits, an 
FBXW7α mutant with a deletion of the F-box was generated (FBXW7αΔF-box). Flag-
FBXW7α or Flag-FBXW7αΔF-box were then co-expressed with HA-XIAP in HEK-
293T cells and the different Flag-FBXW7α proteins were immunoprecipitated via their 
Flag tag. As expected, endogenous SKP1 did not interact with the Flag-FBXW7αΔF-
box mutant, whereas it clearly bound to Flag-FBXW7α. HA-XIAP, on the other hand, 
was found in co-immunoprecipitation with both Flag-FBXW7α and Flag-FBXW7αΔF-
box proteins (Fig. 11A). This shows that the interaction between XIAP and FBXW7α 
is independent of the incorporation of FBXW7α into the SCF complex by its F-box 
domain. 
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Fig. 11: Interaction between FBXW7α and XIAP does not depend on F-box and WD40 domains 
of FBXW7α. 
A: Flag-FBXW7α or Flag-FBXW7αΔF-box were overexpressed together with HA-XIAP in HEK-293T 
cells for 24 h. Cell extracts were used for immunoprecipitations with α-Flag agarose beads. 
Immunoprecipitates were analyzed by Western blotting with α-Flag, α-HA and α-SKP1 antibodies. B: 
Flag-FBXW7α or Flag-FBXW7αΔWD40 were co-expressed with HA-XIAP or Myc-XIAP in HEK-293T 
cells for 24 h. Cell extracts were used for immunoprecipitations with α-Flag agarose beads. 
Immunoprecipitates were analyzed by Western blotting with α-FBXW7α, α-HA and α-Myc antibodies. 
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FBXW7α binds to its substrates through a WD40 repeat domain. The mutation of 
three amino acid residues within the WD40 repeat domain (S462A/T463V/R465A) 
has been shown to abolish FBXW7α substrate binding and turnover (Busino et al., 
2012; Hao et al., 2007). The corresponding WD40 mutant of FBXW7α 
(FBXW7αΔWD40) was used to test whether XIAP binds to the same domain of 
FBXW7α as its substrates. HEK-293T cells were transfected with constructs 
encoding either Flag-FBXW7α or Flag-FBXW7αΔWD40. In addition, the cells were 
transiently transfected with HA-XIAP or Myc-XIAP constructs. Immunoprecipitations 
directed against the Flag tag revealed that HA-XIAP as well as Myc-XIAP bound to 
both the wild-type and ΔWD40 versions of FBXW7α (Fig. 11B). In conclusion, the 
binding site of XIAP within FBXW7α is different from the domain that is bound by 
FBXW7α substrates, indicating that XIAP is not a direct substrate of FBXW7α.  
 
3.2.4. XIAP interacts with the N-terminal domain of FBXW7α 
FBXW7 contains several well-characterized protein domains (Fig. 4). Apart from the 
F-box and WD40 repeat domains, which have already been analyzed in Fig. 11, 
FBXW7 contains a dimerization domain as well as an isoform specific N-terminal 
domain that mediates isoform localizations (reviewed by Davis et al., 2014; Welcker 
and Clurman, 2008). In order to analyze the functional importance of the interaction 
between XIAP and FBXW7α, it is interesting to further characterize the binding site of 
XIAP within FBXW7α. For this purpose, Flag-tagged truncated versions of FBXW7α 
were generated (Fig. 12) and used for interaction studies along with HA-tagged or 
endogenous XIAP.  
As controls, the interactions of SKP1 (SCF subunit, expected to bind to the F-box 
domain) and MYC (known FBXW7 substrate, expected to bind to the WD40 domain) 
with the truncated FBXW7α versions were analyzed. As expected, SKP1 only bound 
to FBXW7α versions that contained the F-box domain (Flag-FBXW7α-FL and Flag-
FBXW7α-N515), whereas the absence of the F-box domain (as in Flag-FBXW7α-
N283, Flag-FBXW7α-C322 and Flag-FBXW7αΔF-box) prevented SKP1 binding (Fig. 
13A). On the other hand, MYC only interacted with FBXW7α fragments that 
contained a functional WD40 domain (Flag-FBXW7α-FL, Flag-FBXW7α-C322 and 
Flag-FBXW7αΔF-box), whereas a partial or complete loss of the WD40 domain (as in 
Flag-FBXW7α-N283 and Flag-FBXW7α-N515) abolished the MYC interaction (Fig. 
13A). 
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Fig. 12: Overview of Flag-tagged FBXW7α mutants. 
Illustration of truncations and deletions in FBXW7α versions used in this study. Positions of N-terminal 
domain (blue), dimerization domain (green), F-box domain (yellow), WD40 domain (red) and NLS 
motifs (black bar) are indicated. 
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HA-XIAP was found to co-immunoprecipitate with Flag-FBXW7α-FL and Flag-
FBXW7αΔF-box (as already observed in Fig. 11A). In addition, HA-XIAP interacted 
with the N-terminal fragments Flag-FBXW7α-N283 and Flag-FBXW7α-N515, 
whereas no interaction could be detected with the C-terminal fragment Flag-
FBXW7α-C322. Consistent with the results presented in Fig. 11, this indicates that 
neither the F-box domain nor the WD40 domain are required for the interaction with 
XIAP. The Flag-FBXW7α-N283 truncated version only contains the isoform specific 
N-terminal domain and the dimerization domain of FBXW7α. As XIAP shows a clear 
interaction with Flag-FBXW7α-N283 (Fig. 13A), this suggests that one of these 
domains could be responsible for mediating the interaction with XIAP. 
In order to confirm these results and further differentiate the importance of the 
isoform specific N-terminus and the dimerization domain for the interaction with XIAP, 
additional truncated FBXW7α versions were analyzed for their interactions with 
endogenous XIAP. Immunoprecipitations of the Flag-tagged truncated FBXW7α 
versions revealed that endogenous XIAP only interacted with the N-terminal 
fragments of FBXW7α (Flag-FBXW7α-N167 and Flag-FBXW7α-N283), whereas no 
interaction was observed with the C-terminal fragments (Flag-FBXW7α-C168 and 
Flag-FBXW7α-C322). Despite great experimental efforts to increase the expression 
levels of the Flag- FBXW7α-N167 fragment, it showed lower protein levels compared 
to the other FBXW7α versions. Nevertheless, this fragment showed a clear 
interaction with XIAP, similar to Flag-FBXW7α-FL and Flag-FBXW7α-N283 (Fig. 
13B). Interestingly, Flag-FBXW7α-N167 represents the isoform specific N-terminal 
domain of FBXW7α. In conclusion, XIAP binds to FBXW7α via its α-isoform specific 
N-terminus. 
FBXW7α contains two nuclear localization signals (NLS). One NLS is located 
between the N-terminal domain and the dimerization domain, whereas the second 
NLS is localized within the α-isoform specific N-terminal domain (Welcker et al., 
2004). In order to test whether XIAP binds to this NLS motif within the N-terminal 
domain, additional truncated FBXW7α versions were generated (Fig. 12) and then 
analyzed for their interactions with endogenous XIAP. As expected and already 
observed in previous experiments (Fig. 13B), Flag-FBXW7α-C168 did not bind to 
XIAP. All the other truncated versions, however, were able to interact with XIAP 
(Flag-FBXW7α-C9, Flag-FBXW7α-C19, Flag-FBXW7α-C40 and Flag-FBXW7α-C85), 
suggesting that XIAP does not bind to the NLS sequence within the N-terminal 
  Results 
67 
domain of FBXW7α (Fig. 13C). Instead, the data generated show that the XIAP 
binding site is localized between amino acid residues 85 and 167 of FBXW7α. 
 
Fig. 13: N-terminal domain of FBXW7α is required for the interaction with XIAP. 
A-D: The indicated Flag-tagged versions of FBXW7α were overexpressed either alone (B-D) or 
together with HA-XIAP (A) in HEK-293T cells for 24 h. Cell extracts were used for 
immunoprecipitations with α-Flag agarose beads. Immunoprecipitates were analyzed by Western 
blotting with α-XIAP, α-HA, α-Flag, α-SKP1, α-MYC or α-RAE1 antibodies. 
 
In order to confirm this finding, the amino acid residues 85-167 were deleted from the 
Flag-FBXW7α protein sequence. This deletion mutant (Flag-FBXW7αΔ85-167) was 
then immunoprecipitated from HEK-293T cell extracts. As expected, XIAP was not 
detected in co-immunoprecipitation with Flag-FBXW7αΔ85-167, although MYC and 
SKP1 clearly bound to the deletion mutant (Fig. 13D). Another deletion mutant, 
where the residues 40-167 had been deleted (Flag-FBXW7αΔ40-167), showed 
similar results (Fig. 13D). On the other hand, XIAP still bound to a mutant with a 
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deletion of only residues 40-84 (Flag-FBXW7αΔ40-84, Fig. 13C). In summary, these 
results confirm that XIAP binds to a region between amino acid residues 85 and 167 
within the N-terminal domain of FBXW7α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: FBXW7α does not form a complex with XIAP in vitro. 
A-B: Either MBP alone or MBP-FBXW7α-N167 were incubated with recombinant His-XIAP (A) or with 
in vitro translated, [35S]-methionine labelled XIAP (B). MBP was pulled down with amylose beads. Pull-
down samples were analyzed by Western blotting with α-XIAP antibodies (A) or SDS-PAGE and 
Colloidal Coomassie staining (B). In vitro translated XIAP was detected by autoradiography. 
 
3.2.5. XIAP does not interact with the N-terminus of FBXW7α in vitro 
In order to test whether XIAP directly binds to the N-terminal domain of FBXW7α, an 
in vitro pull-down assay was performed with recombinant proteins. An MBP-tagged 
version of the FBXW7α specific N-terminal domain (MBP-FBXW7α-N167) was 
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purified from E. coli and incubated with a bacterially purified His-tagged XIAP version. 
As a control, His-XIAP was incubated with the MBP tag alone. MBP and MBP- 
FBXW7α-N167 were then pulled down with amylose beads. The pull-down samples 
were analyzed for the presence of His-XIAP by Western blotting. As shown in Fig. 
14A, His-XIAP was not found to be enriched in the MBP-FBXW7α-N167 pull-down. 
In order to confirm this finding, MBP-FBXW7α-N167 was incubated with in vitro 
translated XIAP. Again, an MBP pull-down was performed. However, in vitro 
translated XIAP was not detected in the MBP-FBXW7α-N167 pull-down sample (Fig. 
14B). These results therefore suggest that the interaction between FBXW7α and 
XIAP is not direct, but is instead mediated by one or several additional proteins. 
 
3.3. RAE1, FBXO45 and MYCBP2 form a complex with FBXW7α and XIAP 
 
3.3.1. Identification of XIAP interaction partners 
As XIAP is not a direct interaction partner of FBXW7α (Fig. 14), a screen for XIAP 
interaction partners was performed in order to identify the protein(s) that mediate the 
indirect interaction between FBXW7α and XIAP. Flag-XIAP was overexpressed in 
HEK-293T cells and immunoprecipitated from the corresponding cell extracts with α-
Flag agarose beads. Immunoprecipitated proteins were eluted from the beads by 
competition with excess Flag peptide. The immunoprecipitate was analyzed for the 
presence of expected interaction partners by Western blotting (Fig. 15A). As 
expected, XIAP was specifically detected in the Flag-XIAP immunoprecipitate. 
Caspase-3, a known interaction partner of XIAP (Deveraux et al., 1997), was also 
found in co-immunoprecipitation with Flag-XIAP. Moreover, FBXW7α was found to 
interact with Flag-XIAP. 
For mass spectrometry analysis, the immunoprecipitates were analyzed by SDS-
PAGE and Colloidal Coomassie staining (Fig. 15B). Several protein bands were 
specifically detected in the Flag-XIAP immunoprecipitate, but not in the control. 
Consistently, mass spectrometry analysis identified proteins that specifically co-
immunoprecipitated with Flag-XIAP (Fig. 15C). Apart from XIAP itself, HTRA2 was 
identified in the Flag-XIAP co-immunoprecipitate. HTRA2 is a known XIAP interaction 
partner that was shown to inhibit XIAP (Suzuki et al., 2001). Although FBXW7α had 
been shown to interact with Flag-XIAP by Western blot analysis (Fig. 15A), it was not 
detected by mass spectrometry. Additional proteins that were identified as putative 
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interaction partners of Flag-XIAP were MYCBP2, RAE1, FBXO45 and SPRYD3 (Fig. 
15C). Interestingly, these proteins had also been identified as putative FBXW7α 
interaction partners (Fig. 5C).  
 
Fig. 15: Identification of XIAP interaction partners. 
A-B: Flag-XIAP was overexpressed in HEK-293T cells for 24 h. An empty vector (EV) was transfected 
as a control. Cell extracts were used for immunoprecipitations with α-Flag agarose beads. 
Immunoprecipitated proteins were eluted by competition with Flag peptide and analyzed by Western 
blotting (A) or by SDS-PAGE and Colloidal Coomassie staining (B). The gel from B was analyzed by 
mass spectrometry. C: Selection of proteins that were specifically identified in the Flag-XIAP 
immunoprecipitate by mass spectrometry. For each identified protein, the MASCOT score, the protein 
mass, the number of significant sequences and the coverage is specified. 
 
3.3.2. XIAP and RAE1 bind to a similar domain within the N-terminus of 
FBXW7α 
RAE1 is a protein that was identified as a putative interaction partner of both 
FBXW7α (Fig. 5C) and XIAP (Fig. 15C). Therefore, it is a candidate protein that could 
be responsible for mediating the indirect interaction between FBXW7α and XIAP. 
RAE1 has originally been described as an mRNA export factor in yeast (Brown et al., 
1995). In vertebrates, it has been further characterized as a regulator of mitotic 
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spindle assembly and was also found to inhibit APC/C activity (Blower et al., 2005; 
Jeganathan et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Overview of N- and C-terminal truncated versions of Flag-FBXW7α for the 
characterization of the XIAP/RAE1 binding site within the N-terminal domain. 
Overview of additional truncated FBXW7α versions. Positions of N-terminal domain (blue), 
dimerization domain (green), F-box domain (yellow), WD40 domain (red) and NLS motifs (black bar) 
are indicated. 
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Fig. 17: A short motif within the N-terminal domain of FBXW7α is required for the interaction 
with XIAP and RAE1. 
A-B: The indicated Flag-tagged truncated versions of FBXW7α were overexpressed in HEK-293T 
cells for 24 h. Cell extracts were used for immunoprecipitations directed against the Flag tag. 
Immunoprecipitates were analyzed by Western blotting with α-RAE1, α-XIAP and α-Flag antibodies. 
 
A protein that forms a link between FBXW7α and XIAP would be expected to bind to 
the same FBXW7α domain as XIAP. In order to test this hypothesis, the interaction 
between FBXW7α and RAE1 was analyzed. For this analysis, Flag-tagged deletion 
mutants of FBXW7α, which had already been used to analyze the interaction with 
XIAP, were immunoprecipitated. Similar to XIAP, RAE1 did not co-immunoprecipitate 
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with the deletion mutants (Flag-FBXW7αΔ85-167 and Flag-FBXW7αΔ40-167), 
whereas it was clearly detected in co-immunoprecipitation with the full-length version 
of Flag-FBXW7α (Fig. 13D). This result indicates that RAE1 binds to a similar domain 
within the N-terminus of FBXW7α as XIAP. 
In order to confirm that RAE1 and XIAP bind to the same region of the N-terminal  
FBXW7α domain, the RAE1 binding site within FBXW7α was characterized in more 
detail. For this purpose, additional truncated versions of Flag-FBXW7α were 
generated. Both N-terminal and C-terminal truncations were analyzed in order to 
narrow down the XIAP and RAE1 binding sites within the N-terminal domain of 
FBXW7α (Fig. 16). Interestingly, XIAP and RAE1 showed a similar binding behaviour 
to the different truncated versions of Flag-FBXW7α. On the one hand, residues 127-
167 were not required for the interaction with FBXW7α because a truncated version 
of FBXW7α that only contained the residues 1-126 (Flag-FBXW7α-N126) was still 
able to bind both XIAP and RAE1. Shorter versions (Flag-FBXW7α-N117 and Flag-
FBXW7α-N105), however, did not bind XIAP nor RAE1 (Fig. 17A). On the other 
hand, residues 1-105 of FBXW7α are not essential for the interactions with XIAP and 
RAE1. A truncated version that lacks these residues (Flag-FBXW7α-C106) is able to 
bind XIAP and RAE1, although the interaction is weaker than the interaction with the 
full-length version of Flag-FBXW7α (Fig. 17B). Truncated versions that lack residues 
1-126 (Flag-FBXW7α-C127, Flag-FBXW7α-C148 and Flag-FBXW7α-C168), 
however, were not found to interact with XIAP and RAE1. This result is consistent 
with the finding that residues 1-126 are sufficient for the interaction with XIAP and 
RAE1 (Fig. 17A). In summary, these results suggest that a sequence motif between 
residues 106 and 126 is essential for the interaction with both XIAP and RAE1. 
In order to confirm this finding, a Flag-tagged mutant of FBXW7α was generated, 
where residues 106-126 were deleted (Flag-FBXW7αΔ106-126, Fig. 18A). 
Immunoprecipitation of this deletion mutant revealed that XIAP and RAE1 were not 
able to bind to Flag-FBXW7α when residues 106-126 were deleted, whereas they 
clearly bound to the full-length version of Flag-FBXW7α (Fig. 18B). As expected, 
SKP1 bound to both full-length Flag-FBXW7 and Flag-FBXW7αΔ106-126. In 
summary, this confirms that a motif between residues 106 and 126 in the N-terminal 
domain of FBXW7α is required for the interaction with XIAP and RAE1. 
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Fig. 18: Deletion of amino acid residues 106-126 of FBXW7α abolishes the interactions with 
XIAP and RAE1. 
A: Illustration of the Flag-FBXW7αΔ106-126 mutant with a deletion of amino acid residues 106-126 in 
the N-terminal domain. B: Flag-FBXW7αΔ106-126 does not interact with XIAP or RAE1. Flag-
FBXW7α-FL and Flag-FBXW7αΔ106-126 were overexpressed in HEK-293T cells for 24 h. An empty 
vector (EV) was transfected as a control. Cell extracts were used for immunoprecipitations with α-Flag 
agarose beads. Immunoprecipitates were analyzed by Western blotting with α-RAE1, α-XIAP, α-SKP1 
and α-Flag antibodies. 
 
3.3.3. Amino acid residues 106-126 of FBXW7α contain a negatively charged 
sequence motif that is highly conserved among vertebrates 
As a short sequence between amino acid residues 106 and 126 of FBXW7α was 
shown to be required for the interaction with both XIAP and RAE1, this part of 
FBXW7α was analyzed in more detail. As shown in Fig. 19A, FBXW7α(106-126) 
contains a high percentage of negatively charged residues (D and E residues). 
Interestingly, comparison of human FBXW7α with homologues from other vertebrate 
species shows that the overrepresentation of negatively charged residues is 
conserved among vertebrates (Fig. 19A). In general, Fig. 19B shows that the N-
terminal domain of FBXW7α (residues 1-167) is less conserved among vertebrates 
than the part of FBXW7α that is shared with the β- and γ-isoforms (residues 168-
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707). However, a part of FBXW7α(106-126) is as conserved as the common domains 
of the FBXW7 isoforms (Fig. 19B). Only the conservation of the first amino acids at 
the extreme N-terminus of FBXW7α, which contain an important NLS motif (Welcker 
et al., 2004), is comparably high.  
 
 
 
Fig. 19: Conservation of amino acid residues 106-126 of FBXW7α among vertebrates. 
A: Alignment of amino acid residues 106-126 from human FBXW7α with homologues from Macaca 
mulatta, Mus musculus, Xenopus laevis and Danio rerio. B: Overview of the conservation of the whole 
FBXW7α protein sequence across the species indicated in A. Highly conserved sequence parts are 
illustrated in yellow. Amino acids with low conservation are shown in brown. 
 
3.3.4. FBXW7α, XIAP and RAE1 form a complex 
The finding that XIAP and RAE1 bind to the same motif within FBXW7α (Fig. 18) 
suggests that FBXW7α could bind to a protein complex that contains both XIAP and 
RAE1. In order to test this, FBXW7α-XIAP protein complexes were 
immunoprecipitated and analyzed for the presence of RAE1. For this purpose, Flag-
FBXW7α was overexpressed in HEK-293T cells and the corresponding cell extract 
was used for a two-step sequential immunoprecipitation. First, Flag-FBXW7α was 
immunoprecipitated with α-Flag agarose beads and the proteins were eluted from the 
beads by competition with Flag peptide. The eluates were used for a second 
immunoprecipitation directed against endogenous XIAP, thereby precipitating 
complexes containing Flag-FBXW7α and XIAP. These immunoprecipitates were then 
analyzed by Western blotting. As shown in Fig. 20A, Flag-FBXW7α and XIAP were 
specifically immunoprecipitated, whereas they were absent in the control, where an 
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empty vector had been transfected instead of the Flag-FBXW7α construct. In 
addition, RAE1 was specifically detected in co-immunoprecipitation with Flag- 
FBXW7α and XIAP. This confirms that FBXW7α, XIAP and RAE1 form a complex. 
 
Fig. 20: Identification of FBXW7α-XIAP complex components by a sequential 
immunoprecipitation approach. 
A: RAE1 interacts with FBXW7α-XIAP complex. Flag-FBXW7α was overexpressed in HEK-293T cells 
for 24 h. Cell extracts were used for an immunoprecipitation with α-Flag agarose beads. 
Immunoprecipitated proteins were eluted by competition with Flag peptide. Eluates were used for a 
second immunoprecipitation with α-XIAP antibodies. Immunoprecipitates were analyzed by Western 
blotting with α-Flag, α-RAE1 and α-XIAP antibodies. B: Immunoprecipitates after sequential 
immunoprecipitation from A were analyzed by SDS-PAGE and stained by Colloidal Coomassie. C: 
Whole lanes were cut out from the gel in B and analyzed by mass spectrometry. The table shows a 
selection of the proteins that were specifically identified in the Flag-FBXW7α-XIAP immunoprecipitate. 
For each identified protein, the MASCOT score, the protein mass, the number of significant sequences 
and the coverage are specified. 
 
3.3.5. Identification of additional FBXW7α-XIAP complex components 
In order to test whether additional proteins interact with the FBXW7α-XIAP complex 
apart from RAE1, the samples obtained after sequential immunoprecipitation were 
analyzed by SDS-PAGE and Colloidal Coomassie staining (Fig. 20B) as well as by 
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mass spectrometry. As expected, FBXW7, XIAP and RAE1 were identified by mass 
spectrometry (Fig. 20C). In addition, the SCF components CUL1 and SKP1 were 
detected. Moreover, MYCBP2, SPRYD3 and FBXO45 were found in co-
immunoprecipitation with Flag-FBXW7α/XIAP. Interestingly, these proteins had 
already been identified as putative interaction partners of Flag-FBXW7α (Fig. 5C) as 
well as Flag-XIAP (Fig. 15C). This indicates that FBXW7α could form a protein 
complex together with XIAP, RAE1, MYCBP2, SPRYD3 and FBXO45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Identification of RAE1 interaction partners. 
A-B: Flag-RAE1 was overexpressed in HEK-293T cells for 24 h. An empty vector (EV) was 
transfected as a control. Cell extracts were used for an immunoprecipitation directed against the Flag 
tag. Immunoprecipitated proteins were eluted by competition with Flag peptide. Eluates were analyzed 
by Western blotting with α-FBXW7α, α-XIAP, α-Flag and α-Vinculin antibodies (A) as well as by SDS-
PAGE and Colloidal Coomassie staining (B). Whole lanes were cut out from the gel in B and analyzed 
by mass spectrometry. C: Selection of proteins that were specifically identified in the Flag-RAE1 
immunoprecipitate by mass spectrometry. For each identified protein, the MASCOT score, the protein 
mass, the number of significant peptides and the coverage are specified. 
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3.3.6. Screen for RAE1 interaction partners  
In order to confirm the results from the interaction studies, a screen for RAE1 
interaction partners was performed. Flag-RAE1 was overexpressed in HEK-293T 
cells and immunoprecipitated from the cell extract with α-Flag resin. After elution by 
the addition of Flag peptide, immunoprecipitates were analyzed by Western blotting 
as well as SDS-PAGE for subsequent mass spectrometry analysis. As expected, 
FBXW7α and XIAP were detected in co-immunoprecipitation with Flag-RAE1 by both 
Western blotting (Fig. 21A) and mass spectrometry analysis (Fig. 21C). Known 
interaction partners of RAE1, as BUB1/BUB1B and NUP98 (Pritchard et al., 1999; 
Wang et al., 2001), were identified by mass spectrometry, thus validating the screen. 
Importantly, MYCBP2, FBXO45 and SPRYD3 were identified as putative interaction 
partners of Flag-RAE1 (Fig. 21C), again confirming that these proteins could be 
additional components of the complex that contains FBXW7α, XIAP and RAE1. 
 
3.3.7. Both FBXO45 and MYCBP2 interact with the N-terminal domain of 
FBXW7α 
In order to verify that FBXO45 is an interaction partner of FBXW7α, an 
immunoprecipitation experiment of Flag-FBXO45 was performed. As shown in Fig. 
22A, FBXW7α was found in co-immunoprecipitation with Flag-FBXO45. As expected, 
XIAP and RAE1 also interacted with Flag-FBXO45.  
To test whether FBXO45 interacts with the same motif of FBXW7α as XIAP and 
RAE1, the deletion mutant Flag-FBXW7αΔ106-126 was immunoprecipitated. Similar 
to XIAP and RAE1, endogenous FBXO45 was not detected in co-
immunoprecipitation with Flag-FBXW7αΔ106-126, whereas it clearly interacted with 
the full-length version of Flag-FBXW7α (Fig. 22B). This shows that FBXO45 interacts 
with a similar motif within FBXW7α as XIAP and RAE1. 
Also MYCBP2 was confirmed to interact with FBXW7α as Myc-tagged MYCBP2 was 
detected in co-immunoprecipitation with Flag-FBXW7α (Fig. 22C). However, it did not 
interact with Flag-FBXW7αΔ85-167, indicating that MYCBP2 also binds to the N-
terminus of FBXW7α (Fig. 22C). 
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Fig. 22: FBXO45 and MYCBP2 interact with the N-terminal domain of FBXW7α. 
A: Flag-FBXO45 interacts with endogenous FBXW7α. Flag-FBXO45 was overexpressed in HEK-293T 
cells for 24 h. Cell extracts were used for an immunoprecipitation directed against the Flag tag. 
Immunoprecipitates were analyzed by Western blotting with α-FBXW7α, α-RAE1, α-XIAP and α-Flag 
antibodies. B: FBXO45 interacts with the N-terminal domain of FBXW7α. Flag-FBXW7α-FL or Flag-
FBXW7αΔ106-126 were overexpressed in HEK-293T cells for 24 h. Cell extracts were used for α-Flag 
immunoprecipitations. Immunoprecipitates were analyzed by Western blotting with α-FBXO45, α-
XIAP, α-RAE1 and α-Flag antibodies. C: MYCBP2 interacts with the N-terminal domain of FBXW7α. 
Flag-FBXW7α-FL and Flag-FBXW7αΔ85-167 were overexpressed together with Myc-MYCBP2 in 
HEK-293T cells for 24 h. Cell extracts were used for immunoprecipitations with α-Flag agarose beads. 
Immunoprecipitates were analyzed by Western blotting with α-Myc, α-RAE1, α-XIAP and α-Flag 
antibodies. 
 
3.3.8. FBXW7α and FBXO45 bind to the central domain of MYCBP2 
MYCBP2 is a large protein of about 500 kDa that contains several characterized 
domains, such as an RCC1-like domain, two PHR domains, a central MYC-binding 
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domain and a C-terminal RING domain (Fig. 23) (reviewed by Grill et al., 2016). 
FBXO45 is a known interaction partner of MYCBP2 that has been shown to bind to 
the MYC-binding domain (Liao et al., 2004). Also RAE1 was shown to bind to a 
region close to the MYC-binding domain (Grill et al., 2012; Tian et al., 2011). In order 
to reproduce these data, Flag-tagged fragments of MYCBP2 were generated (Fig. 
23). As expected, immunoprecipitations of these fragments revealed that Myc-
FBXO45 (Fig. 24B) and endogenous RAE1 (Fig. 24A) bound to the Flag-
MYCBP2(1951-2950) fragment containing the central MYC-binding domain. 
Moreover, endogenous FBXW7α and XIAP bound to the Flag-MYCBP2(1951-2950) 
fragment (Fig. 24A). 
 
 
Fig. 23: Overview of Flag-tagged MYCBP2 fragments. 
Illustration of MYCBP2 fragments. Positions of RCC1-like domain (blue), PHR domains (green), MYC-
binding domain (yellow) and RING domain (red) are shown. 
 
 
 
 
 
RCC1-like domain 
PHR domains 
MYC-binding domain 
RING domain 
FL 
1-1050 
1051-1950 
1951-2950 
2951-3600 
3601-4640 
  Results 
81 
FBXW7α 
FBXW7α 
RAE1 
RAE1 
IP: Flag 
WCE 
Flag-MYCBP2(3601-4640) 
Flag-MYCBP2(2951-3600) 
Flag-MYCBP2(1951-2950) 
Flag-MYCBP2(1051-1950) 
Flag-MYCBP2(1-1050) 
EV + 
+ 
+ 
+ 
+ 
+ 
XIAP 
XIAP 
Flag 
Flag 
95 
43 
55 
95 
43 
55 
130 
95 
170 
130 
95 
Flag 
Flag 
Myc 
Myc 
Myc-FBXO45 
Flag-MYCBP2(3601-4640) 
Flag-MYCBP2(2951-3600) 
Flag-MYCBP2(1951-2950)  
Flag-MYCBP2(1051-1951) 
Flag-MYCBP2(1-1050) 
+ + + + + + 
+ 
+ 
+ 
+ 
+ 
IP: Flag 
WCE 
43 
43 
95 
130 
170 
95 
130 
A 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24: FBXW7α, XIAP, RAE1 and FBXO45 interact with the central domain of MYCBP2. 
A-B: The indicated Flag-tagged MYCBP2 fragments were overexpressed alone (A) or together with 
Myc-FBXO45 (B) in HEK-293T cells for 24 h. Cell extracts were used for α-Flag immunoprecipitations. 
Immunoprecipitates were analyzed by Western blotting with α-FBXW7α, α-RAE1, α-XIAP, α-Myc, and 
α-Flag antibodies. 
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3.3.9. FBXW7α forms a complex with MYCBP2 and FBXO45 
Both MYCBP2 and FBXO45 were identified as interaction partners of FBXW7α, XIAP 
and RAE1 by mass spectrometry (Fig. 5C, 15C, 21C). They were also identified as 
interactors of the FBXW7α-XIAP complex by sequential immunoprecipitation (Fig. 
20C). Moreover, both MYCBP2 and FBXO45 bind to the same domain of FBXW7α 
(Fig. 22B-C), whereas both FBXW7α and FBXO45 bind to the same part of MYCBP2 
(Fig. 24A-B). These findings suggest that FBXW7α, MYCBP2 and FBXO45 could be 
part of a larger protein complex together with XIAP and RAE1. In order to confirm 
this, a two-step sequential immunoprecipitation was performed. HEK-293T cells were 
transfected with plasmids expressing either Flag-MYCBP2(1951-2950) and HA-
FBXO45 or HA-FBXO45 alone. The first immunoprecipitation was directed against 
the Flag tag and precipitated proteins were eluted by competition with Flag peptide. 
Eluates were used for a second immunoprecipitation with α-HA resin. Analysis of 
immunoprecipitates by Western blotting (Fig. 25) revealed that FBXW7α bound to the 
MYCBP2-FBXO45 complex. As expected, also RAE1 was found in this complex. In 
summary, this suggests that FBXW7α, XIAP, RAE1, MYCBP2 and FBXO45 form a 
complex. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25: FBXW7α forms a complex with MYCBP2 and FBXO45. 
Flag-MYCBP2(1951-2950) and HA-FBXO45 were co-expressed in HEK-293T cells for 24 h. Cell 
extracts were used for an immunoprecipitation with α-Flag agarose beads. Immunoprecipitated 
proteins were eluted by competition with Flag peptide. Eluates were used for a second 
immunoprecipitation directed against the HA tag. Immunoprecipitates obtained after the sequential 
immunoprecipitation were analyzed by Western blotting with α-FBXW7α, α-RAE1, α-HA and α-Flag 
antibodies. 
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3.3.10. FBXO45 interacts with FBXW7α in vitro 
In order to find out which FBXW7α interaction partner directly binds to FBXW7α 
within the complex, in vitro pull-down assays were performed. As a direct interaction 
between FBXW7α and XIAP had not been observed (Fig. 14), only MYCBP2, 
FBXO45 and RAE1 were analyzed regarding their interaction with FBXW7α. 
Bacterially purified MBP or the MBP-tagged N-terminal domain of FBXW7α (MBP-
FBXW7α-N167) were incubated with in vitro translated versions of FBXO45, RAE1 or 
the MYC-binding domain containing MYCBP2 fragment. A subsequent MBP pull-
down with amylose beads revealed that only FBXO45 interacted with MBP-FBXW7α-
N167 in vitro, whereas RAE1 and the MYCBP2 fragment showed no interaction with 
the N-terminal domain of FBXW7α (Fig. 26). This indicates that FBXW7α is directly 
bound by FBXO45, whereas the interactions with the other complex components are 
possibly indirectly mediated by FBXO45. 
Fig. 26: FBXO45 directly interacts with the N-terminus of FBXW7α. 
A-C: Either MBP alone or MBP-FBXW7α-N167 were incubated with in vitro translated and [35S]-
methionine containing FBXO45 (A), MYCBP2(1951-2950) (B) or RAE1 (C). MBP was pulled down with 
amylose beads. Pull-down samples were analyzed by SDS-PAGE and Colloidal Coomassie staining. 
In vitro translated proteins were detected by autoradiography. 
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3.3.11. FBXO45 specifically interacts with FBXW7α 
FBXO45 interacts with the N-terminal domain of FBXW7α (Fig. 22B, 26A). This 
suggests that FBXO45 might specifically interact with the α-isoform of FBXW7 
because the β- and γ-isoforms contain different N-termini. In order exclude that there 
are other FBXO45 binding sites in FBXW7β or FBXW7γ, Flag-tagged versions of the 
three human FBXW7 isoforms were immunoprecipitated (Fig. 27). As expected, 
endogenous FBXO45 was only found in co-immunoprecipitation with Flag-FBXW7α, 
but not with Flag-FBXW7β or Flag-FBXW7γ. This result confirms that FBXO45 
specifically interacts with the FBXW7α isoform. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27: FBXO45 specifically interacts with the α-isoform of FBXW7. 
Flag-FBXW7α, Flag-FBXW7β or Flag-FBXW7γ were overexpressed in HEK-293T cells for 24 h. 
FBXW7 isoforms were immunoprecipitated by their Flag tags. Immunoprecipitates were analyzed by 
Western blotting with α-FBXO45, α-Flag and α-Tubulin antibodies. Tubulin was used as a loading 
control. 
 
3.4. Characterization of FBXO45 and MYCBP2 as novel regulators of FBXW7α 
 
3.4.1. FBXW7α protein levels decrease during mitotic arrest 
FBXW7α is a nuclear protein (Kimura et al., 2003), whereas FBXO45 and MYCBP2 
are mainly found in the cytosol (Chen et al., 2014; Pierre et al., 2004). Also XIAP is 
mainly localized in the cytosol (Liston et al., 2001). RAE1 shuttles between the 
nucleus and the cytosol (Kraemer and Blobel, 1997). It is therefore conceivable that 
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an effect of the identified complex on FBXW7α protein levels can be observed in 
mitosis upon nuclear envelope breakdown. 
In order to test whether there is a putative regulation of FBXW7α protein levels during 
mitotic arrest, HeLa cells were treated with nocodazole for 2 h. Mitotic cells were then 
collected by a mitotic shake-off and further incubated with nocodazole. Cells were 
harvested at different time points after addition of nocodazole and cell extracts were 
analyzed by Western blotting. MCL1 is a known FBXW7 substrate that has been 
described to be degraded during mitotic arrest (Inuzuka et al., 2011; Wertz et al., 
2011). As expected, this decrease in MCL1 protein levels could be confirmed (Fig. 
28). Interestingly, FBXW7α and MYC protein levels also decreased during mitotic 
arrest. This indicates that FBXW7α protein levels are negatively regulated during 
mitotic arrest. 
 
 
Fig. 28: FBXW7α protein levels decrease during prolonged mitotic arrest. 
HeLa cells were treated with 250 ng/mL nocodazole for 2 h. Mitotic cells were collected by mitotic 
shake-off and further incubated with 250 ng/mL nocodazole. The cells were harvested at different time 
points by a mitotic shake-off. Cell extracts were prepared and analyzed by Western blotting with α-
FBXW7α, α-MCL1, α-MYC and α-Vinculin antibodies. Vinculin was used as a loading control. Relative 
FBXW7α signal intensities were quantified. 
 
3.4.2. The FBXO45/MYCBP2 ubiquitin ligase regulates FBXW7α protein levels 
FBXO45 and MYCBP2 have been shown to form an E3 ubiquitin ligase complex that 
mediates the proteasomal degradation of several substrates. Since I could observe a 
binding of FBXO45 and MYCBP2 with FBXW7α, it is conceivable that FBXW7α is a 
substrate of the FBXO45/MYCBP2 ubiquitin ligase. It is possible that the decrease in 
FBXW7α protein levels during mitotic arrest is mediated by this complex. In order to 
test this, FBXO45 and MYCBP2 were downregulated in HeLa cells by siRNA 
treatment. The cells were treated with nocodazole in order to arrest them in mitosis 
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and harvested by a mitotic shake-off. As a control, asynchronous cells were 
harvested. In subsequent Western blot analysis (Fig. 29A), Cyclin B1 protein levels 
served as a mitotic marker. As expected, Cyclin B1 levels were increased in 
nocodazole-treated cells compared to asynchronous cells, confirming the mitotic 
arrest upon nocodazole treatment. Interestingly, FBXO45 and MYCBP2 
downregulation in nocodazole-arrested cells caused an increase in FBXW7α protein 
levels compared to control cells, which had been treated with control siRNA directed 
against firefly luciferase GL2. This increase in FBXW7α protein levels upon depletion 
of FBXO45 and MYCBP2 was not observed in asynchronous cells. These results 
suggest that the observed decrease in FBXW7α protein levels during mitotic arrest 
(Fig. 28) is mediated by FBXO45 and MYCBP2. Moreover, as the effect was not 
observed in asynchronous cells, it is conceivable that the regulation of FBXW7α by 
FBXO45 and MYCBP2 is specific for a prolonged mitotic arrest. 
In order to further analyze the specificity of the impact of FBXO45 and MYCBP2 on 
FBXW7α protein levels, the effect of FBXO45 and MYCBP2 was compared in a 
prolonged mitotic arrest and in unperturbed mitosis. For this purpose, mitotic cells 
were collected by mitotic shake-off after a release from a thymidine block and 
compared to nocodazole-treated cells (Fig. 29A). As expected, Cyclin B1 protein 
levels were increased in unperturbed mitotic cells compared to asynchronous cells. 
However, an increase in FBXW7α protein levels upon depletion of FBXO45 and 
MYCBP2 could only be observed in nocodazole-treated cells, but not in mitotic cells 
after release from a thymidine block. This indicates that the effect of FBXO45 and 
MYCBP2 on FBXW7α protein levels specifically occurs in a prolonged mitotic arrest, 
but not in unperturbed mitosis. 
In order to exclude that the observed effects on FBXW7α protein levels are caused 
by side-effects of the transfected siRNAs, siRNAs targeting different regions of 
FBXO45 and MYCBP2 mRNA were used (Fig. 29C). In mitotic HeLa cells, FBXW7α 
protein levels increased upon FBXO45 or MYCBP2 downregulation mediated by 
different siRNAs. The downregulation of FBXO45 and MYCBP2 by the different 
siRNAs was confirmed by Western blotting (Fig. 29B-C). 
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Fig. 29: FBXW7α protein levels are negatively regulated by FBXO45 and MYCBP2 during 
prolonged mitotic arrest. 
A: HeLa cells were transfected with 30 nM FBXO45 and MYCBP2 siRNAs for 72 h. GL2 siRNA was 
used as a control. The cells were arrested in mitosis by nocodazole (noco.) treatment (100 ng/mL for 
17 h) and collected by a mitotic shake-off. Alternatively, mitotic cells were enriched after a release 
from a double-thymidine block (thym. release), followed by a mitotic shake-off when the cells reached 
the mitotic peak. The mitotic cells were compared with an asynchronous (asy.) cell population. Cell 
extracts were analyzed by Western blotting with α-FBXW7α, α-Cyclin B1, α-FBXO45 and α-Vinculin 
antibodies. Vinculin was used as a loading control. A quantification of relative FBXW7α signal 
intensities is shown. Relative FBXW7α signals in the GL2 controls were set to 1. Average signal 
intensities and standard deviations from n=5 experiments were calculated. Statistical significance was 
analyzed by a two-tailed, unpaired t-test with unequal variance. * p<0.05; n.s.: not significant. B: HeLa 
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cells were transfected with 30 nM of different MYCBP2 siRNAs for 72 h. Cell extracts were analyzed 
by Western blotting with α-MYCBP2 and α-Vinculin antibodies. Vinculin was used as a loading control. 
C: HeLa cells were transfected with 30 nM of GL2, three different FBXO45 siRNAs or two different 
MYCBP2 siRNAs for 72 h. In addition, the cells were treated with 100 ng/mL nocodazole for 17 h 
before they were collected by a mitotic shake-off. Cell extracts were analyzed by Western blotting with 
α-FBXW7α, α-FBXO45 and α-Vinculin antibodies. Vinculin was used as a loading control. Relative 
FBXW7α signal intensities were quantified. Relative signal intensity in the GL2 control was set to 1. 
Average signal intensities and standard deviations from n=3 experiments were calculated. Statistical 
significance was analyzed by a two-tailed, unpaired t-test with unequal variance. * p<0.05; ** p<0.01. 
 
3.4.3. FBXO45 and MYCBP2 promote the ubiquitylation of FBXW7α 
My results reveal that FBXO45 and MYCBP2 negatively regulate FBXW7α protein 
levels during mitotic arrest (Fig. 29). In order to test whether this regulation is 
mediated by the ubiquitylation of FBXW7α, HEK-293T cells were transfected with 
constructs encoding Myc-FBXO45 and HA-Ubiquitin. Additionally, cells were treated 
with nocodazole to arrest them in mitosis and with MG132 in order to inhibit the 
proteasome and to allow the accumulation of ubiquitylated proteins. Cell extracts 
were then used for immunoprecipitations directed against endogenous FBXW7α. 
Western blot analysis of the FBXW7α immunoprecipitates revealed that Myc-
FBXO45 overexpression caused a strong, ladder-like HA signal pattern in co-
immunoprecipitation with FBXW7α (Fig. 30A). In contrast, HA signals could not be 
detected upon immunoprecipitation with a control antibody as well as in the absence 
of Myc-FBXO45 or HA-Ubiquitin. This indicates that FBXO45 promotes the 
ubiquitylation of FBXW7α. 
A similar experiment was performed in order to test a putative ubiquitylation of 
FBXW7α by MYCBP2. Flag-FBXW7α and Myc-MYCBP2 or Flag-FBXW7α alone 
were overexpressed in HEK-293T cells. After treatment of the cells with nocodazole 
and MG132, the cells were harvested. Cell extracts were used for 
immunoprecipitations directed against the Flag tag. Immunoprecipitates were 
analyzed for the presence of endogenous Ubiquitin signals by Western blotting. As 
shown in Fig. 30B, overexpression of Myc-MYCBP2 caused an increase in the 
ubiquitylation pattern intensity in the Flag-FBXW7α immunoprecipitate. This indicates 
that, in addition to FBXO45, also MYCBP2 promotes FBXW7α ubiquitylation. 
Moreover, these results suggest that the regulation of FBXW7α protein levels by 
FBXO45 and MYCBP2 depends on the ubiquitin-proteasome system. 
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Fig. 30: FBXO45 and MYCBP2 promote the ubiquitylation of FBXW7α. 
A: Myc-FBXO45 and HA-Ubiquitin were overexpressed in HEK-293T cells for 48 h. 4 h before 
harvesting, cells were treated with MG132. Cell extracts were prepared and immunoprecipitations with 
FBXW7α antibodies were performed. Rabbit IgG was used for a control immunoprecipitation. 
Immunoprecipitates were analyzed by Western blotting with α-HA, α-FBXW7α, α-Myc and α-Tubulin 
antibodies. Tubulin was used as a loading control. B: Myc-MYCBP2 and Flag-FBXW7α were 
overexpressed in HEK-293T cells for 48 h. 4 h before harvesting, cells were treated with MG132. Cell 
extracts were used for immunoprecipitations directed against the Flag tag. Immunoprecipitates were 
analyzed by Western blotting with α-Ubiquitin, α-Flag, α-Myc and α-Tubulin antibodies. Tubulin was 
used as a loading control. 
 
 
Results 
90 
3.4.4. FBXO45 mediates FBXW7α destabilization during mitotic arrest 
Proteins that are regulated by the ubiquitin-proteasome system are stabilized upon 
depletion of their upstream E3 ubiquitin ligases. In order to determine protein stability 
experimentally, synthesis of new proteins needs to be inhibited. The inhibition of 
cellular protein synthesis can be achieved by treatment of the cells with 
cycloheximide, an inhibitor of translation produced by the bacterium Streptomyces 
griseus. 
In order to study the effect of FBXO45 on FBXW7α protein stability during mitotic 
arrest, cells were transfected with GL2 or FBXO45 siRNA. In addition, cells were 
treated with nocodazole. Mitotic cells were collected by a mitotic shake-off and further 
incubated with nocodazole and cycloheximide. Cells were then harvested at different 
time points and cell extracts were prepared. Western blot analysis of the extracts 
revealed that FBXW7α was readily degraded in the control cells. Upon 
downregulation of FBXO45, however, FBXW7α was clearly stabilized (Fig. 31). This 
suggests that FBXO45 destabilizes FBXW7α, thus confirming that FBXO45 promotes 
the degradation of FBXW7α. 
 
 
Fig. 31: FBXW7α is stabilized upon siRNA-mediated downregulation of FBXO45. 
HeLa cells were transfected with 30 nM GL2 or FBXO45 siRNA for 72 h. 17 h before harvesting, the 
cells were treated with 100 ng/mL nocodazole. Mitotic cells were collected by a mitotic shake-off and 
further incubated with 100 ng/mL nocodazole and 100 µg/mL cycloheximide (CHX). The cells were 
harvested at different time points after the addition of cycloheximide by a mitotic shake-off. Cell 
extracts were analyzed by Western blotting with α-FBXW7α and α-Vinculin antibodies. Vinculin was 
used as a loading control. Relative FBXW7α signal intensities were quantified and average signal 
intensities as well as standard deviations from n=3 independent experiments are shown. 
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Fig. 32: FBXW7α interacts with the C-terminus of FBXO45. 
A: Overview of truncated FBXO45 versions. Positions of F-box domain (blue) and SPRY domain 
(green) are illustrated. B: The indicated Flag-tagged FBXO45 versions were overexpressed in HEK-
293T cells for 24 h. Cell extracts were used for α-Flag immunoprecipitations. Immunoprecipitates were 
analyzed by Western blotting with α-FBXW7α, α-Flag, α-SKP1 and α-Tubulin antibodies. Tubulin was 
used as a loading control. 
 
3.4.5. FBXW7α interacts with the C-terminus of FBXO45 
FBXO45 contains two well-characterized domains, an N-terminal F-box domain and a 
C-terminal SPRY domain. The SPRY domain has been shown to mediate FBXO45 
substrate binding (Chen et al., 2014; Kugler et al., 2010). As previous results suggest 
that FBXW7α is a substrate of FBXO45, it was analyzed whether FBXW7α interacts 
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with the SPRY domain containing C-terminus of FBXO45. In order to test this, Flag-
tagged versions of an N-terminal (Flag-FBXO45-N110) and a C-terminal FBXO45 
fragment (Flag-FBXO45-C111) were generated (Fig. 32A). The FBXO45 fragments 
as well as a full-length version of FBXO45 were overexpressed in HEK-293T cells. 
The cell extracts were used for immunoprecipitations with α-Flag agarose beads. As 
expected, SKP1 only interacted with the full-length version of FBXO45 and the Flag-
FBXO45-N110 fragment, which contains the F-box domain (Fig. 32B). In contrast, 
FBXW7α was only detected in co-immunoprecipitation with the full-length version of 
FBXO45 and the Flag-FBXO45-C111 fragment, which contains the SPRY domain 
(Fig. 32B). These results indicate that the interaction between FBXW7α and FBXO45 
depends on the SPRY domain of FBXO45, thus further supporting the finding that 
FBXW7α is a novel FBXO45 substrate. 
 
3.4.6. FBXO45 and MYCBP2 promote mitotic slippage 
FBXW7 has been described to regulate mitotic cell fate. In cells that have been 
treated with antimicrotubule drugs in order to arrest them in mitosis, FBXW7 
promotes mitotic cell death (Wertz et al., 2011). This function is consistent with the 
role of FBXW7 as a tumor suppressor protein as cancer cells are often able to evade 
mitotic cell death, thereby causing chemoresistance. 
As FBXO45 and MYCBP2 mediate the degradation of FBXW7α during mitotic arrest, 
they are expected to have a negative effect on mitotic cell death, thus promoting 
mitotic slippage. In order to test this, siRNA-mediated downregulation of FBXW7, 
FBXO45, MYCBP2 or FBXO45 in combination with MYCBP2 were performed in 
U2OS cells. The cells were treated with nocodazole and the mitotic cell fate was 
analyzed by live-cell imaging (Fig. 33A). 
As expected, siRNA-mediated downregulation of FBXW7 caused a significant 
increase in mitotic slippage from about 61±9% in the control to about 74±4%. 
FBXO45 downregulation led to a slight decrease in mitotic slippage to about 54±14%, 
whereas MYCBP2 downregulation reduced mitotic slippage to about 51±8%. 
However, these differences were not significant. On the other hand, co-depletion of 
FBXO45 and MYCBP2 caused a significant reduction of mitotic slippage to about 
43±10% (Fig. 33B). 
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In summary, these results show that FBXW7 and FBXO45/MYCBP2 have opposing 
effects on mitotic cell fate. This is consistent with our model that FBXW7α protein 
levels are regulated by the FBXO45/MYCBP2 ubiquitin ligase. 
 
Fig. 33: FBXO45 and MYCBP2 promote mitotic slippage. 
A-B: U2OS cells were transfected with 30 nM GL2, FBXW7, FBXO45 or MYCBP2 siRNA for 72 h and 
treated with 250 ng/mL nocodazole. 4 h after nocodazole addition, cells were analyzed by live-cell 
imaging. Representative images from live-cell imaging are shown in A. Time point 0 marks induction of 
mitotic cell death or mitotic slippage. Scale bars: 20 µm. Percentages of cells undergoing mitotic cell 
death or mitotic slippage were quantified and are presented in B. Cells from n=4 independent 
experiments were analyzed. In each experiment, 50-80 cells were quantified. Statistical significance 
was analyzed by a two-tailed, unpaired t-test. * p<0.05; n.s.: not significant.  
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4. Discussion 
 
4.1. Identification of novel FBXW7α interaction partners 
FBXW7 is a well-characterized tumor suppressor protein with a broad spectrum of 
known interaction partners. So far, most studies have focused on the identification 
and characterization of downstream FBXW7 substrates, whereas upstream ubiquitin 
ligases regulating FBXW7 protein levels remain to be identified. In addition to auto-
ubiquitylation, Parkin is the only E3 that has been described to regulate FBXW7 
protein stability and this regulation is specific for the FBXW7β isoform (Ekholm-Reed 
et al., 2013; Galan and Peter, 1999). Because FBXW7 exerts crucial functions within 
the cell, I hypothesized that FBXW7 protein levels need to be tightly controlled by 
different upstream ubiquitin ligases. It is for this reason that I performed a screen for 
novel FBXW7 interaction partners in order to identify ubiquitin ligases that are 
involved in the regulation of FBXW7. For the screen, which was based on 
immunoprecipitation and mass spectrometry analysis, I chose FBXW7α as the bait 
protein because Parkin was already described as a regulator of the FBXW7β isoform 
and because FBXW7α is the most ubiquitously expressed isoform with broad 
functions in different tissues (Matsumoto et al., 2006; Spruck et al., 2002). 
The fact that there are already many known FBXW7 interaction partners was used to 
validate the screen. Several known FBXW7 interaction partners were identified by 
mass spectrometry (Fig. 5), including the SCF components CUL1, SKP1 and RBX1, 
the CRL regulators NEDD8 and ARIH1 as well as the FBXW7 substrates MYC, 
NOTCH1/NOTCH2, MED13/MED13L, Aurora-B and mTOR (Davis et al., 2013; 
Feldman et al., 1997; Freed et al., 1999; Hubbard et al., 1997; Mao et al., 2008; 
Osaka et al., 1998; Read et al., 2000; Scott et al., 2016; Teng et al., 2012; Yada et 
al., 2004). 
Also other screens for interaction partners that were performed in this study could be 
validated in this manner. For XIAP, the known interaction partner HTRA2 was 
identified, whereas mass spectrometry detected NUP98 and BUB1/BUB1B in the 
RAE1 screen (Pritchard et al., 1999; Suzuki et al., 2001; Wang et al., 2001). 
 
4.2. WDR5 is a putative FBXW7 substrate 
Apart from focusing on FBXW7 regulators, I performed an initial characterization of 
WDR5 as a putative FBXW7 substrate. WDR5 is an interesting candidate because it 
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was identified in the screen (Fig. 5C) and has important functions as part of a histone 
methyltransferase complex and as a mitotic regulator of spindle assembly (Ali et al., 
2017; Rao and Dou, 2015). Interestingly, WDR5 was described to cooperate with 
MYC, which is a known substrate of FBXW7. MYC was shown to directly interact and 
to colocalize with WDR5 on chromatin. MYC mutants that cannot interact with WDR5 
partly lose their oncogenic potential, which supports an oncogenic role of WDR5 in 
MYC-mediated transcription (Thomas et al., 2015). Moreover, the MYC-WDR5 axis 
was found to support pancreatic cancer cell proliferation and to protect cancer cells 
from DNA damage (Carugo et al., 2016). In addition, WDR5 was found to interact 
and cooperate with NMYC, an oncogenic member of the MYC protein family and a 
known substrate of FBXW7, in neuroblastoma (Otto et al., 2009; Sun et al., 2015; 
Yada et al., 2004). FBXW7 has already been shown to regulate important pathways 
by mediating the degradation of several pathway components. For example, FBXW7 
controls the NOTCH pathway by regulating NOTCH and its activator Presenilin 
(Hubbard et al., 1997; Li et al., 2002; Wu et al., 1998). Therefore, it is conceivable 
that FBXW7 could regulate the important oncogenic MYC pathway via both MYC and 
WDR5. Interestingly, analysis of the human WDR5 protein sequence reveals that 
WDR5 contains a motif (PTPSSS, amino acids 17-22), which nicely matches the 
CPD consensus motif (Table 1). 
WDR5 protein levels were already shown to be regulated by the ubiquitin system. 
CUL4B-DDB1 was suggested as a ubiquitin ligase for WDR5 in the regulation of 
neuronal gene expression (Nakagawa and Xiong, 2011). 
Initial experiments presented in this thesis showed an endogenous interaction 
between FBXW7α and WDR5 (Fig. 6A). Moreover, depletion of FBXW7 caused an 
increase in WDR5 protein levels (Fig. 6B-C), supporting a putative regulation of 
WDR5 by FBXW7. 
However, I cannot exclude that the observed interaction between FBXW7 and WDR5 
is indirectly mediated by MYC. Additionally, the effects on WDR5 protein levels could 
be indirect. Indeed, the transcription of the WDR5 gene was shown to be upregulated 
by the FBXW7 substrate NMYC (Sun et al., 2015). Therefore, further experiments will 
be required in order to validate the direct regulation of WDR5 protein levels by 
FBXW7. 
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4.3. Analysis of putative FBXW7α regulators 
Ubiquitin ligases that had been identified as putative FBXW7α interaction partners by 
mass spectrometry (Fig. 5C) were considered as putative regulators of FBXW7α 
protein levels. Their effects on FBXW7α protein levels were analyzed by siRNA-
mediated downregulation of the corresponding E3s in HeLa cells. None of the 
analyzed siRNAs had a positive effect on FBXW7α protein levels (Fig. 7B, 8A-B). 
There are several possible explanations for this observation. First, the experiment 
was performed with an asynchronous cell population under standard growth 
conditions. It is possible that the putative regulators only show an effect on FBXW7 
protein levels in a specific context, for example in a specific cell-cycle stage or upon 
activation by a specific stimulus. Second, the putative ubiquitylation of FBXW7 by the 
candidate E3s does not necessarily have to cause proteasomal degradation of 
FBXW7. Depending on the type of ubiquitylation, there are alternative effects apart 
from degradation. For example, FBXW7 ubiquitin ligase activity or localization could 
be changed upon ubiquitylation (reviewed by Dikic et al., 2009). Third, the analyzed 
ubiquitin ligases could be FBXW7 substrates instead of FBXW7 regulators. Finally, 
the putative interactions between FBXW7 and the analyzed ubiquitin ligases could be 
indirect or unspecific. 
It is for these reasons that I decided to choose only one ubiquitin ligase (XIAP) from 
the list of putative FBXW7 regulators in order to study the interaction as well as 
putative effects on FBXW7 in more detail.  
 
4.4. XIAP, RAE1, FBXO45, MYCBP2 and SPRYD3 form a complex with FBXW7α 
As described above, I decided to characterize the interaction between XIAP and 
FBXW7α in more detail. I chose XIAP for further characterization because it is a well-
characterized protein with oncogenic functions, which is considered as a promising 
target in cancer therapy (reviewed by Fulda and Vucic, 2012). An interaction of an 
oncoprotein with a tumor suppressor protein seems likely. Moreover, XIAP was 
identified with one of the highest MASCOT scores in the screen for FBXW7α 
interaction partners (Fig. 5C). 
In the course of this project, XIAP was shown to interact with the N-terminal domain 
of the FBXW7α isoform in vivo (Fig. 13). XIAP could not be shown to directly bind the 
N-terminal domain of FBXW7α (Fig. 14), which rules out that there is a direct effect of 
XIAP on FBXW7α. Therefore, additional screens based on immunoprecipitation and 
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mass spectrometry were performed in order to identify the protein(s) that indirectly 
mediate the interaction between XIAP and FBXW7α. Interestingly, the screen for 
XIAP interaction partners identified RAE1, FBXO45, MYCBP2 and SPRYD3 with high 
MASCOT scores (Fig. 15C), which had already been identified in the screen for 
FBXW7α interaction partners (Fig. 5C). Detailed interaction studies revealed that 
RAE1 interacted with the same part of the N-terminal FBXW7α domain as XIAP (Fig. 
17, 18). Moreover, sequential immunoprecipitation suggested that FBXW7α, XIAP 
and RAE1 form a complex (Fig. 20A). In order to identify putative additional 
components of this complex, the samples obtained after sequential 
immunoprecipitation were analyzed by mass spectrometry. Interestingly, FBXO45, 
MYCBP2 and SPRYD3 were also identified in this screen (Fig. 20C). These results 
were supported by another screen for RAE1 interaction partners, where XIAP, 
FBXO45, MYCBP2, SPRYD3 and FBXW7 were identified (Fig. 21C). Finally, 
FBXO45 and MYCBP2 bound to the same part of the N-terminal FBXW7α domain as 
XIAP and RAE1 (Fig. 22B-C). An additional sequential immunoprecipitation approach 
revealed that FBXW7α, FBXO45 and MYCBP2 form a complex (Fig. 25). Taken 
together, these results strongly suggest that FBXW7α, XIAP, RAE1, FBXO45, 
MYCBP2 and SPRYD3 are found in a complex in vivo. 
Importantly, this conclusion is supported by the literature. On the one hand, FBXO45 
is a known interaction partner of MYCBP2 (Liao et al., 2004; Saiga et al., 2009; Wu et 
al., 2007). Also RAE1 was shown to interact with MYCBP2 (Grill et al., 2012; Tian et 
al., 2011). On the other hand, several published screens found putative interactions 
between some of the complex components identified in this study. A published 
screen for FBXW7α interaction partners identified MYCBP2, FBXO45, RAE1 and 
SPRYD3 (Kourtis et al., 2015). The authors suggested an indirect interaction 
between FBXW7α and FBXO45/MYCBP2 via the SCF complex without showing any 
experimental evidence for this. However, the results obtained in the presented thesis 
do not support this speculation. The F-box domain of FBXW7α was not required for 
the interaction with FBXO45 and MYCBP2. Instead, FBXO45 and MYCBP2 (as well 
as XIAP and RAE1) bound to the N-terminal domain of FBXW7α (Fig. 22B-C). 
Moreover, FBXO45 interacted with the N-terminal domain of FBXW7α in vitro (Fig. 
26A). 
Yet another published screen for protein interaction networks identified putative 
interactions between FBXW7 and MYCBP2, FBXO45 as well as RAE1 (Huttlin et al., 
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2017). In summary, these published data support the interactions that are 
characterized in the presented thesis. 
 
4.5. FBXO45 and MYCBP2 promote the degradation of FBXW7α during mitotic 
arrest 
Putative direct interactions between the N-terminal domain of FBXW7α and XIAP, 
RAE1, FBXO45 as well as MYCBP2 were analyzed (Fig. 14, 26). Only FBXO45 
bound to the N-terminal FBXW7α domain in vitro (Fig. 26A). FBXO45 has been 
described to form a ubiquitin ligase complex with MYCBP2 (Liao et al., 2004; Saiga 
et al., 2009; Wu et al., 2007). Therefore, I focused on the analysis of 
FBXO45/MYCBP2-mediated effects on FBXW7α protein levels in this thesis. 
Interestingly, FBXO45 and MYCBP2 specifically regulated FBXW7α protein levels in 
a mitotic arrest, whereas no effects were observed in unperturbed mitosis or in 
asynchronous cells (Fig. 29A). The presented data in this thesis suggest that the 
negative regulation of FBXW7α protein levels by FBXO45/MYCBP2 depends on the 
ubiquitin-proteasome system based on the following observations: (1) 
Overexpression of both FBXO45 and MYCBP2 induce an increased ubiquitylation of 
FBXW7α (Fig. 30) and (2) siRNA-mediated downregulation of FBXO45 increased the 
stability of FBXW7α protein in a cycloheximide experiment (Fig. 31). 
Interestingly, several links between MYCBP2 and FBXW7 substrates have been 
described in the literature. MYCBP2 was originally identified as a MYC interaction 
partner (Guo et al., 1998). MYCBP2 binds to a region of MYC that contains the CPD 
motif, which is recognized and bound by FBXW7 (Yada et al., 2004). MYC and 
FBXO45 bind to the same domain of MYCBP2 (Saiga et al., 2009). A MYCBP2 
fragment that contains the MYC- and FBXO45-binding domains interacts with 
FBXW7α (Fig. 24). Therefore, although the interaction between MYC and MYCBP2 
was shown in vitro, it is possible that the interaction could partly be mediated by 
FBXW7α in vivo. 
Other publications described a positive effect of MYCBP2 on mTOR signaling and a 
link between MYCBP2 and the circadian regulator REV-ERBα (Han et al., 2008; 
Maeurer et al., 2009; Murthy et al., 2004; Yin et al., 2010). However, the effects of 
MYCBP2 on REV-ERBα have only been observed in combination with another 
ubiquitin ligase called HUWE1. Therefore, the specific role of MYCBP2 in the 
regulation of REV-ERBα remains elusive. 
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4.6. Degradation of FBXW7α by FBXO45/MYCBP2 might promote resistance to 
spindle poisons 
Spindle poisons, such as nocodazole, vincristine or paclitaxel (Taxol), are drugs that 
prevent the assembly (nocodazole, vincristine) or the disassembly (paclitaxel) of 
microtubules (reviewed by Field et al., 2014). By preventing normal microtubule 
dynamics, spindle poisons inhibit spindle function and chromosome segregation 
during mitosis. Treatment with spindle poisons therefore activates the spindle 
assembly checkpoint (SAC) and the corresponding cells arrest in mitosis. Cells that 
have been arrested in mitosis after treatment with spindle poisons frequently undergo 
mitotic cell death. It is for this reason that spindle poisons, for example paclitaxel and 
vincristine, are widely used in chemotherapy in order to prevent proliferation of 
cancer cells and to induce cancer cell death (reviewed by Topham and Taylor, 2013). 
However, cells that are arrested in mitosis do not always undergo mitotic cell death. 
Alternatively, cells can perform mitotic slippage, which means that they exit from 
mitosis without completing a normal cell division, resulting in tetraploid cells. Mitotic 
slippage is a problem with respect to chemotherapy as cancer cells are often able to 
evade mitotic cell death by performing mitotic slippage. Mitotic slippage can therefore 
promote chemoresistance of cancer cells. Resistance to drugs is a big problem in 
chemotherapy and often impairs their result. In addition, the formation of tetraploid 
cells by mitotic slippage supports aneuploidy and cancer formation (reviewed by 
Topham and Taylor, 2013). 
The decision whether a cell undergoes mitotic cell death or mitotic slippage depends 
on the balance between different signals. On the one hand, there are death signals 
that result in the activation of caspases. On the other hand, Cyclin B gets slowly 
degraded during mitotic arrest, promoting the exit from mitosis (Brito and Rieder, 
2006). Originally, residual APC/C activity has been thought to mediate the 
degradation of Cyclin B while the SAC is active. However, this view is challenged by 
the discovery of a CRL2 complex that degrades Cyclin B during mitotic arrest 
(Balachandran et al., 2016). If one of the opposing signals, caspase activation or 
Cyclin B degradation, reaches a specific threshold, mitotic cell death or mitotic 
slippage will be induced (Topham and Taylor, 2013). 
Several oncoproteins and tumor suppressors are involved in the regulation of mitotic 
cell fate. For example, MCL1 is an inhibitor of apoptosis and a key regulator of cell 
death signals during mitotic arrest. MCL1 is unstable during mitotic arrest, allowing 
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death signals to increase with time. Overexpression of MCL1 in cancer delays the 
increase in death signals, thereby promoting mitotic slippage (Schwickart et al., 
2010). Two different ubiquitin ligases have been shown to promote the degradation 
of MCL1 during mitotic arrest. On the one hand, the APC/C causes a decrease in 
MCL1 protein levels in prolonged mitosis (Harley et al., 2010). On the other hand, the 
SCF-FBXW7 complex was identified as a regulator of MCL1 both in interphase and in 
mitosis (Inuzuka et al., 2011; Wertz et al., 2011). Indeed, deletion of FBXW7 was 
found to promote mitotic slippage, which is consistent with its function to mediate the 
degradation of MCL1, thereby promoting cell death signals during mitotic arrest 
(Wertz et al., 2011). The promotion of mitotic cell death by FBXW7 is also consistent 
with its role as a tumor suppressor, as it counteracts cancer cell death evasion. 
In the presented thesis, the effect of FBXW7 on mitotic cell fate was confirmed. As 
expected, siRNA-mediated downregulation of FBXW7 promoted mitotic slippage (Fig. 
33). As FBXO45 and MYCBP2 promoted the degradation of FBXW7α specifically 
during mitotic arrest, it was conceivable that they would indirectly also affect mitotic 
cell fate. Indeed, siRNA-mediated downregulation of FBXO45 and MYCBP2 
promoted mitotic cell death (Fig. 33), which is consistent with their roles as negative 
regulators of FBXW7α protein levels. In conclusion, it is possible that FBXO45 and 
MYCBP2 are involved in the regulation of cell death signals during mitotic arrest, 
thereby modulating the balance between mitotic cell death and mitotic slippage. 
Overexpression of FBXO45 and MYCBP2 in cancer might promote mitotic slippage, 
thereby supporting resistance of cancer cells to spindle poisons.  
Consistent with this putative oncogenic function of the FBXO45/MYCBP2 complex, 
FBXO45 amplification is frequently found in different cancer types (cBioPortal for 
Cancer Genomics, Cerami et al., 2012; Gao et al., 2013). Moreover, FBXO45 was 
already described to have a negative effect on apoptosis by the regulation of p73 and 
PAR4 (Chen et al., 2014; Peschiaroli et al., 2009). 
 
4.7. Different FBXW7 substrates could mediate the effect of FBXO45/MYCBP2 
on mitotic cell fate 
As described above, FBXW7 is thought to induce mitotic cell death by promoting the 
degradation of MCL1 (Wertz et al., 2011). However, the exact role of FBXW7 in 
mitotic MCL1 degradation is still under debate because the APC/C-CDC20 has been 
shown to regulate MCL1 in the same cellular context (Harley et al., 2010). It is 
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possible to argue that the SCF-FBXW7 complex could be solely responsible for 
MCL1 ubiquitylation during prolonged mitotic arrest with active SAC signaling 
because the APC/C should be inhibited under these conditions. However, the APC/C 
is able to promote the degradation of specific substrates, for example Cyclin A, 
independently from SAC activation (den Elzen and Pines, 2001; Geley et al., 2001). It 
is therefore still unclear whether the APC/C and the SCF-FBXW7 complex cooperate 
or compete regarding mitotic degradation of MCL1. Furthermore, it is possible that 
the effect of FBXW7 on mitotic cell fate is mediated by additional substrates apart 
from MCL1. 
Similar to FBXW7, MYC has been shown to promote mitotic cell death (Topham et 
al., 2015). At first glance, this suggests that MYC cannot be the FBXW7 substrate 
mediating the effects of FBXW7 on mitotic cell fate. However, the pro-apoptotic 
function of MYC mainly stems from an apoptotic transcription program that is induced 
upon MYC overexpression during interphase (Topham et al., 2015). It is possible that 
MYC could have other anti-apoptotic effects specifically during mitotic arrest that 
cannot be observed upon overexpression of MYC during the whole cell cycle. In this 
case, specific regulation of MYC by the FBXO45/MYCBP2-FBXW7α axis during 
mitotic arrest would be able to affect only the mitotic function of MYC. Indeed, MYC 
protein levels were observed to decrease during prolonged mitotic arrest, similar to 
MCL1 protein levels (Fig. 28). Moreover, there is published experimental evidence 
that the effect of MYC on mitotic cell fate could be complex and multilayer. MYC 
negatively regulates the expression of the anti-apoptotic protein BCL-XL (Eischen et 
al., 2001). Consistent with the anti-survival function of MYC, overexpression of BCL-
XL prevented mitotic cell death. However, prevention of mitotic cell death upon BCL-
XL overexpression was much more efficient than upon MYC downregulation 
(Eichhorn et al., 2014; Topham et al., 2015). This suggests that MYC could have 
additional functions opposing its role as a promoter of mitotic cell death. Consistent 
with this, it was suggested that MYC has a stabilizing effect on MCL1 protein 
(Topham et al., 2015). Therefore, it could be intriguing to analyze whether the 
suggested effect of FBXW7 on MCL1 during mitotic arrest could be partly mediated 
by MYC. 
Furthermore, cancer-specific Cyclin E isoforms and JUN have been suggested to 
promote mitotic slippage (Bagheri-Yarmand et al., 2010; Duan et al., 2007). In 
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summary, these findings suggest that other FBXW7 substrates apart from MCL1 
could be involved in FBXW7 dependent regulation of mitotic cell fate. 
 
4.8. A negatively charged motif within the N-terminal domain of FBXW7α is 
recognized by FBXO45/MYCBP2 
In this study, a short motif within the N-terminal domain of FBXW7α, which is 
required for the interactions with XIAP, RAE1, FBXO45 and MYCBP2, was identified 
(Fig. 22). Interestingly, the motif is negatively charged because of its high content of 
acidic amino acid residues (glutamate and aspartate). Moreover, the motif is highly 
conserved among vertebrate orthologues of FBXW7 (Fig. 19). 
FBXO45 is the direct interaction partner of FBXW7α within the identified protein 
complex (Fig. 26A). An FBXO45 fragment containing the SPRY domain was shown 
to bind FBXW7α (Fig. 32). The SPRY domain has already been shown to bind 
substrates of the FBXO45/MYCBP2 complex (Chen et al., 2014; Kugler et al., 2010). 
Sequence motifs within substrates that are recognized by SPRY domain containing 
proteins have only poorly been characterized so far. One of the only known 
sequence motifs that were shown to bind to SPRY domains was identified in the 
Drosophila protein VASA. The VASA motif (DINNNN) is recognized by the SPRY 
domain and SOCS box containing (SPSB) protein GUSTAVUS (Styhler et al., 2002). 
Human SPSB proteins have been shown to interact with a similar motif (ELNNNL) of 
the human protein PAR4 (Woo et al., 2006). Additional studies suggested that this 
motif of PAR4 is also recognized by the SPRY domain of FBXO45 and that FBXO45 
binds to two similar motifs (DMNDNR and DVNDNP) within CDH2 (Chen et al., 2014; 
Chung et al., 2014). However, a similar motif is not included in the N-terminal 
FBXW7α sequence that is required for the interaction with FBXO45 (Fig. 19). 
Interestingly, however, there is another interaction between a SPRY domain and a 
sequence motif in the literature that has been characterized extensively. ASH2L and 
RBBP5, two components of a histone methyltransferase complex, interact via the 
SPRY domain of ASH2L. The motif in RBBP5, which interacts with the SPRY domain 
of ASH2L, has been identified in several publications (Cao et al., 2010; Zhang et al., 
2015). Importantly, the RBBP5 motif contains a high percentage of negatively 
charged D and E residues, suggesting that SPRY domains might be able to bind 
acidic patches within protein sequences. This is consistent with the finding that the 
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FBXO45 binding motif within the N-terminal domain of FBXW7α contains a cluster of 
acidic residues (Fig. 19). 
 
4.9. Putative roles of RAE1, XIAP and SPRYD3 in the complex with FBXW7α, 
FBXO45 and MYCBP2 
RAE1, XIAP and SPRYD3 were identified as putative components of the complex 
with FBXW7α, FBXO45 and MYCBP2. However, RAE1 and XIAP did not interact 
with FBXW7α in vitro (Fig. 14, 26). The interaction between SPRYD3 and FBXW7α 
has not been analyzed in this thesis. Therefore, the question remains what the roles 
of RAE1, XIAP and SPRYD3 could be in the complex. 
RAE1 has been described as a conserved interaction partner of MYCBP2. It was 
shown to cooperate with MYCBP2, but the specific function of RAE1 in complex with 
MYCBP2 is not completely clear. Drosophila RAE1 was suggested to stabilize 
Highwire by preventing its autophagy-dependent degradation (Tian et al., 2011). On 
the other hand, another publication suggested that C. elegans RAE1 functions 
downstream of RPM-1 (Grill et al., 2012). In the same publication, the authors 
showed that binding of RAE1 to RPM-1 is required for RPM-1 function, whereas they 
did not observe an effect of RAE1 on RPM-1 protein levels. Therefore, it remains 
unclear whether RAE1 could have different roles in different organisms. Alternatively, 
RAE1 could act downstream of MYCBP2 and could simultaneously feed back on 
MYCBP2 protein levels or activity. 
So far, XIAP has not been described as an interaction partner of FBXW7α, FBXO45, 
MYCBP2, RAE1 or SPRYD3. Since FBXO45 and MYCBP2 had a specific effect on 
FBXW7α protein levels during mitotic arrest, it is interesting to discuss the known 
mitotic functions of XIAP. XIAP was shown to be deubiquitylated and stabilized by 
USP9X during mitotic arrest. USP9X and XIAP promoted chemoresistance (Engel et 
al., 2016). On the other hand, XIAP gets phosphorylated by CDK1-Cyclin B1 during 
mitotic arrest, which prevents the anti-apoptotic activity of XIAP, thus promoting 
mitotic cell death induced by spindle poisons (Hou et al., 2017). The role of XIAP in 
the regulation of mitotic cell death could be a link to the FBXO45/MYCBP2-
dependent degradation of FBXW7α during mitotic arrest. XIAP could inhibit mitotic 
cell death not only by the inhibition of caspases or stimulation of NF-κB signaling, but 
also by promoting the FBXO45/MYCBP2-dependent degradation of FBXW7α. XIAP 
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could possibly promote the degradation of FBXW7α by promoting FBXO45/MYCBP2 
complex formation or by stimulating FBXO45/MYCBP2 ubiquitin ligase activity. 
SPRYD3 is an uncharacterized protein whose cellular function is still unknown. It was 
identified as a putative interaction partner of FBXW7α, FBXO45, MYCBP2, RAE1 
and XIAP in this thesis. Interestingly, SPRYD3 contains a SPRY domain similar to 
FBXO45. The SPRY domain of FBXO45 was shown to bind substrates of the 
FBXO45/MYCBP2 complex (Chen et al., 2014; Kugler et al., 2010). Also FBXW7α 
binds to an FBXO45 fragment that contains the SPRY domain (Fig. 32). Therefore, it 
is possible that SPRYD3 serves as an additional substrate recognition subunit in the 
complex with MYCBP2. Indeed, there is evidence in the literature that MYCBP2 could 
use additional substrate recognition subunits apart from FBXO45. For example, the 
MYCBP2 substrate TSC2 (Tuberin), a negative regulator of mTOR signaling, shows 
increased protein levels in mice with Phr mutation, but not in mice with a Fbxo45 
deletion. Moreover, overexpression of Phr leads to an activation of mTOR signaling, 
which is not observed upon overexpression of Fbxo45 (Han et al., 2012). 
If SPRYD3 served as an additional substrate recognition subunit for MYCBP2 
complexes, it could be interchangeable with FBXO45 in MYCBP2 complexes. This 
would be comparable to the interchangeability of F-box proteins within the SCF 
complex. Interchangeability of substrate recognition subunits in MYCBP2 complexes 
would allow the targeting of different substrate subsets under different conditions, for 
example in different cell-cycle stages. On the other hand, SPRYD3 could cooperate 
with FBXO45 to specifically target substrate proteins for ubiquitylation by MYCBP2. 
This would be comparable with the F-box protein SKP2, which uses the cofactor 
CKS1 to bind its substrate p27 (Ganoth et al., 2001; Spruck et al., 2001). 
 
4.10. Outlook and perspectives 
 
4.10.1. WDR5 as a putative FBXW7 substrate 
Initial experiments suggested that WDR5 could act as a substrate of FBXW7. 
However, it cannot be excluded that the observed interaction between FBXW7 and 
WDR5 as well as the effect of FBXW7 on WDR5 protein levels are indirect. 
Therefore, it will be important to show a direct interaction between FBXW7 and 
WDR5 in vitro in future experiments. Moreover, in order to exclude that the effects on 
WDR5 protein levels are indirectly caused by an increase in WDR5 transcript levels 
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upon FBXW7 depletion, cycloheximide chase experiments can be performed. These 
experiments will show whether FBXW7 affects the protein stability of WDR5. 
All of the known FBXW7 substrates bind to the WD40 domain of FBXW7. Thus, it 
would be interesting to analyze whether WDR5 also binds to the WD40 domain of 
FBXW7. Recognition of WDR5 by the WD40 domain would support the putative role 
of WDR5 as an FBXW7 substrate. On the other hand, FBXW7 substrates contain a 
conserved sequence motif, the CDC4 phosphodegron or CPD (Table 1). As 
discussed above, WDR5 contains a putative CPD motif. In future experiments, it 
could be tested if point mutations within the putative CPD of WDR5 affect the 
interaction with FBXW7. Moreover, it would be interesting whether WDR5 mutations 
within the CPD have an effect on its stability or on a putative ubiquitylation by 
FBXW7. 
 
4.10.2. Verification of the FBXW7α regulation by FBXO45/MYCBP2 
The obtained data in the presented thesis suggest that the FBXO45/MYCBP2 protein 
complex interacts with a negatively charged motif within the N-terminal domain of 
FBXW7α (Fig. 19, 22). The binding of FBXW7α by the FBXO45/MYCBP2 complex is 
mediated by a direct interaction between FBXW7α and FBXO45 (Fig. 26A). In future 
experiments, it will be necessary to further confirm this interaction. It should be tested 
whether a deletion of the binding site within the N-terminal domain of FBXW7α also 
prevents the in vitro interaction between FBXW7α and FBXO45. Moreover, the in 
vitro interaction between FBXW7α and FBXO45 could be confirmed in experiments 
that only analyze the interaction between recombinant, bacterially purified proteins 
instead of using in vitro transcription and translation approaches with rabbit 
reticulocyte extracts. 
FBXO45 and MYCBP2 promoted the degradation of FBXW7α upon nocodazole-
mediated mitotic arrest (Fig. 29A). In this context, it would be interesting to analyze if 
the effect on FBXW7α protein levels can also be observed upon treatment with other 
spindle poisons, for example paclitaxel or vincristine. These spindle poisons are 
frequently used in chemotherapy. The putative finding that FBXO45/MYCBP2 
regulate the tumor suppressor FBXW7α upon treatment with a broad spectrum of 
spindle poisons could impact our understanding of how chemoresistance might arise. 
Furthermore, the effects of FBXO45/MYCBP2 on FBXW7α were specifically 
observed during mitotic arrest, while they were not detected during unperturbed 
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mitosis or in asynchronous cells (Fig. 29A). This regulation of FBXW7α in a specific 
cell-cycle stage might be caused by a specific interaction between FBXO45/MYCBP2 
and FBXW7α during mitosis. Indeed, FBXO45 and MYCBP2 are mainly localized in 
the cytosol, whereas FBXW7α resides in the nucleus (Chen et al., 2014; Kimura et 
al., 2003; Pierre et al., 2004). Nuclear breakdown during mitosis might promote the 
interaction between FBXO45/MYCBP2 and FBXW7α. The transient interaction during 
unperturbed mitosis might not be long enough to cause visible effects on FBXW7α 
protein levels. Alternatively, additional signals, such as posttranslational modifications 
of one of the interaction partners, might be required to induce the interaction. These 
signals might be specific for a mitotic arrest. In future experiments, it will be important 
to verify that FBXO45/MYCBP2 specifically interact with FBXW7α during mitotic 
arrest. 
The deletion mutant of FBXW7α, which did not bind to FBXO45, XIAP, RAE1 or 
MYCBP2 (Fig. 22), could be analyzed in comparison to the wild-type version of 
FBXW7α in future ubiquitylation assays and in cycloheximide chase experiments. 
The deletion mutant of FBXW7α should not be ubiquitylated upon FBXO45/MYCBP2 
overexpression and its stability should be increased compared to wild-type FBXW7α. 
These experiments could support a direct effect of FBXO45/MYCBP2 on FBXW7α 
ubiquitylation and stability. 
Although most studies described FBXO45 in complex with MYCBP2, one publication 
suggested that FBXO45 can be incorporated into the canonical SCF complex in 
addition to its complex formation with MYCBP2 (Peschiaroli et al., 2009). In the 
presented thesis, I showed that FBXO45 and MYCBP2 form a complex with FBXW7α 
(Fig. 25). Moreover, single analysis of only FBXO45 or only MYCBP2 revealed that 
they both promote the ubiquitylation and degradation of FBXW7α (Fig. 29, 30). 
Nevertheless, it would be supportive to further verify that it is the complex formation 
between FBXO45 and MYCBP2 that is required for the degradation of FBXW7α. In 
the literature, it has been shown that the ectopic overexpression of the MYCBP2 
domain that contains the FBXO45 binding site is able to inhibit the downstream 
functions of the FBXO45/MYCBP2 complex (Sharma et al., 2014). Therefore, the 
corresponding MYCBP2 fragment could be used as a tool to study the dependency 
of FBXW7α protein levels on FBXO45/MYCBP2 complex formation. 
FBXW7α binds to a fragment of FBXO45 that contains the SPRY domain (Fig. 32). 
Other substrates of FBXO45 have already been described to interact with the SPRY 
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domain (Chen et al., 2014; Kugler et al., 2010). As already discussed above, the 
SPRY domain of ASH2L binds a negatively charged motif of RBBP5, which is similar 
to the FBXO45 binding motif of FBXW7α (Cao et al., 2010; Zhang et al., 2015). 
Because of these similarities between the ASH2L/RBBP5 and FBXO45/FBXW7α 
interactions, it is possible that further details about the interaction between FBXO45 
and FBXW7α can be concluded from the ASH2L/RBBP5 complex. For example, 
specific residues within the SPRY domain of ASH2L were identified as important 
mediators of RBBP5 binding (Zhang et al., 2015). Sequence alignment of the ASH2L 
and FBXO45 SPRY domains could be used in order to identify corresponding 
residues in the FBXO45 SPRY domain that mediate the interaction with FBXW7α. 
Point mutations of these residues could be introduced in the FBXO45 protein, which 
could serve as a dominant-negative mutant for further experiments. 
 
4.10.3. Unraveling the roles of RAE1, XIAP and SPRYD3 in the complex 
RAE1 and XIAP do not directly interact with FBXW7α (Fig. 14, 26C). However, RAE1 
is a known component of the FBXO45/MYCBP2 complex (Grill et al., 2012; Tian et 
al., 2011). XIAP has not been linked to the FBXO45/MYCBP2 complex so far, but it is 
a known regulator of mitotic cell fate (Engel et al., 2016; Hou et al., 2017). They were 
both identified in a complex with FBXO45/MYCBP2 and FBXW7α (Fig. 21, 25). 
Therefore, it would be interesting to analyze putative functional links between RAE1, 
XIAP and FBXO45/MYCBP2. First, the direct interaction partners of RAE1 and XIAP 
in the complex should be identified. As RAE1 was suggested as a regulator of 
Highwire stability in Drosophila (Tian et al., 2011), putative effects of RAE1 on 
MYCBP2 protein levels could be analyzed. As XIAP is a well-characterized ubiquitin 
ligase, the effects of its ubiquitin ligase activity on the stabilities of other complex 
components or on FBXW7α/FBXO45/MYCBP2 complex formation could be 
determined. As an alternative to siRNA-mediated downregulation of XIAP, cells could 
be treated with SMAC mimetics in order to inhibit the ubiquitin ligase activity of XIAP 
in future experiments (reviewed by Fulda and Vucic, 2012). 
As already discussed above, SPRYD3 is an uncharacterized protein. But since both 
FBXO45 and SPRYD3 contain SPRY domains, SPRYD3 could fulfill a similar 
function as FBXO45 in the protein complex. In future experiments, the putative 
interactions between SPRYD3 and the other complex components should be verified. 
In addition, in order to determine whether SPRYD3 might cooperate with FBXO45 in 
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the regulation of FBXW7α, siRNA-mediated downregulation of SPRYD3 and 
FBXO45 alone as well as co-depletion of SPRYD3 and FBXO45 could be compared 
with respect to their effects on FBXW7α protein levels. 
 
4.10.4. Identification of mitotic FBXW7 substrate(s) 
As discussed above, regulation of FBXW7α by FBXO45/MYCBP2 during mitotic 
arrest might affect mitotic cell fate (Fig. 33). In future experiments, it will be necessary 
to identify the FBXW7α substrate(s) that mediate(s) the effect of FBXO45/MYCBP2 
on mitotic cell fate. Overexpression of such a substrate should be able to rescue the 
increase in mitotic cell death observed upon downregulation of FBXO45 and 
MYCBP2. This kind of rescue experiment would also verify a direct link between 
FBXO45/MYCBP2 and FBXW7α in the regulation of mitotic cell fate. 
An alternative strategy to identify FBXW7α substrates that are affected by 
FBXO45/MYCBP2 would be the analysis of different FBXW7α substrate levels upon 
overexpression of FBXO45/MYCBP2 in mitotic cells. Because of the negative effect 
of FBXO45/MYCBP2 on FBXW7α protein levels, downstream mitotic substrates of 
FBXW7α should be upregulated in such an experiment. 
Finally, substrates that are specifically targeted by FBXW7α during mitotic arrest 
could be identified by immunoprecipitation combined with mass spectrometry 
analysis. Similar to a published screen for FBXW7 substrates (Busino et al., 2012), 
wild-type FBXW7 and a WD40 mutant of FBXW7 could be used as bait proteins for 
immunoprecipitations. Substrates should bind to the wild-type FBXW7, but not to the 
WD40 mutant. Immunoprecipitations could be performed with extracts from cells 
arrested in different cell-cycle stages or from asynchronous cells. FBXW7α 
substrates that are specifically identified upon mitotic arrest would be promising 
candidates to mediate the effect of FBXW7α on mitotic cell fate. 
 
Altogether, the presented thesis identifies novel interaction partners of FBXW7α. The 
FBXO45/MYCBP2 complex is identified as a regulator of FBXW7α protein levels 
during mitotic arrest. This regulation contributes to our understanding of regulation 
mechanisms for the important tumor suppressor FBXW7. As FBXW7 is a known 
regulator of mitotic cell fate, its regulation during mitotic arrest has the potential to 
impact strategies for the efficient treatment of cancer cells with spindle poisons. 
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Future studies on the exact mechanism of FBXW7α regulation by FBXO45/MYCBP2 
and the roles of other FBXO45/MYCBP2 complex components will be required. 
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6.1. Abbreviations 
APS ammonium peroxodisulfate 
APC/C anaphase-promoting complex/cyclosome 
BIR baculoviral IAP repeat 
bp base pairs 
BSA bovine serum albumin 
BTB bric-a-brac-tramtrack-broad complex 
CAND1 Cullin-associated and neddylation-dissociated 1 
CPD CDC4 phosphodegron 
CRL Cullin-RING ubiquitin ligase 
ctrl control 
DCAF DDB1- and CUL4-associated factor 
DD dimerization domain 
DDB1 DNA damage-binding protein 1 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
DUB de-ubiquitylating enzyme 
E1 ubiquitin activating enzyme 
E2 ubiquitin conjugating enzyme 
E3 ubiquitin ligase 
EDTA ethylenediaminetetraacetic acid 
EV empty vector 
FBS fetal bovine serum 
Fig. Figure 
HECT Homologous to E6-AP carboxyl terminus 
HRP horseradish peroxidase 
IBR in-between-RING 
IAP inhibitor of apoptosis protein 
IP immunoprecipitation 
K lysine 
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kDa Kilodalton 
M methionine 
MBP maltose binding protein 
min minute 
MYCBP2 MYC binding protein 2 
NEM N-ethylmaleimide 
NLS nuclear localization signal 
OD optical density 
PAM protein associated with MYC 
PEI polyethylenimine 
PCR polymerase chain reaction 
PEI polyethylenimine 
RBR RING-betweenRING-RING 
RING Really Interesting New Gene 
RNA ribonucleic acid 
RT room temperature 
SAC spindle assembly checkpoint 
SCF SKP1-CUL1-F-box protein 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA small interfering RNA 
SKP1 S phase kinase-associated protein 1 
SOCS suppressor of cytokine signaling 
Tm melting temperature 
TMD transmembrane domain 
UBD ubiquitin-binding domain 
WCE whole cell extract 
wt wild-type 
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